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Iron oxide nanoparticles are highly researched for their use in biomedical applications
such as drug delivery, diagnosis, and therapy. The inherent biodegradable and biocompatible
nanoparticle properties make them highly advantageous in nanomedicine. The magnetic
properties of iron oxide nanoparticles make them promising candidates for magnetic fluid
hyperthermia applications. Designing an efficient iron oxide nanoparticle for hyperthermia

requires synthetic, surface functionalization, stability, and biological investigations. This
research focused on the following three areas: optimizing synthesis conditions for maximum
radiofrequency induced magnetic hyperthermia, designing a simple and modifiable surface
functionalization method for specific or broad biological stability, and in vitro and in vivo testing
of surface functionalized iron oxide nanoparticles in delivering effective hyperthermia or
radiotherapy.
The benzyl alcohol modified seed growth method of synthesizing iron oxide
nanoparticles using iron acetylacetonate as an iron precursor was investigated to identify
significant nanoparticle properties that effect radiofrequency induced magnetic hyperthermia.
Investigation of this synthesis under atmospheric conditions revealed a combination of thermal
decomposition and oxidation-reduction mechanisms that can produce nanoparticles with larger
crystallite sizes and decreased size distributions.
Nanoparticles

were

easily

surface

functionalized

with

(3-Glycidyloxypropyl)

trimethoxysilane (GLYMO) without the need for organic-aqueous phase transfer methods. The
epoxy ring on GLYMO facilitated post-modifications via a base catalyzed epoxy ring opening to
obtain nanoparticles with different terminal groups. Glycine, serine, γ-aminobutryic acid (ABA),
(S)-(-)-4-amino-2-hydroxybutyric acid (SAHBA), ethylenediamine, and tetraethylenepentamine
were successful in modifying GLYMO coated-iron oxide nanoparticles to provide colloidal and
varying biological stability while also allowing for further conjugation of chemotherapeutics or
radiotherapeutics. The colloidal stability of cationic and anionic nanoparticles in several
biologically relevant media was studied to address claims of increased cellular uptake for
cationic nanoparticles.

The surface functionalized iron oxide nanoparticles were investigated to determine
effects on cellular uptake and viability. In vitro tests were used to confirm the ability of iron
oxide nanoparticles to provide effective hyperthermia treatment. S-2-(4-Aminobenzyl)-1,4,7,10tetraazacyclododecane tetraacetic acid (DOTA) was coupled to SAHBA and carboxymethylated
polyvinyl alcohol surface functionalized iron oxide nanoparticles and radiolabeled with

177

Lu.

The capability of radiolabeled iron oxide nanoparticles for delivering radiation therapy to a
U87MG murine orthotopic xenograft model of glioblastoma was initially investigated.

Chapter 1: Introduction and Background

1.1 Radiofrequency Induced Hyperthermia: Treatment of Cancer
The hyperthermia treatment of cancer with magnetic particles was first introduced by
Gilchrist in 1957.4 Hyperthermia can be subcategorized into three temperature ranges: mild
hyperthermia, moderate hyperthermia, and thermoablation. Each of these has varying degrees of
effects and can interact with different therapies.5,6 Increasing the body temperature above 37°C to
non-lethal ranges of 39-42°C is referred to as mild hyperthermia and can increase drug perfusion
and oxygenation which can sensitize cells to radiotherapy or chemotherapy.6-8 When the
temperature is increased to moderate hyperthermia temperatures, 41-46°C, the heat stress will
stimulates degradation of proteins, interferes with essential cell processes, and causes programed
cell death or apoptosis.9-11 Further increase of temperature above 45°C is termed
thermoablation.9,11-14 At these extreme temperatures cells will begin to die as a direct result of the
temperature increase causing carbonization, coagulation and necrosis.9,11-14 In terms of heat
sensitivity there has been no reported evidence of a difference between normal and cancerous
tissue.15,16 However, due to the vasculature of cancerous tumors there are regions of low pH and
hypoxia that sensitize tumors to hyperthermia at temperatures between 40-44°C.15 These levels
of hyperthermia can be achieved utilizing magnetic particles in an external radiofrequency (RF)
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alternating current (AC) magnetic field. Heating is produced by eddy currents, hysteretic heating,
and dielectric losses, but the material characteristics and properties such as conductivity, size,
and magnetic properties determine the extent of heating for a given magnetic field strength and
frequency.4,5,17-20 Dielectric loss can damage tissue when high magnetic field strengths and
frequencies are applied.4 To maximize the amount of hysteretic heating of the particles and limit
unwanted damage to normal tissues it has been suggested that the frequency be kept below 100
MHz as they have the required RF penetration with minimal RF absorption and are used in
magnetic resonance imaging (MRI).21 The magnetic field strength and frequency product (Hxf)
𝐴

of 5×109 𝑚𝑠 is considered the maximum threshold for safe heating of a human torso for 1 hour.22
Above this threshold nonspecific and potentially detrimental eddy current heating can occur.22 In
the treatment of smaller tissues of a healthy patient and depending on the location of the tumor
the H×f product can be surpassed in some cases.22 Therefore, the goal of magnetic hyperthermia
with particles has focused on maximizing achievable heating rates while minimizing the
magnetic field strengths and/or frequencies required.22 The RF coil used within this research was
designed so that small solution volumes in microcentrifuge tubes or similar containers could be
easily heated. Reports have indicated that there is a linear relationship between increased heating
and H×f values, however these higher H×f values require the time of heating to be reduced to
limit possible detrimental side effects or patient discomfort.23The RF heating values reported in
𝐴

this work were conducted under 1.01x1010 𝑚𝑠 H×f values. This was deemed to be acceptable for
in vitro and small animal in vivo studies.24 Additionally, the heating times used were well below
one hour.
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1.2 Néel and Brownian Relaxation Mechanisms
Since Gilchrist’s research there has been a significant change in magnetic particle based
hyperthermia. Multi-domain particles have been replaced by the use of superparamagnetic
nanomaterials. Nanoparticles small size lends them a tremendous advantage in navigating the
complexities of biological systems. Superparamagnetic nanoparticles are beneficial because of
their greater efficiency of absorbing the applied radiofrequency to generate heat.5 The ability to
generate more heat with lower required power reduces the nonspecific heating of normal tissue
that may occur with prolonged treatment times.
Néel and Brownian relaxation mechanisms are responsible for producing heat in
superparamagnetic nanoparticles exposed to a RF alternating current (AC) magnetic field. When
an AC magnetic field is applied, the superparamagnetic nanoparticles will adjust the magnetic
moment orientation to match the direction of the applied field. This reorientation results from
either rapid alteration of magnetic moment directions within the crystal lattice (Néel mechanism)
(Figure 1.1 A) or by the nanoparticle physically rotating to align the internal magnetic moments
with the external magnetic field (Brownian mechanism) (Figure 1.1 B).9,25,26 The Néel
mechanism is also referred to as internal heating; as heat is first generated by internal friction
between the crystal lattice and the rotating magnetic spins and is then lost as thermal energy to
the surrounding medium.25,26 More specifically, the Néel mechanism produces heat when the AC
magnetic field provides a sufficient amount of energy for the dipole to overcome an energy
barrier and alter directions.25,27 The volume of the nanoparticle and the magnetocrystalline
anisotropy are determining factors of the energy barrier.25,27 Equation 1a shows the relationship
between the magnetocrystalline anisotropy constant (K), volume of the core particle (Vc), and the
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energy barrier (EA). The Brownian mechanism generates and releases mechanical heat generated
from friction

Figure 1.1. Illustration of (A) Néel and (B) Brownian mechanisms in response to an alternating
current magnetic field. The dashed arrow represents either the internal magnetic spins (A) or the
entire nanoparticle (B) rotating in response to a 180° magnetic field direction change.

between the rotating nanoparticle and solution.25,26 The amount of friction is dependent upon the
viscosity of the solution.25,26 Heat is generated simultaneously by both mechanisms at all relevant
superparamagnetic nanoparticle sizes.17,18,25,28-31

Depending on the crystallite size of the

nanoparticle one mechanism will have a faster relaxation time and is thus the dominate source of
heating.17,18,25,28-31 The effective relaxation time (1/τ) (Equation 1b) is used to describe the
combination of heating mechanisms. Néel heating is dominant at smaller nanoparticle sizes. For
example, this heating mechanism dominates below 15-16 nanometers (nm) for iron oxide (FeOx)
nanoparticles. In the equation for Néel relaxation time (τN)28 (Equation 1c) it can be seen that
4

below 8 nm crystallite diameters the Néel relaxation time is dictated by the pre-exponential term
(τ𝑜 E𝐴 ) and at crystallite diameters between 8 and 15-16 nm the relaxation time is dictated by the
E

exponential term (𝑘 𝐴T).17,27,29,32,33 Above 15-16 nm crystallite diameters the Brownian relaxation
𝐵

time (τB)28,34 (Equation 1d)

is much faster than Néel relaxation time and becomes

dominant.17,29,32,33 The Brownian relaxation time depends on the medium viscosity (η),
hydrodynamic volume of the particle (Vh), and inversely on temperature (T) and Boltzmann
constant (kB).
𝐸𝐴 = KV𝑐
1
τ

=

1
τ𝑁

+

(1a)
1

(1b)

τ𝐵
E

τ𝑁 = τ𝑜 E𝐴 exp (𝑘 𝐴T)
𝐵

τ𝐵 =

3ηVℎ
𝑘𝐵 T

(1c)
(1d)

From Equations 1a-d it becomes apparent that the heating mechanisms are determined by
nanoparticle size, crystal structure, polydispersity, shape, and magnetocrystalline anisotropy.25,26
When a large size distribution is used (large polydispersity) heat will be generated by a varying
degree of combined heating mechanisms and is typically unfavorable.25
The ability to quantifiable measure and compare the effectiveness of hyperthermia
between nanoparticles is important. In 1993 Jordan et al. attempted this through the use of
determining what they termed the specific absorption rate (SAR).17 However, SAR values are
often misunderstood or improperly determined and lead to improperly reporting the efficiency of
magnetic nanoparticles.23 The SAR equation (Equation 2a) has since been expanded to
normalize SAR values depending on the magnetic field strength and frequency of the coil
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used.23,35 The new equation is referred to as effective SAR (Equation 2b) or intrinsic loss of
power (ILP) (Equation 2c).23,35,36

𝑐

𝑆𝐴𝑅 = 𝑚

𝑛𝑝

𝐸𝑓𝑓𝑒𝑐𝑡𝑖𝑣𝑒 𝑆𝐴𝑅 =

Δ𝑇

( Δ𝑡 )

(2a)

𝑐𝐻2 𝑂 𝑚𝐻2 𝑂 +𝑐𝑛𝑝 𝑚𝑛𝑝 Δ𝑇
𝑚𝑛𝑝

𝐼𝐿𝑃 = 𝐻 2

( Δ𝑡 ) (𝐻 2

1

𝑎𝑝𝑝𝑙𝑖𝑒𝑑 ×𝑓

)

𝑆𝐴𝑅

(2b)
(2c)

𝑎𝑝𝑝𝑙𝑖𝑒𝑑 ×𝑓

In Equations 2a-c, specific heat capacity of water and nanoparticles are denoted 𝑐𝐻2 𝑂 and 𝑐𝑛𝑝
W×s

with units of ( g×K ), mass of total nanoparticles and water are denoted mnp and 𝑚𝐻2 𝑂 , initial
Δ𝑇

K

linear increase in temperature per unit time is denoted ( Δ𝑡 ) in units of ( s ), magnetic field
A

strength is H in units of (m), and AC magnetic field frequency (f) in units of kHz.29,31 From
Equations 1 and 2 it has been determined that to maximize energy absorption and thus produce
the most efficient heating, the crystallite size and monodispersity must be controlled.20,37
Additional benefits of switching to nanoparticles include more uniform heating,
decreased invasiveness, and reduced chances of causing adverse damage to surrounding normal
tissue.5 The superparamagnetism of these small nanoparticles are additionally useful as they lose
their magnetism when the external magnetic field is removed.38 This is essential in biological
applications as magnetic aggregation of stable nanoparticles are less likely to occur which
prolongs the blood circulation time.38 The advent of nanomedicine has allowed for numerous
new targeting strategies specifically for cancer cells to provide confined local heating while
limiting invasiveness.5,9,20,39,40 The extraordinary advantages of nanoparticle hyperthermia are
responsible for the vast amount of recent literature and research being conducted on magnetic
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hyperthermia treatment of cancer. Several issues that must be addressed for successful clinical
implementation of magnetic nanoparticle hyperthermia include increasing ILP values, biological
stability, blood circulation, and cellular uptake while minimizing immunogenicity and
toxicity.22,24,25,41 Maximizing ILP values is essential to lower the required amount of nanoparticles
for effective heating. However, there is evidence that hyperthermia without detectable
temperature increases can provide sufficient treatment of cancer.25,42,43 This gives evidence to
suggest that SAR and ILP values are often misleading and may not always indicate the best
magnetic hyperthermia.25 Biocompatible nanomaterials with biologically suitable surface
modifications may offer the best chance of addressing the current challenges of transitioning
more nanoparticle hyperthermia into clinical trials.

1.3 Iron Oxide Nanoparticles for Magnetic Hyperthermia: Ideal
Properties and Challenges to Overcome
Nanomaterials

have

remained

an

important

research

area

in

nanomedicine.

Biocompatible nanomaterials make excellent nanomedicine therapeutics, such as magnetic fluid
hyperthermia. For example, FeOx is a biocompatible material with RF induction heating
potential that allow for its application in magnetic fluid hyperthermia (MFH).25,38,41,44 FeOx
nanoparticles can be cleared from the body by opsonization or through degradation via the
body’s metabolism forming iron ions that are then used by erythrocytes to form hemoglobin. 45,46
Biocompatible FeOx nanoparticles can furthermore act as a theranositc agent47-50 by providing
therapy via magnetic fluid hyperthermia41,51,52 and diagnosis in the form of magnetic resonance
imaging.51,53 FeOx nanoparticles are one of the only US FDA approved nanoparticles for their
use as MRI contrast agents54 of the liver and as iron supplements55-57. In Germany, aminosilane
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functionalized superparamagnetic FeOx nanoparticles are already being investigated for
glioblastoma and prostate cancer treatment with MFH at the clinical level.39,52,58
MFH research using FeOx nanoparticles has revealed that the optimal crystallite size is
15-16 nm with minimal size distribution.29,59 Within this size range Néel relaxation is still
dominant, but has a fast Brownian relaxation time as well which results in the best theoretical
superparamagnetic heating.13 Crystallite sizes above 16 nm that have dominant Brownian heating
usually have less effective heat generation.13 Hyperthermia is not a new medical procedure and
can be delivered via thermoseeds, water bath, microwave, infrared or ultrasound radiation.25,60
However, nanoparticle delivered MFH offers the ability to less invasively deliver effective MFH
to smaller cancerous regions.25,60 Nanoparticles offer a unique solution to the problem that some
conventional drugs have with regards to being ineffective due to poor solubility or
bioavailability.61 Due to their small size nanoparticles can in some cases cross biological
membrane barriers such as mucus membranes or the absorptive epithelium in the small
intestine.62,63 Additionally, surface modifiable nanoparticle can be used as a nanoplatform or a
nanocarrier to deliver a surface conjugated drug or drugs to the target of interest by either passive
or active uptake.64,65 Active uptake can be facilitated by surface functionalized targeting ligands
that can direct nanoparticles to overexpressed targets in cancerous tissues.63,66 An additional
benefit of FeOx nanoparticles is that they are inherently biodegradable. This means that once the
drug has been delivered the nanoparticles can be easy cleared from the body or metabolized.
Also, due to the size range of superparamagnetic nanoparticles they can be passively uptaken by
cancerous tissue through the enhanced permeation and retention (EPR) effect.25,67
Research on nanomaterials for biological applications continues to suffer from a lack of
broad stability and/or ease of surface functionalization, which impedes the advancement of many
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synthesized nanoparticles into actual nanomedical applications. Moreover, the definition of
stability is often misused or misleading when claiming a “stable” nanomaterial surface
functionalization. True stability is very complex and can be defined in regards to colloidal,
chemical, physical, pharmaceutical, and/or biological stability.68 For efficient magnetic
hyperthermia stability should be defined as a combination of the above listed stability terms. The
colloidal stability can most simply be defined as having higher repulsive forces than attractive
forces with respect to solid nanoparticles dispersed in an aqueous medium (colloid). The
pharmaceutical stability refers to how long the solution is physically and chemically stable, and
can effectively deliver a pharmaceutical dose. Chemical and physical stability refers to the
protection against factors such as temperature, pH, humidity, etc. that may alter the nanoparticle
composition or render the nanoparticle inert. With respect to biological stability this refers to
overcoming attractive forces that may arise from immersion into different biological
environments where counter ions, proteins, pH, and other molecules vary.
An alarming number of studies on nanoparticles rely on the assumption that a surface
coating will provide the required colloidal stability to properly investigate certain parameters of
interest. It should be noted that nanoparticles displaying colloidal stability upon synthesis or after
surface functionalization may aggregate and precipitate in when introduced to different
biologically relevant medium or biological environments. This can drastically alter or affect the
results of biological testing and investigations. Therefore, it is vital to understand what
constitutes a stable nanoparticle solution, the biological and chemical challenges of surface
functionalizing nanoparticles for stability, and ideal biological and chemical properties of surface
functionalized nanoparticles for nanomedical applications. These topics will be covered in the
following subsections.
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1.3.1 Colloidal Stability
Nanoparticles small size lends them a tremendous advantage in navigating the
complexities of biological systems. However, nanoparticles exhibit a greater propensity to
aggregate in aqueous solutions, than their bulk counterparts, due to surface properties,
interactions between nanoparticles, and size.69 Aggregation must be addressed to achieve
colloidal stability in buffered or saline based medium which is paramount to permit sterile
filtration (or other sterilization methods; for example sterile buffer exchange) before use with in
vitro studies or in vivo administration.

Additionally, without proper colloidal stability in

biologically relevant medium the nanoparticles may aggregate or interact unfavorably when
administered in vitro or in vivo.66,70 Colloidal stability in buffered solutions is also necessary for
reactions involving conjugation to biological targets, such as proteins and antibodies, and for
other reactions such as radiolabeling and chelation. Nanoparticles that do not possess intrinsic
colloidal stability cannot be used effectively in biomedical applications, but colloidal stability
can be provided by functionalizing the surface with hydrophilic ligands.70-72
Nanoparticle surface functionalization is most often used to overcome nanoparticles
greater tendency to aggregate. The small size of nanoparticles and Brownian motion offers a
simple explanation for nanoparticles propensity to aggregate.69 In Equations 3a and 3b we can
see the relationship between particle size (dp) and extent of three dimensional Brownian motion
displacement (Δx).69 Where Db is Einstein’s Brownian diffusion coefficient, Δt is change in time,
T is temperature, kB is Boltzmann’s constant, and μ is the solution viscosity.
𝛥𝑥 = √6𝐷𝑏 𝛥𝑡

𝐷𝑏 =

𝑘𝐵 𝑇
3𝜋𝜇𝑑𝑝
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(3a)
(3b)

Equation 3b clearly shows that as particle size decreases the displacement due to Brownian
motion increases. This results in a greater chance for aggregation between nanoparticles due to
Van der Waal attraction forces.69 More precisely, there usually exists a relatively strong
attraction between solid phase nanoparticles that are dispersed in an aqueous phase.69,73 This
attractive force can result in aggregation.69,74 While the size of nanoparticles offers a simple
explanation for greater aggregation probability, factors such as surface charge and chemistry can
also influence aggregation tendency, further complicating obtaining colloidal stability.
Therefore, the surface modification must sufficiently increase van der Waal repulsion to prevent
aggregation and achieve colloidal stability.72,73 Surface ligands can provide nanoparticles with
steric, electrostatic, or electrosteric stability.72,75 These types of stability are shown in Figure 1.2.

Figure 1.2. A) Electrostatic, B) steric, or C) electrosteric colloidal stabilization of nanoparticles
provided by surface charge properties, surface ligands, or charged surface ligands respectively.

Electrostatic stability prevents aggregation due to charged nanoparticle surfaces that repel
neighboring nanoparticles with greater force as they approach.73 An electrostatic double layer,
shown in Figure 1.3, forms due to counter ions in solution being attracted to the charged surface
11

forming the ‘diffuse layer’ and repelling nanoparticles with the same ‘surface layer’.76 The
surface and diffuse layers are also termed Stern and Guoy layers respectively. Addition of
surface ligands to the nanoparticle can also provide steric stability. Steric repulsion is provided
by the steric hindrance of the ligands and is determined by how dense and compressed the
ligands can pack as the nanoparticles approach.73 Surface ligands with charged functional groups
utilize both steric and electrostatic stabilization to prevent aggregation and are often referred to
as electrosteric stabilization.73

Figure 1.3. Scheme of the electrostatic double layer of small positively charged solid particle in
an ionic liquids. The double layer is comprised of the positively charged (blue circle with +
inside) surface layer and the surrounding negatively charged (red circle with – inside) layer
(Stern layer). This is encompassed by a diffuse layer of equal positive and negative charges
(Guoy layer).
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The stabilization distance provided by the electrostatic double layer is typically between 1-100
nm for colloids and is compacted as the concentration of ionic electrolytes increases.74,76 The
formed layer of counter ions has a certain thickness (1/κ) or is inversely proportional to the
Debye Hückel parameter (κ) which is dependent upon concentration of ions and the interaction
between charged surfaces and ions.74,76 Therefore, factors such as concentration of counter ions,
and nanoparticle surface charges as well as the size of nanoparticles can play a crucial role in
colloidal stability.73 This offers a simple explanation for the nanoparticle instability upon transfer
from water to biological medium such as PBS that contain higher ion concentrations. A model
that is most commonly used to describe the repulsive force generated due to the electrostatic
interactions is the Derjaguin, Landua, Verwey, and Overbeek (DLVO) model.69,77-80 In this model
several simplifications are used, mainly the co-ions, counter ions, and nanoparticle surface
charges are represented as spheres that interact through short range potentials and Coulomb
interactions.73,80 The change of energy as charged nanoparticles approach each other is
quantitated within the DLVO model and relates to the extent of stability. 73,80 The double layer
thickness is used to calculate the amount of Coulomb repulsion between approaching
nanoparticles.73,80 The DLVO theory can be simply stated as the total interparticle potential
(ΨTOT) which is the combination of overlapping electrostatic double layers providing repulsive
forces (ΨR) and van der Waal attractive forces (ΨA), shown in Equation 4a.73,80 The simplified
equations for van der Waal attractive forces and repulsive forces are shown in Equations 4 b
and c. The equation for attractive forces is simplified by assuming particles are of identical
radius (a) and that the radius of particles is much greater than the distance between particles,
center-to-center (r).73,80 Likewise the equation for repulsive forces can be simplified by assuming
the radius of particles and zeta potential (ζ)
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are identical.73 The Hamacker constant (AH)

describes the forces between two particles in solution and the interaction between the surface of
the nanoparticle and solution medium.73
Ψ𝑇𝑂𝑇 = Ψ𝐴 + Ψ𝑅
𝐴 𝑎

𝐻
Ψ𝐴 = − 12𝑟

Ψ𝑅 = 2πεaζ2 ln(1 + 𝑒 −𝜅𝑎 )

(4a)
(4b)
(4c)

It should be noted that the attractive force decreases drastically as the distance between
nanoparticles increases (1/r2) and that the attractive force exists over larger distances compared
to the repulsive forces.74,80 This can be represented by graphing r/a vs. interparticle potentials
(Figure 1.4) where a positive potential represents repulsive forces and a negative potential
represents an attractive force.

Figure 1.4. Graph illustrating interparticle potentials for stable dispersions (solid line),
flocculated dispersions (dotted line), and aggregated dispersions (dashed line).
14

For stable dispersions (Figure 1.4 solid line) the particles repel nanoparticles effectively at all
distances.74 Particles that are starting to flocculate or are starting to aggregate (Figure 1.4 dotted
line) have greater attractive forces at certain distances (r/a) which is termed the equilibrium
separation distance.74 Unstable particles (Figure 1.4 dashed line) that do not have sufficient
repulsive forces will have very large attractive forces as they approach and will irreversibly
aggregate and precipitate.74 This exemplifies why nanoparticles can be dispersed in solutions, but
may require stabilization by means such as surface modifications to attain colloidal stability. 75
Dynamic light scattering (DLS) is a useful characterization tool that can determine the zeta
potential of the nanoparticles and assess the stability of the nanoparticles in solution.
There are numerous different strategies for functionalizing the surface of FeOx
nanoparticles to provide colloidal stability. Such strategies include modifying the surface with
hydrophilic biomolecules, small molecules, dendrimers, surfactants, or polymers.71 In addition to
the electrostatic forces provided by the surface ligands, the stability is also due to an osmotic and
elastic involvement.61,81-85 When two nanoparticles with a surface coating approach each other the
increase in concentration of surface ligands will cause water to enter the volume and force the
nanoparticles apart to restore osmotic equilibrium.81-84 Additionally, when the nanoparticles are
in a confined area the surface ligands will have an reduction in conformational entropy which
will ultimately repel the particles to increase entropy.81-84 Once colloidal stability is achieved, it
should be assessed in multiple biologically relevant media since colloidal stability in water or
phosphate buffered saline (PBS) may not translate to stability when introduced to the biological
environment of interest.
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Effective use of nanoparticles for treatment of cancer requires colloidal stability.
However, there are several additional factors that need to be addressed when choosing and
designing a surface functionalization strategy. These challenges can be subcategorized into
biological and chemical challenges of modifying the surface of nanoparticles.

1.3.2 Biological Challenges for Surface Functionalization
FeOx nanoparticles without post-modifications are generally not stable in biological
conditions. Additionally, nanoparticles can exhibit low probability of reaching the desired target,
non-specific interactions with proteins that can cause aggregation, adsorption of opsonins leading
to phagocytosis and subsequent clearance from the body, and toxicity issues.61,63 To prolong the
circulation time and enhance passive uptake the optimal surface functionalized nanoparticle size
should be between 30-100 nm.61,86 Below this size range the nanoparticles are susceptible to
leakage into the blood capillaries and above this size they become more likely to be opsonized
and cleared by macrophages.61,86,87 The ideal surface ligand should therefore provide colloidal
stability in biological media while maintaining a small size to increase circulation time and
enhance cellular uptake probability. It is also advantageous in radiofrequency magnetic
hyperthermia to choose a surface functionalization that can be easily conjugate additional
therapeutics, diagnostics, and targeting ligands to aid in delivery, treatment, and/or diagnosis.
The biological concerns and requirements are addressed in further detail below.
Opsonization is the process by which opsonin tags a foreign object for phagocytosis and
clearance from the body.46 A potential way to overcome the challenge of avoiding opsonization
is to use a surface functionalization technique using polymers.46 Utilizing these biomolecules
could prevent opsonization by mimicking biology to create ‘stealth’ like properties for the
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nanoparticle.61,81,88 Stealth property of some nanoparticles refers to a surface coating that
increases the circulation time allowing for a greater chance of passive targeting by reduce protein
adsorption and recognition by opsonin.61,81,88 This is especially important in cancer treatment
since some tumors are known to have leaky vasculature, as a result of reduced lymphatic
drainage and increased angiogenesis, which improves the accumulation of nanoparticles in these
regions.61,63 The intercellular junctions of normal tissue is typically less than 10 nm reducing the
potential for nanoparticles to accumulate.61 In comparison it has been reported that tumor
intercellular spaces can range from 0.5-2.5 μm.89,89,90 The passive uptake resulting from both
leaky vasculature and increased intercellular spaces is termed the enhanced permeation and
retention (EPR) effect. Nanoparticles in the size range of about 20-150 nm can take advantage of
the EPR effect most efficiently.63
While passive targeting via the EPR effect increases the accumulation of nanoparticles in
tumors as compared to normal tissue it should not be exclusively relied upon. For this reason the
ability for further conjugation of targeting moieties, therapeutics, and/or diagnostic agents is
highly advantageous for medical applications. Addition of targeting moieties such as ligands,
proteins, or antibodies facilitates active accumulation of nanoparticles by targeting
overexpressed receptors on tumor cells.63,66,91,92 One popular way of conjugating targeting
moieties is to use 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) coupling to form an
amide bond between a carboxyl group and a primary amine.93 This method is beneficial as
amines and carboxyl groups aid in providing aqueous stability and are typically found on surface
functionalizations used for biological stability.93 Additionally, targeting biomolecules typically
contain a primary amine and/or carboxyl group.
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Another significant biological challenge that nanomaterials face is accurate assessment of
stability. Nanoparticles’ colloidal stability must be assessed not only in water and PBS, but also
in biologically relevant medium before conducting any in vitro experiments, such as uptake or
toxicity. This is important as colloidal instability due to the introduction of nanoparticles into cell
medium can drastically alter results.66,94 When the nanoparticles are introduced to cell culture
medium, blood, cerebral spinal fluid, or other medium, aggregation can result. This can be
caused by differences in pH, ion concentrations, or presence of interacting or adsorbing proteins.
Instability due to aggregation reduces the circulation time and prevents the nanoparticles from
reaching or remaining at the region of interest.66 Aggregation can also decrease cellular uptake
and internalization, or drastically reduce the effectiveness of targeting.61,66 In some cases
adsorption can lead to recognition by the immune system leading to clearance from the body. It
is therefore very important that the biological stability of the surface functionalized FeOx
nanoparticles be investigated in several relevant media such as complete tissue culture medium,
cerebral spinal fluid, and human serum. For the treatment of glioblastoma multiform (GBM) it is
important to modify the surface for stability in cerebral spinal fluid. This can be tested by using
artificial cerebral spinal fluid (CSF). Additionally, the use of convection enhanced delivery
(CED) reduces the need for active targeting as the nanoparticles are directly administered at the
tumor site. The use of CED also reduces the issue of nanoparticles crossing the blood brain
barrier.
Toxicity is another biological obstacle that must be kept in mind when modifying the
surface of the nanoparticles.63 It has been suggested that cationic surface functionalizations can
improve the cellular uptake, however there is some evidence that suggests potential toxicity due
to surface functionalizations containing positive amine groups.63,95,96 The charge of the surface
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modification is thought to not only affect cellular uptake of nanoparticles, but also where the
nanoparticles localize within the cell.95,96 Cellular toxicity can be significantly affected by where
a nanoparticle localizes.95,96 Therefore the possible tradeoff between potential toxicity and
potential increased cellular uptake must be considered for specific applications.
In conclusion factors such as charge, size, chemical composition, and toxicity must all be
considered when designing a nanoparticle surface for biological stability and targeting of
cancerous cells. Further understanding of factors that influence biological stability and the ability
to produce stable nanoparticle solutions in a broad range of medium is paramount in progressing
nanomedical agents into the clinic. Ideally, surface functionalized nanoparticles will provide
protection against clearance and aggregation as they interact with different biological
environments, exhibit low toxicity, and offer potential for further conjugation of targeting
ligands and/or additional therapeutic or diagnostic agents.

1.3.3 Chemical Challenges for Surface Functionalization
When choosing a surface functionalization strategy the chemical challenges of
functionalizing the surface must also be considered and addressed. The nanoparticles surface
chemistry can pose several challenges to surface modification. Such chemical issues to be
avoided include use of toxic chemicals, difficult surface functionalization methods, and large
surface functionalizations that cannot be sterile filtered. Other challenges include washing and
isolating the surface functionalized nanoparticles, and retaining colloidal stability when
conjugating additional targeting ligands or drugs.
Washing and isolating the stable surface functionalized nanoparticles is vital to remove
unreacted ligands, chemicals, and partially or incomplete surface functionalized nanoparticles.
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This becomes extremely necessary if toxic chemicals are used or toxic byproducts are present
during surface functionalization. Additionally it is important to be able to buffer exchange the
nanoparticles directly into different biologically relevant medium without the need to completely
dry the nanoparticles. Often when surface functionalized nanoparticles are dried to a powder the
surface chemistry is altered or even removed resulting in colloidal instability upon resuspension.
Difficult surface functionalizations are frequently required to obtain colloidal stability in
water or PBS. The nanoparticles that usually require these difficult methods are synthesized by
organic methods which result in only organic media stability. For these nanoparticles a phase
transfer process is generally required to transition the nanoparticle from organic stability to
aqueous stability. Facilitating this transition requires a mixture of organic and aqueous phases
with a surface functionalization or stabilizer. The two phases are allowed to separate and then the
nanoparticles in the aqueous phase are extracted. Additional steps must then be taken to ensure
complete removal of these organic chemicals. If the chemical, polymer, or molecule used to
modify the surface is soluble in the organic phase then removal of the chemical, polymer, or
molecule is easily done by washing with the organic phase. Synthetic approaches with facile
surface functionalization methods without the need for potentially toxic organic chemicals are
highly sought after.

1.4 Methods of Synthesizing Iron Oxides
There is a plethora of synthetic methods reported in the literature including mechanical
alloying or ball milling97-99, electron beam lithography100, laser pyrolysis101-105, electrospray106,
and gas-phase deposition107.51 It is desirable to avoid these synthetic methods for FeOx
nanoparticles used in hyperthermia because these methods are often complex and/or do not have
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sufficient nanoscale size control. Synthetic methods that produce more applicable nanoparticles
for hyperthermia include aqueous co-precipitation108-113, sol-gel114, hydrothermal reaction115,
flow injection synthesis116, microemulsion117, chemical vapor deposition (CVD)118,119,
glycol53,120-122, thermal decomposition(83-86), and sonochemical syntheses123.27,124,125

Co-

precipitation of iron salts is mentioned in spite of its sufficient lack of size distribution control
because it produces nanoparticles that have some degree of water stability without postmodification steps.27,126
Thermal decomposition synthesis of FeOx nanoparticles are worthy of particular
emphasis. This method is extremely versatile and the size and morphology can be controlled. 27
Synthesis parameters of time, reactant concentration, ratios of reactants, temperature, intrinsic
solvent or iron precursor properties, and seed growth techniques can be utilized to obtain
morphology and size control.27,127 Utilizing non-polar solvents is beneficial to obtain highly
crystalline FeOx nanoparticles with tunable size, narrow size distribution and facile scale-up
potential. To produce 15 nm crystallite sizes, with non-polar solvents, the nanoparticles must be
synthesized with seed growth steps that require multiple solvents, capping agents, and/or
intermediate wash steps.128,129 However, the downside of non-polar solvent use is that they
require difficult or complex phase transfer steps to obtain aqueous dispersions and stability. It is
crucial that a biologically stable colloidal solution of nanoparticle be easily obtain by postsynthetic methods such as surface functionalization. The importance of biological stability and
conjugation potential of targeting ligands provided by surface functionalization is critical for
FeOx nanoparticles for use in MFH or nanomedical applications especially where targeting to
tumor cells is required.39,40,130
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1.5 Benzyl Alcohol Synthesis of Metal Oxides
Benzyl alcohol, a polar solvent, provides the benefits of non-polar solvent synthetic
methods of control of size, high crystallinity, narrow size distribution, and potential facile scaleup with the added benefit of being more easily surface functionalized for the required biological
stability post synthesis.131 Size control has been achieved for crystalline titania nanoparticles
synthesized with benzyl alcohol from titanium tetrachloride by modifying the reaction
temperature and precursor concentrations.132 Scale-up was demonstrated in recent reports of
benzyl alcohol synthesis with vanadium and tungsten chlorides to produce gram quantities.133
Thermal decomposition of iron (III) acetylacetonate (Fe(acac)3) in benzyl alcohol has several
benefits. Benzyl alcohol is simultaneously acting as a solvent, capping agent, and reducing agent
to synthesize FeOx nanoparticles. Furthermore, when the reaction is carried out under the
presence of air the reduction of Fe(acac)3 is increased due to increased oxidation of benzyl
alcohol to benzaldehyde.94 The oil of plants naturally contain benzyl alcohol.134 Commercial
applications have been found for benzyl alcohol in products such as cosmetics products135,
injectable drug preservative134, and as fragrance and flavor additives135-137.
Over 35 metal oxides have been synthesized using benzyl alcohol and metal precursor
salts such as alkoxides, acetates, acetylacetonates, and halides.138-143 Literature reports relatively
few benzyl alcohol synthesis studies of FeOx nanoparticles especially using Fe(acac)3 as a metal
precursor.138,139 FeOx has been synthesized in a microwave mediated benzyl alcohol synthesis
with the metal precursor Fe(acac)3 which had the benefits of producing highly crystalline
nanoparticles very rapidly (5 minutes), but only 5 nm crystallite sizes were obtainable.139 A more
complicated benzyl alcohol synthesis with Fe(acac)3 was recently done using an autoclave
method and requiring a glovebox, and heating in a furnace for two days to obtain 15-25 nm
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crystallite sizes.143 A simple, well controlled and understood benzyl alcohol reaction that
produces 15-16 nm crystallite sizes is highly desirable. Therefore, a simple benzyl alcohol
synthesis under nitrogen and atmospheric conditions was used to gain mechanistic insight into
the benzyl alcohol Fe(acac)3 synthesis of FeOx nanoparticles. Initial studies will be used to
acquire enhanced control over crystallite size and size distribution that is vital for increasing the
effectiveness in radiofrequency hyperthermia.

1.6 Surface Functionalization of nanoparticles for Biological
Applications
The initial stability of FeOx nanoparticles depends on whether they were synthesized by
an aqueous or organic method. Aqueous synthesis such as co-precipitation typically results in
some degree of aqueous stability. Organic synthesis such as thermal decomposition of Fe(acac)3
results in stability in organic solvents and requires difficult phase transitions to modify the
surface for aqueous stability.144 However, organic synthesis is favored for producing FeOx
nanoparticles where precise control of size and size distribution is required. FeOx nanoparticles
synthesized by the benzyl alcohol modified seed growth synthesis have the advantages of
organic synthesis of tunable size and size distribution and can be easily surface functionalized for
aqueous stability without complicated phase transfer processes.94 There is an ever increasing
demand for surface functionalizations that provide true biologically relevant colloidal stability
despite the numerous reported methods in literature.124 Typical surface functionalizations have
terminal amine and/or carboxyl groups to provide stability and have the added benefit of further
conjugation of targeting ligands, chelates, or radiolabels.94,124,145 Some examples of commonly
used surface functionalizations for biological stability include use of polymers or organosilanes.
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1.6.1 Carboxymethylated Polyvinyl Alcohol Surface Functionalization
Polyvinyl alcohol can be carboxymethylated to form carboxymethylated polyvinyl
alcohol (CMPVA) a biodegradable, cheap, and hydrophilic biopolymer.130 The carboxyl groups
of CMPVA interact strongly with the surface of FeOx.131 The carboxyl groups that do not
interact with the surface provide the colloidal and biological stability as well as sites for further
conjugation of targeting ligands, therapeutic and/or diagnostic agents. One possible disadvantage
of using CMPVA is that the length of the polymer increases the possibility of bridging and/or
multiple nanoparticles adsorbing the same polymer which will ultimately lead to clusters of
stable nanoparticles or instability. Large stable clusters of nanoparticles are undesirable as this
can potentially affect the cellular uptake, blood circulation time, and increase the chance of
becoming opsonized.

1.6.2 Organosilane Surface Functionalization
Organosilanes offer the advantage of protecting the surface of FeOx from undesirable
reactions and are often used to provide stability based on the terminal functional group of the
organosilane.146-148

Two of the more commonly used organosilanes for FeOx surface

functionalization

include

(3-Aminopropyl)trimethoxy

silane

(APTS)

and

(3-

aminominopropyl)triethoxysilane (APTES). These organosilanes offer an efficient and easy
method to modifying the surface of FeOx nanoparticles through a silanization reaction resulting
in a Fe-O-Si bond and a silica shell around each nanoparticle.124,149 The resulting modified
surface contains terminal amine groups giving the nanoparticles a positive zeta potential at
neutral pH.146 More specifically the charge of the nanoparticles offers stabilization through an
electrostatic double layer and steric hindrance of the organosilane.73-76 The number of silica shells
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that form in addition to how quickly and effectively the silanization occurs depends on several
factors such as time, pH, temperature, hydrolysis rate, concentration and type of catalyst
used.124,149,150 There is a plethora of reported methods for APTS or APTES surface
functionalization of FeOx nanoparticles, however few have sufficiently been optimized or
characterized to properly show biologically relevant stability or extent of silanization.149
Additionally, the methods employed will need to be modified or optimized depending on the
FeOx nanoparticle synthesis used.
Another organosilane of particular interest is (3-Glycidyloxypropyl)trimethoxysilane
(GLYMO) which contains a terminal three membered epoxy ring that can be used to easily alter
the chemistry at the surface. The epoxide ring initially prevents aqueous stability after
silanization, but also hinders the possibility of creating additional silane shells, and bridging or
coating of multiple nanoparticles. Through the use of acid or base-catalyzed epoxy ring opening
reactions aqueous stability can be achieved by coupling different biomolecules containing an
amine group or strong nucleophile.151 When selecting an appropriate biomolecule it is
advantageous to select one with only one reactive site to prevent possible bridging or cross
linking between nanoparticles. This bridging would result in larger hydrodynamic diameters,
wider size distributions, and ultimately aggregation and precipitation. Overall, modifying the
surface of FeOx nanoparticles with GLYMO grants the ability to conjugate a wide array of
biomolecules providing and even tuning the colloidal stability for specific biological
environments.
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1.7 Project Overview
Herein, the research into FeOx nanoparticles for radiofrequency induced magnetic
hyperthermia treatment of cancer is split into three main objectives. The first objective was to
design and optimize the benzyl alcohol synthesis of FeOx nanoparticles with ideal properties for
hyperthermia applications. The second objective was to devise and tailor a simple surface
functionalization strategy suitable for biological applications with further conjugation potential.
The third objective was to conduct biological tests to determine the nanoparticles efficacy in for
biological applications including RF hyperthermia and brachytherapy delivery.
Chapter 1 introduced the relevant and essential background information to understand
radiofrequency induced magnetic hyperthermia. More specifically this chapter discussed the
plethora of FeOx nanoparticle synthesis and surface functionalization strategies that are suitable
for RF hyperthermia applications. The challenges and ideal properties of surface
functionalization for translation to biological applications are also discussed.
In Chapter 2 the different FeOx nanoparticles are introduced. The numerous applications
for FeOx nanoparticles and the different crystal structures are briefly reviewed with focus on the
inverse spinel crystal structure of magnetite and maghemite ordinarily used in magnetic RF
hyperthermia.
In Chapter 3 the results and discussion from the investigation into synthetic parameters of
the benzyl alcohol synthesis are presented. Emphasis is placed on altering the reaction
environment, concentration, and temperature to optimize the resulting FeOx nanoparticle
properties. LaMer growth and Ostwald ripening principles are used to speculate on the observed
effects of reaction parameters on nanoparticle properties. For further optimization and control of
nanoparticle properties a modified seed growth method is investigated. The complex interactions
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between reaction parameters and nanoparticle properties, as well as between nanoparticle
properties and RF heating are analyzed using JMP effect screening models.
Chapter 4 presents the ease of surface functionalization for FeOx nanoparticles
synthesized by the benzyl alcohol method. The surface functionalization with CMPVA, APTS,
APTES, and GLYMO are discussed with emphasis on the stability properties in different
biologically relevant media. The GLYMO modification with different amino acid and
nucleophiles is investigated to obtain a method that allows for tailoring of stability properties.
Additionally, the CMPVA-FeOx and SAHBA-FeOx nanoparticles are further functionalized
with a DOTA chelate and radiolabeled with 177Lu to confirm their use as a nanoplatform.
Chapter 5 presents biological testing of surface functionalized FeOx nanoparticles. In
vitro cellular uptake, proliferation, and hyperthermia test results are presented and discussed. An
initial in vivo survival study using a murine orthotopic xenograft model of glioblastoma
multiforme is used to investigate the efficacy of CMPVA-FeOx and SAHBA-FeOx nanoparticles
to deliver brachytherapy.
Chapter 6 concludes the dissertation with a brief summary of important findings. The
combination of investigating synthetic methods, surface functionalization strategies, and
biological testing in this project will be extremely beneficial to gain knowledge applicable to
magnetic hyperthermia applications, nanotechnology, and nanomedicine. The work herein will
be beneficial and intriguing to experts in areas of material synthesis, surface coating technology,
medicine, physics, radiology, molecular biology, and other disciplines.
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Chapter 2: Iron Oxide Nanoparticles

2.1 Iron Oxides in Nanotechnology
Nanotechnology, especially FeOx nanoparticles, can be utilized in countless ways. FeOx
nanoparticles are useful materials in biosensors,152-156 high density information data storage,157160

catalysts,124,157,161-163 magnetic sensors,164-167 and permanent magnets.159,160,168,169 FeOx

nanoparticles with specific surface functionalizations have proven very useful in biosensing
applications using diagnostic magnetic resonance (DMR) technology to detect cells and
biomolecules such as DNA, pathogens, mRNA, proteins, drugs, and tumors.156 Understanding
and manipulation of magnetocrystalline anisotropy of FeOx has given rise to innovative ways to
magnetically store information data.158 The high surface area to volume ratio property of
nanoparticles has led to a significant interest in utilizing FeOx nanoparticles for catalysts and
magnetic sensors.161 Additionally, catalysts and magnetic sensors benefit from nanoparticles
stability, selectivity, and increased efficiency as compared to bulk sized materials.161 The
magnetic properties of FeOx nanoparticles are often sought after because they can be
magnetically extracted and recycled after use as catalysts, biosensors, or in other
applications.156,161 Significant amounts of research time have been invested into creating
permanent magnets and finding new applications for them. Permanent magnet materials combine
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the ideal properties of a soft magnet’s large coercivity property and a hard magnet’s large
magnetization saturation property by exchange coupling.160 FeOx nanoparticles are extremely
advantageous in biotechnology and nanomedicine as they can be used in both theranostics and
diagnostics. Diagnostically they are used as magnetic resonance imaging contrast agents due to
their strong T2-weighted and T2* image improvement.28,170,171 FeOx nanoparticles continue to be
rigorously investigated to find new and better applications and improve their efficacy in
applications such as magnetic hyperthermia where their superparamagnetic behavior, size,
biocompatibility, and inherent imaging capabilities are utilized.29,44,170,172-174

2.2 Iron Oxide Crystal Structures
Iron oxides in nature typically consist of iron (II) and/or iron (III) cations and certain
oxygen containing anions.125,175,176 Iron oxides can be referred to as oxides, hydroxides, or oxidehydroxides depending on if the crystal structure contains O2- and/or OH- anions. The term iron
oxide is often used as an encompassing term of the many different iron oxides, hydroxides, or
oxide-hydroxides.125 Stoichiometry and crystal structures differences have been used to identify
the sixteen known pure phase iron oxides.1,125,175 Table 2.1 lists the known iron oxides and are
subcategorized into iron oxides, iron hydroxides, and iron oxide-hydroxides.1 In the following
sections hematite, wüstite, maghemite, and magnetite crystal structures are briefly introduced.
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Table 2.1. The mineral name and formula for the sixteen known pure phase iron oxides
subcategorized into iron oxide, iron hydroxide and iron oxide-hydroxide. Reproduced from 1.

Iron Oxide
Mineral Name

Formula

Wüstite
Magnetite
Hematite
β-Maghemite
Maghemite
ε-maghemite
High pressure iron oxide

FeO
Fe3O4
α-Fe2O3
β-Fe2O3
γ-Fe2O3
ε-Fe2O3
Fe4O5

Iron Hydroxide
Mineral Name

Formula

Iron(II) hydroxide
Bernalite (Iron(III) hydroxide)

Fe(OH)2
Fe(OH)3

Iron Oxide-Hydroxide
Mineral Name

Formula

Goethite
Akaganéite
Lepidocrocite
Feroxyhyte
High Pressure FeOOH
Ferrihydrite
Schwertmannite
Green Rusts

α-FeOOH
β-FeOOH
γ-FeOOH
δ-FeOOH
FeOOH
Fe5HO8•4H2O approx.
Fe16O16(OH)y(SO4)z•nH2O
Fex3+Fey2+(OH)3x+2y-z(A-)z ; A-=Cl- ,1/2SO42-,CO32-

2.2.1 Magnetite Crystal Structure
Magnetite is the preferred crystal structure for magnetic fluid hyperthermia.
The inverse spinel structure of magnetite is depicted in Figure 2.12.1,28,157,175,177,178 The inverse
spinel crystal structure consists of 32 oxygen atoms close packed in a face centered cubic (FCC)
orientation with iron ions located within 16 of the 32 octahedral holes and 8 of the 64 tetrahedral
holes.28,177
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in
Figure 2.1. Diagram showing the side view and top view of wüstite (a), magnetite (b), and
hematite(c). Two top views are shown for magnetite and hematite to visualize the different layers
of the crystal structure. From 2

The magnetite inverse spinel crystal structure contains eight Fe2+ and eight Fe3+ ions the
octahedral vacancies, and eight Fe3+ ions in the tetrahedral vacancies.28,175,177 The magnetite
inverse spinel formula is therefore Fe3O4 or Fe3+(Fe2+Fe3+)O4.28,175,177 The octahedral and
tetrahedral holes make up the sublattices within the oxygen FCC lattice. The ferrimagnetism
intrinsic to magnetite results from the coupling between the iron ions.175,177 More specifically, we
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can see that from Hund’s rule that Fe2+ and Fe3+ have magnetic moments of 4 and 5 Bohr
magnetons (μB) respectively.177 Magnetite has a calculated μB=4.07 per formula unit which is
much closer to the 4 μB of Fe2+.177,178 This can be explained due to the antiferromagnetic
arrangement of the Fe3+ in the octahedral and tetrahedral vacancies leaving the Fe2+ ions as the
significant contributor to the magnetization.177,178 In summary, the ferrimagnetic property is a
result of the difference in Bohr magnetons of each iron ion, the arrangement between the two
sublattices, and the unequal Fe2+ and Fe3+ amounts. The properties of magnetite, maghemite,
Wüstite, and hematite are summarized in Table 2.2.1

Table 2.2. Properties of magnetite, maghemite, hematite and wüstite. Reproduced from 1.
Mineral Name

Cell Dimensions
(nm)
Formula units, per
unit cell, Z
Density (g/cm3)
Octahedral
occupancy
Color
Hardness
Magnetism
Currie (Néel)
Temperature (K)
Melting point (°C)
Boiling point (°C)

Magnetite

Maghemite

Hematite

Wüstite

Cubic

8

8

Rhombohedral
hexagonal
a= 0.50356
c= 1.37489
6

Cubic

a= 0.8396

Cubic or
tetragonal
a= 0.83474

5.18
-

4.87
-

5.26
2/3

5.9-5.99
-

Black
5.5
Ferrimagnetic

Reddish-brown
5
Ferrimagnetic

Black
5
Antiferromagnetic

850

820-986

Red
6.5
Weekly ferromagnetic
or antiferromagnetic
956
1350

1377
2512

1583-1597
2623

1) Néel Temperature
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a= 0.4302-0.4275
4

203-2111)

2.2.2 Maghemite Crystal Structure
Maghemite also

displays

an inverse spinel

crystal

structure

and is

more

thermodynamically favored than magnetite.1,2,157,179,180 The properties of maghemite are
summarized in Table 2.2.1 It is important to note that maghemite is a ferrimagnet and has a
reddish-brown color. This color helps to first distinguish it from magnetite as the two inverse
spinel structures cannot be differentiated by powder XRD. The metastable maghemite, γ-Fe2O3,
cubic unit cell can be stoichemetrically written as (Fe3+)8[Fe3+5/61/6]16O32 where  indicates a
cation vacancy and the tetrahedral and octahedral positions are indicated by () and []
respectively.1,175,179,180 Maghemite can be obtained from heating magnetite in organic compounds
which causes the Fe2+ cations to become oxidized and result in some cation vacancies.175,180,181
At high temperatures, around 400°C depending on crystallinity and size the crystal structure of
maghemite can be converted to the more thermodynamically favored hematite crystal
structure.1,180

2.2.3 Hematite Crystal Structure
The red colored ferromagnetic iron oxide, hematite (α-Fe2O3), is nature’s most abundant
iron oxide.1,157,180,181 Figure 2.1 depicts hematite’s crystal structure which is similar to
rhombohedral corundum.1,2 Properties of hematite are summarized in Table 2.2.1 It has a
rhombohedrally centered hexagonal close packed crystal structure with

two-thirds of the

octahedral sites filled with Fe3+ ions.1,157,180 Hematite’s weak ferromagnetic state is due to the
magnetic spins being canted about 5° at temperatures between the Morin Temperature (TM) and
the Néel Temperature (TN).180 The ferromagnetism of hematite transitions to antiferromagnetism
below TM=260 K, and to paramagnetism above TN=950 K.180 Hematite is the most
33

thermodynamically favored structure of all the iron oxides and so under the correct conditions
magnetite, maghemite, etc. will all undergo oxidation and/or rearrangement to hematite.180,181

2.2.4 Wüstite Crystal Structure
Wüstite has a similar crystal structure to that of sodium chloride (NaCl) where the Fe2+
ions exist in octahedral sites of the oxygen anions closed packed FCC lattice.1 The crystal
structure is shown in Figure 2.1 and the summarized properties are listed in Table 2.2.1
Interestingly this crystal structure is only formed at temperatures exceeding 843K and the
stoichiometric formula is Fe1-xO because of 5-15% oxidation of Fe2+ ions to Fe3+ ions.175,182 The
amount of oxidation is dependent upon the temperature and partial pressure of oxygen.175,182
Below 843K this crystal structure will disproportionate to more thermodynamically favored
states of Fe metal and Fe3O4.1

2.3 Magnetic Properties of Iron Oxide
The magnetic, biodegradable and biocompatible properties of magnetite (Fe3O4) and
maghemite (γ-Fe2O3) make them the most desirable FeOx nanoparticles for magnetic
hyperthermia.9,25,28,183 Bulk FeOx particles are comprised of multi-domain particles, but as the
size is decreased into the nanometer region the FeOx nanoparticles will behave as single-domain
particles and eventually superparamagnets. For example it has been estimated that below 166 nm
diameter the particles will behave as single-domain particles.160 Likewise, magnetite has a
theoretical multi-domain to single-domain transition at approximately 80-100 nm.184,185 Further
reduction in diameter below approximately 20-30 nm the nanoparticles will start to display
superparamagnetism depending on the crystal structure.184 Multi-domain particles will not be
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discussed in detail as these are above the desirable size range for efficient magnetic
hyperthermia.
Superparamagnetism is an interesting phenomenon that arises in certain magnetic
materials when the size is sufficiently small. The non-interacting magnetic moments of
superparamagnets will respond to thermal fluctuations when the thermal energy (KBT) is greater
than the anisotropic energy.124,159,169 When the thermal energy exceeds the anisotropic energy the
individual magnetic moments will alter directions in response to thermal fluctuations.169 The
nanoparticles magnetic spin direction will eventually reach an equilibrium comparable to thermal
equilibrium.169 It should be noted that the size limit of superparamagnetism depends on the
material of interest and is termed the superparamagnetic limit.28,124 Superparamagnets exhibit
very large saturation magnetization and susceptibility values as a result of considering the
nanoparticles total magnetic moments (as high as 104-105 Bohr magnetons) instead of the
individual magnetic moment of a single atom.28,169 A representative hysteresis loop for a
superparamagnet is shown in Figure 2.2. The negligible coercivity and magnetic remanence can
be seen in the hysteresis curve in Figure 2.2. Coercivity refers to force required in terms of
magnetic field strength required to return the magnetization to zero.28,124,169 Magnetic remanence
defines the residual magnetism that remains after the magnetic field is removed.28,124,169 These
properties make FeOx superparamagnets ideal candidates for use in biological applications such
as magnetic hyperthermia as they will not exhibit magnetization after removal of the externally
applied magnetic field. Additionally, when the radiofrequency alternating current magnetic field
is applied the nanoparticles will rapidly respond to changes in the applied external magnetic
field. The negligible remnant magnetization is important to mention as this reduces the
probability of aggregation due to room temperature magnetism between nanoparticles.28,124 It
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would be advantageous to use metallic nanoparticles instead of oxide nanoparticles because of
their higher magnetization values, however they are generally toxic and not applicable in medical
applications.124

Figure 2.2. Representative hysteresis loop for single domain ferromagnetic (a) and
superparamagnetic (b) crystals plotted as magnetization (M) versus magnetic field (H). M S, Mr,
and Hc correspond to magnetization saturation, remnant magnetization, and coercive field
respectively. From 168

Single-domain particles in the nanorange, outside of the superparamagnetic size range,
are also useful in biomedical applications. Single-domain particles do not have domain walls and
therefore exhibit large magnetic coercivities. 124,159,169 Also, these single-domain particles have a
net magnetic spin direction.124,159,169 The lack of domain walls is due to the unfavorable
magnetostatic energy at such small volumes.159 External magnetostatic energy is allowed rather
than creating energetically unfavorable domain walls.124 Therefore, when the size of the particle
increases it will eventually become energetically favorable to create multiple walls resulting in
multi-domain particles.124,159 At these larger sizes several factors determine the size and shape of
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the domains; these include anisotropy, energy of exchange and magnetostatic interactions.159 It is
worth mentioning that the coercivity can be increased with differing shape anisotropy of singledomain particles.124
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Chapter 3: Benzyl Alcohol Synthesis of Iron Oxide
Nanoparticles

3.1 Experimental Section
3.1.1 Reagents, Materials, and Equipment
All chemicals and materials were used as received.

Tetramethylammonium hydroxide

(TMAOH) solution (Alfa Aesar, 25% w/w aq.), iron (III) acetylacetonate (Fe(acac)3) (Acros
Organics, 99+%), benzyl alcohol (Alfa Aesar, 99%), copper TEM grids (Ted Pella Inc., 200
mesh Formvar carbon type B), Fe inductively coupled plasma (ICP) standard (Alfa Aesar, Iron,
plasma standard solution, Specpure®, Fe 1000 µg/mL), hydrochloric acid solution (HCl)
(Electron Microscopy Sciences, 2%), potassium ferrocyanide aqueous solution (Prussian Blue)
(Electron Microscopy Sciences, 2%), two-neck 100 mL round bottom flask (Chemglass), coil
style reflux condenser (Chemglass), and acetone (Fisher Scientific, ACS grade)

3.1.2 Modified Seed Growth of Iron Oxide Nanoparticles
Synthesis of FeOx nanoparticles in benzyl alcohol was conducted under nitrogen flow or
open to air in a two-neck 100 mL round bottom flask (Chemglass) equipped with a coil style
reflux condenser (Chemglass). The volume of benzyl alcohol (Alfa Aesar, 99%) for all reactions
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was 20 mL. Iron (III) acetylacetonate (Fe(acac)3) (1, 2, 3, 4, or 6 g) (Acros Organics, 99+%) was
dissolved in benzyl alcohol with vigorous magnetic stirring and then immediately heated to
reflux or a set temperature. In the nitrogen syntheses, nitrogen was initially bubbled in the benzyl
alcohol and Fe(acac)3 for 30 minutes prior to heating. After the solution color changed from a
dark red to black, the reaction was carried out for 2 or 24 hours. At the end of the reaction, the
round bottom flask was removed from heat and stirred for 15 minutes while cooling. Acetone
(Fisher Scientific, ACS grade) was then used to precipitate and wash the FeOx nanoparticles
with magnetic extraction. This wash step was repeated 3-5 times with intermittent and brief
sonication (Cole Parmer, Ultrasonic Cleaner 8892) between wash steps. The nanoparticles were
then dried down to a powder with nitrogen flow.
The modified seed growth procedures followed the procedure as stated above, but after
the 24 hour reaction an additional amount of Fe(acac)3 (1, 2, 3, 4, or 6 g) was added as a dry
powder directly to the hot reaction. Reaction was then carried out for an additional 24 hours
before removal from heat. The nanoparticles were then precipitated, washed, magnetically
extracted, and dried as stated above.
The heating mantle (Thermoscientific, electrothermal heating mantle) used in initial
studies was replaced with a silicone oil bath (Alfa Aesar) with the temperature controlled by a
magnetic stirring hot plate (VWR, VMS-C7) equipped with a temperature control unit (VWR,
VT-5 S40) to better and more precisely control the temperature. The maximum heating ramp rate
was used for either the heating mantle or silicon oil bath and hotplate setup. The temperature and
color of the solution was observed and documented every 60 seconds in the initial heating to
reflux or set temperature. This was important to determine important temperature thresholds such
as when high levels of nanoparticles were forming indicated by a solution color change to black.
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3.2 Characterization Techniques
3.2.1 X-ray Diffraction (XRD)
Determining the crystal structure of a material by x-ray diffraction (XRD)
characterization is advantageous as it is a non-destructive technique.1,186-189 XRD utilizes x-rays
that will interact with the sample and form a diffraction pattern that is used in determining the
bulk crystalline structure.188,189 More specifically, electromagnetic radiation in the form of x-rays
are used to analyze the arrangement of the atoms within a crystal. Typically the wavelength (λ)
of the x-rays is approximately 0.1 nm as this wavelength is similar to the crystal’s interatomic
distance resulting in elastically scattered x-rays.1,188-190 The constructive and destructive
interference of scattered x-rays produces a diffraction pattern that is unique to different crystal
structures of crystalline materials.1,188,189 The atoms in a crystalline material are consistently
arranged resulting in the incident x-rays elastically scattering at specific angles and interatomic
lattice distances which causes constructive interference in specific directions.1,188 Bragg’s law
(Equation 5) states the distance between atomic planes of the lattice (dhkl) and the incident
angle (θ), specific to an incident x-ray wavelength (λ) spaced at integer multiples (n) of the path
difference where constructive interference of elastically scattered x-rays occur.1,188
𝑛𝜆 = 2𝑑ℎ𝑘𝑙 sin θ

(5)

The resultant XRD pattern’s peak positions are used to determine the lattice parameter, size, and
symmetry.188 Additionally, the peak intensities are useful in determining the organization of
atoms.188 The database of known crystallography data can be searched to find similar XRD
patterns and thus verify the crystal structure of a material of interest.188 Powder XRD is very
useful for the characterization of crystalline nanomaterials. This technique exploits the large
number of crystals present in a powder and allows the incident x-ray to interact with the material
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at numerous orientations or angles at the same time.189 A diffractometer investigates all possible
crystal orientations of the powder by analyzing the resultant diffraction cones of the powder
sample which are used to determine the diffraction pattern.189 It is important to note that
magnetite and maghemite crystal structures are indistinguishable by XRD.1
The crystallite size of nanoparticles can also be determined by analyzing the XRD line
broadening with the Scherrer formula (Equation 6).1 The Scherrer formula relates the corrected
peak width at an angle in the XRD measurement to the crystallite size, but will underestimate the
smaller crystallite sizes when multiple crystallites are present.1 In other words, the formula is
biased towards larger crystallite size when the mean crystallite size is determined from the
coherently scattering domain perpendicular to the hkl plane (MCLhkl).1 This is due to larger
crystallites more intensely scattering x-rays.
𝑀𝐶𝐿ℎ𝑘𝑙 =

𝐾𝜆
𝑏 cos 𝜃

(6)

The formula uses the shape factor (K), full width half maximum (FWHM) of the measured peak
(b), and wavelength of the x-ray (λ).1 The instrument error is accounted for by subtracting the
instrument width from the value of b.
A PANalytical X'Pert Pro Materials Research Diffractometer was used to obtain powder
XRD patterns. The sample was prepared by drying the material to a powder with nitrogen and
mild grinding to acquire a fine powder that was then transferred to a low background silicon
disk. The material was scanned at 20-80° 2θ using a Cu Kα x-ray source. X’Pert High Score
Plus software was used to analyze the pattern and calculate the crystallite size based on
diffraction peak broadening using the Scherrer formula. Several of the peaks in the XRD pattern
were used to calculate crystallite size and standard deviation.
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3.2.2 Dynamic Light Scattering (DLS)
Characterizing nanoparticles in solution provides useful information about hydrodynamic
size, size distribution, diffusion coefficients, and surface charge. Dynamic light scattering (DLS)
is a technique that can be used to rapidly assess these properties of a nanoparticle solution
without destroying the nanoparticles.191,192 DLS requires a stable colloidal suspension for best
results. DLS utilizes a monochromatic light source to probe the colloidal suspension and record
the time variation of the intensity of the light scattered by diffusing nanoparticles throughout a
solution.191,192 The intensity at two specific time points are correlated by the intensity
autocorrelation function.192 Since, the colloidal nanoparticles have kinetic energy the diffusion
coefficient can be measured.191 The intensity of scattered light at certain angles over time is
related to the diffusion of the nanoparticles throughout the solution.191 Therefore, it is important
to know the viscosity, refractive index, and temperature of the solution being analyzed to
effectively characterize nanoparticles using DLS. The hydrodynamic diameter and size
distribution in terms of polydispersity index (PDI) values are calculated from the measured
diffusion coefficients.192 In Equation 7, the magnitude of the scattering wave (q) is calculated
using the range of scattering angles (θDLS), wavelength of the incident light (λ), and refractive
index of the solution (n).191
4𝜋𝑛

𝑞=(

𝜆

𝜃𝐷𝐿𝑆

) 𝑠𝑖𝑛 (

2

)

(7)

The hydrodynamic radius (RH) is calculated using the Stokes-Einstein equation shown in
Equation 8 where the following abbreviations are used: T is the solution temperature, KB is
Boltzmann constant, and η is the medium viscosity.191,192 Thus it can be seen that the
hydrodynamic radius is directly related to the diffusion coefficient (Df).191
𝐷𝑓 =

𝐾𝐵 𝑇
6𝜋𝜂𝑅𝐻
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(8)

Next, the size distribution is calculated, in terms of the PDI, using the average decay rate ( ⟨Γ ⟩)
and the variance of the decay rate distribution (μ2) (Equation 9).191
μ

𝑃𝐷𝐼 = 〈Γ〉22

(9)

Absolute monodispersity is highly improbable, therefore the correlation function calculated ⟨Γ ⟩
and q values can be used to obtain an average hydrodynamic radius (Equation 10).191 Depending
on the instrument used, a weighted function can be used to calculate the summation of all
possible decay rates for each nanoparticle to determine a size distribution.192 The size distribution
determined using a weighted average should be considered “semi-quantitative” representation of
the size distribution and not an exact size distribution.192
𝑅𝐻 =

𝐾𝐵 𝑇
6𝜋𝜂〈Γ〉

𝑞2

(10)

The DLS data can be presented based on the number, volume, or intensity of
nanoparticles because the data is an average of the nanoparticles in solution. Larger nanoparticles
more intensely scatter light than smaller nanoparticles causing a bias towards larger
nanoparticles when the results are presented as intensity. For nanoparticles in solution, it is better
to analyze the data presented based on number or volume of nanoparticles rather than intensity as
this is a more indicative of the actual hydrodynamic diameter. Hydrodynamic diameter is also
useful in determining the surface functionalization thickness on nanoparticles. This is
accomplished by measuring the nanoparticles before and after surface functionalization and
subtracting the non-surface functionalized nanoparticles. However, the nanoparticle surface and
the surface functionalization ligands may interact with water differently and thus skew the
thickness measurement.
Zeta potential (ζ) determined by dynamic light scattering is often used to characterize the
electro-kinetic phenomenon of the stabilization offered by the double layer. This measurement
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utilizes electrophoresis, the movement of charged particles in response to an external applied
electric field, to calculate the mobility which is the velocity divided by the field intensity.73 When
spherical nanoparticles are sufficiently small (where κa is small enough that spherical
nanoparticles can be considered a point charge) and are measured at low electrolyte
concentrations and potentials the Hückel-Onsager equation (Equation 11) can be used to relate
electrophoretic mobility (μE) to zeta potential.73 The value of κa is a dimensionless term that
represents the thickness of the double layer and nanoparticle radius respectively.73 The viscosity
(η) of the solution and permittivity (ε) also play key roles in determining the electrophoretic
mobility. The permittivity is a combination of permittivity of free space (ε0) and relative
permittivity (εr) and is shown in Equation 12.

𝜇𝐸 =

𝜀𝜁

(11)

6𝜋𝜂

ε = 4πε0 ε𝑟

(12)

For particles too large to use the Hückel equation, a generalized equation (Equation 13) is used
instead to relate electrophoretic mobility and zeta potential.

𝜇𝐸 =

𝜀𝜁
6𝜋𝜂

𝑓(𝜅𝑎)

(13)

A Malvern Zetasizer Nano-ZS (Malvern Instruments, U.K.) was used to analyze the
hydrodynamic diameter, polydispersity index, and zeta potential of FeOx nanoparticles and
surface functionalized FeOx nanoparticles at ambient conditions. This instrument uses a He-Ne
laser (633 nm, max 4 mW) light source. For initial hydrodynamic diameter and PDI
measurements the FeOx nanoparticles at a concentration of 20 mg/mL were dispersed by
sonication for 180 minutes in a 0.25% tetramethylammonium hydroxide (TMAOH) solution.
Next, the solution was incubated at room temperature overnight and then a 1 mL 1:100 dilution
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with water was made for DLS analysis. These samples were transferred to a low volume
disposable cuvette and DLS was run 5 times with each run containing 11 measurements. For zeta
size measurements the surface functionalized nanoparticles were concentration and pH matched
and then loaded into a folded capillary zeta cell (Malvern Instruments, U.K.) prewashed with
ethanol and water to remove any contaminants.
Several concentrations of TMAOH solution were used to disperse the FeOx nanoparticles
to verify that the hydrodynamic diameter was not significantly altered by the TMAOH
concentration. Additionally, this is important because different concentrations of TMAOH may
be required to efficiently disperse different sizes of nanoparticles. FeOx nanoparticles produced
by a modified seed growth method were dispersed in several TMAOH concentrations and their
hydrodynamic size and PDI values were measured using DLS, the results are shown in Table
3.1.

Table 3.1. Initial hydrodynamic diameters and PDI values for various v/v % concentration of
TMAOH.

a

% TMAOH

Hydrodynamic
Diameter (nm)

PDIa

0.0625

25.99

0.38

0.125

29.96

0.363

0.25

23.61

0.39

0.5

26.12

0.41

Polydispersity Index (PDI) determined by DLS.
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3.2.3 Vibrating Sample Magnetometry (VSM)
The magnetic properties of FeOx nanoparticles can be determined from vibrating sample
magnetometry (VSM) determined hysteresis loop. A hysteresis loop is produced by loading a
sample of known mass into a magnetometer and measuring the magnetization as the external
magnetic field applied is increased from zero to a set magnetic field where the magnetization
reaches a maximum or becomes saturated.1,189 Once the magnetization saturation is reached for
the positive external magnetic field, the direction of external magnetic field is then reversed to
reach a “negative” magnetization saturation and reversed a second time to the original “positive”
magnetic field direction to complete the hysteresis loop.1,189 A representative hysteresis loop for
superparamagnetic and ferromagnetic materials determined by VSM is displayed in Figure 2.2.
Several important properties can be discerned from the shape, height, and width of the hysteresis
loop. These properties include magnetization saturation (Ms), initial magnetic susceptibility (X),
remnant magnetization (Mr), and coercivity (Hc). The magnetization saturation refers to the
magnetization where all of the magnetic moments are oriented in the same direction of the
externally applied magnetic field.1,189 Furthermore, the magnetization will not increase above the
magnetization saturation when the external magnetic field is increased.1,189 The initial linear
increase of the magnetization when the external magnetic field is increased from 0 is used to
calculate the initial magnetic susceptibility. When the external magnetic field (H) is returned to 0
any remaining magnetization is termed the remnant magnetization.1,189

The coercivity or

coercive field refers to the magnetic field required to force the magnetization back to 0 or
demagnetize the material after magnetization.1,189 It is important to note that for FeOx
nanoparticles the presence of ferrimagnetic magnetite and maghemite will overpower the
magnetism of other iron oxides detected.1
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VersaLab 3 Tesla Cryogen-Free Vibrating Sample Magnetometer (Quantum Design) was
used to probe the iron oxide materials and determine their magnetic properties. VSM sample
capsule (Quantum Design) were loaded with 5-15 mg of dry FeOx powder and scanned for an
offset of 35 mm. Next, the moment versus field measurements were recorded at a purged
pressure of <50 Torr, sweep rate of 150 Oersted/second (Oe/s), and scanned in 5 quadrants from
0 Oe to 15,000 Oe (Hmax) to -15,000 Oe (Hmin) without automatic centering. The hysteresis
curve was examined to determine the magnetization saturation and was mass corrected using
thermogravimetric analysis (TGA) in units of emu/g.

3.2.4 Thermal Gravimetric Analysis (TGA)
Thermal gravimetric analysis (TGA) characterization is beneficial in determining the
weight loss of a material as the temperature is increased.1 This technique can be used to correct
the mass of impurities within a sample such as water, organic compounds, excess chemicals,
surface functionalities, etc. in dry FeOx nanoparticles. Sample preparation for TGA involves first
calibrating the tare weight of the TGA pan with a highly sensitive balance and then loading a
sample (laden weight) on to the TGA pan and recording the sample weight as the temperature is
increased at rates of 2-10 °C/min.1 The amount of mass lost is expressed as mass percent loss and
can be used to correct the mass of sample used in techniques such as VSM where the mass of the
magnetic material is critical to determine magnetization in terms of emu/g.
A Q5000 TGA instrument (TA Instruments) was used to perform TGA and mass correct
samples of FeOx nanoparticles. The platinum TGA pans were loaded with 5-50 mg of dry FeOx
nanoparticles, under a nitrogen flow rate of 25 mL/min, and the temperature was ramped at 10
°C/min from room temperature to 150°C and held isothermal for 15 minutes. This was followed
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by additional temperature increase to 400°C at 10 °C/min and held isothermal for 60 minutes.

3.2.5 Transmission Electron Microscopy (TEM)
Direct imaging of nanoparticles with atomic scale resolution can be performed with
transmission electron microscopy (TEM) which uses a beam of electrons to acquire the
image.192,193 TEM uses an electron beam gun to produce a beam of electrons that will probe a
sample.193 The transmitted electron beam is dependent upon the amount of diffraction, the atomic
number of the material, and phase contrast.193 To enhance the contrast and gain higher resolution
images the sample stage should have different properties than the sample being analyzed.192,193
A Zeiss LIBRA® 120 PLUS TEM was used to acquire bright field TEM images of the
FeOx nanoparticles. Sample preparation was done by drying a drop of dilute FeOx nanoparticles
(20 mg/mL) in 0.25% TMAOH solution on copper TEM grids (Ted Pella Inc., 200 mesh
Formvar carbon type B). For CMPVA-FeOx the cleanup, desalting, and centrifuge filters were
all done as described above prior to TEM sample preparation. Image J software was used to
analyze the TEM images and calculate the nanoparticle size.

3.2.6 Radiofrequency Heating
FeOx nanoparticle heating characteristics were investigated with a 1.2-2.4 kW EasyHeat
induction heating system with a coil designed at a set point of 200 Ampere (A) to run at 1222
watt (W) and frequency (f) of 269 kHz to produce an alternating magnetic field with a magnetic
field strength (H) of 37.4 kA/m at 175.4 A. Other magnetic field strengths were used for small
time length investigations of heating nanoparticles in cells. Ampere’s law can be used to
calculate the magnetic field strength (H) (Equation 14) produced by a coil with length (L), and
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number of turns (N), in a magnetic field (B), current (I) and using the permeability of free
space(µo.).194
BL = µo NIo

(14)

The magnetic field strength is related to the magnetic field as shown in Equation 15.189
By substituting Equation 14 into Equation 15 we can approximate the magnetic field strength
produced inside the coil (Equation 16). The coil used in these studies had 8 turns (N=8) and a
length of 0.0375 m (L=0.0375 m) which corresponds to H= 37.4 kA/m at 175.4 A.
B = µo H
H=

N

I
𝐿 o

(15)
(16)

An OpSens fiber optic temperature sensor measured the in situ nanoparticle solution
temperature when RF AC magnetic fields were applied. SoftSens software was used to record
temperature every 1.4 seconds. The RF heating of 3 mL of 0.25% TMAOH aqueous FeOx
nanoparticle (20 mg/mL) solution was used to compare the RF heating rates of samples at 175.4
A and H=37.4 kA/m over 600 seconds. All solutions were corrected for potential convective
heating by measuring a control 3 mL sample of water under identical conditions. The initial
linear increase of temperature per unit time (dT/dt) of the water control (0.549°C/min) was
subtracted from the initial linear increase of all TMAOH nanoparticle samples tested.
The RF heating data collected must be corrected based on iron concentration to more
accurately compare samples. The iron concentration was determined using a Prussian blue assay.
A serial dilution of Fe inductively coupled plasma (ICP) standard (Alfa Aesar, Iron, plasma
standard solution, Specpure®, Fe 1000 µg/mL) was used to build a standard curve as measured
by UV-Vis absorbance assay (λ=685 nm) using a Nanoquant plate reader (Tecan). As prepared
RF heating FeOx TMAOH nanoparticle solutions were diluted 1:100 and 2.14 μL of 70% nitric
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acid (BDH Chemicals) was added to 30 μL of the diluted sample. This sample was heated at
90°C for 1 hour. The dissolved FeOx sample (10 μL) was added to 1 μL of 20% potassium
ferrocyanide (Prussian blue) aqueous solution (Electron Microscopy Sciences, 20%) and 0.5 μL
of 20% HCl solution (Electron Microscopy Sciences, 20%). After 15 minutes of incubation at
room temperature the UV-Vis absorbance was measured at λ=685 nm.

3.3 Results and Discussions
3.3.1 Investigation of Synthesis Parameters
Magnetic fluid hyperthermia requires a specific crystallite size with minimal size
distribution to obtain the most efficient nanoparticle heating effect. To improve and optimize the
benzyl alcohol synthesis of FeOx nanoparticles several reaction parameters were investigated.
The parameters of interest are concentration, temperature, and addition of extra iron precursor
(modified seed growth). The reaction concentration was modulated by concentration of iron
precursor in a constant 20 mL volume of benzyl alcohol. The reaction parameters and
nanoparticle properties were analyzed using JMP software’s effect screening to ascertain trends
of reaction parameters upon the resultant nanoparticle properties.
A naming system was used to track of the large number of reaction conditions performed.
The first and second additions of Fe(acac)3 are denoted as “A” and “B” and separated with an
underscore. The gram amount of Fe(acac)3 added to the 20 mL of benzyl alcohol are listed
immediately following A and B. The length of time, in hours, the reaction was carried out is
listed as “-X” for both A and B additions. Temperature is listed in parenthesis for reactions
where precise control of temperature was investigated. When temperature is not listed the
reaction was heated to reflux using a heating mantle that was shown to have similar temperatures
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and rate of reflux. For example a reaction carried out in 20 mL of benzyl alcohol with 2 g of
Fe(acac)3 added initially and heated at 175°C for 24 hours and followed by an addition of 2 g of
Fe(acac)3 and heated at 175°C for an additional 24 hours is named A2-24(175)_B2-24(175). For
reactions that were carried out under nitrogen flow the reaction name begins with a “N2”. A
reaction of 20 mL of benzyl alcohol with 2g of Fe(acac)3 added initially and reacted at 205°C for
24 hours is named N2-A2-24(205).
Characterization of nanoparticles was done using XRD, DLS, VSM corrected by TGA,
and RF heating measurements to identify their crystallite size, hydrodynamic diameter and PDI
values, saturation magnetization, and RF heating capabilities for internal comparisons.
Nanoparticles were first characterized by XRD to verify the nanoparticles are indeed FeOx and
to calculate the crystallite size. The XRD patterns for FeOx nanoparticles produced by reactions
N2-A2-24, A2-24, and A2-24_B2-24 are displayed in Figure 3.1. It is not necessary to show all
of the XRD patterns as they all indicate FeOx. It is important to reiterate that XRD cannot
distinguish between magnetite and maghemite.
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Figure 3.1. XRD peaks of samples: N2-A2-24 (blue), A2-24 (red), and A2-24_B2-24 (green). An
offset of 100 count increments was used to clearly show each reactions pattern.

Next, it is important to examine the hydrodynamic diameter and determine the size distribution
in terms of PDI values with DLS. These measurements are very useful in determining how the
reaction conditions affected the resultant nanoparticle. Figure 3.2 and Table 3.2 respectively
show the DLS determined hydrodynamic diameter and peak data for reaction A4-24(195)_B424(195). Figure 3.2 displays the DLS pattern based on percent intensity and percent volume to
show that intensity results are biased towards larger sizes. It is important to note that the results
based on intensity are biased towards larger sized nanoparticles as they will more intensely
scatter the light. Therefore, the results based on volume were used when reporting the
hydrodynamic diameter as it more accurately represents the total population of nanoparticles.
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A

B

Figure 3.2. The DLS hydrodynamic size measurements displayed in terms of percent intensity
(A) and percent volume (B) for reaction A2-24(195)_B2-24(195). The Z-average hydrodynamic
diameter was equal to 47.75 nm and the PDI was equal to 0.219.

Table 3.2. The DLS determine hydrodynamic size, percent composition, and width of each peak
for the size distribution by percent intensity and size distribution by percent volume for reaction
A2-24(195)_B2-24(195).

Peak 1
Peak 2
Peak 3

Peak 1
Peak 2
Peak 3

Size Distribution by Percent Intensity
Hydrodynamic Diameter (nm)
% Intensity
47.08
86.8
313.3
13.2
0
0
Size Distribution by Percent Volume
Hydrodynamic Diameter (nm)
% Volume
37.52
99.3
328.1
0.7
0
0

Width (nm)
14.31
95.5
0
Width (nm)
11.26
109.5
0

The magnetic properties of the nanoparticles were next investigated with VSM and weight
corrected using TGA. The hysteresis curve from VSM and mass percent loss over time from
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TGA is shown in Figure 3.3 and Figure 3.4 respectively. The TGA determined weight loss was
between 94.6% and 85.9% for all samples. The VSM determined MS values were between 48.54
and 57.69 emu/g for samples synthesized under nitrogen and were between 55.5 and 84.57
emu/g for samples synthesized under atmospheric conditions.
100
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Figure 3.3. VSM measured hysteresis loop of TGA mass corrected (10.901 mg * 0.945164 =
10.303 mg) A2-24(195)_B2-24(195) nanoparticles.
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Figure 3.4. TGA of A2-24(195)_B2-24(195) nanoparticles revealing a final mass percent of
0.945164 at 400°C.

RF heating measurements were calculated from fiber optic temperature collected data for
concentration matched TMAOH FeOx nanoparticle solutions. Sample heating curves for
deionized water, N2-A2-24, A2-24, A2-24_B2-24, and A2-24(195)_B2-24(195) reactions are
shown in Figure 3.5. Prussian blue assay was used to normalize the concentrations of iron for
internal comparisons. Altering the synthetic parameters we were able to obtain RF heating
measurement between 0.01 and 5.55 [°C/min]/mg.
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Figure 3.5. RF heating curves of water and FeOx samples dispersed in 0.25% TMAOH. Prussian
Blue assay determined the iron concentrations for deionized water (blue), A2-24 under nitrogen
(green), A2-24 (red), A2-24_B2-24 (purple), and A2-24(195)_B2-24(195) (black) to be 0, 14.48,
15.40, 14.00, and 15.36 mg/mL respectively. Temperature was recorded every 1.4 seconds in an
alternating magnetic field set at 175.4 A for 600 seconds or until reaching approximately 70°C.

3.3.2 Effect of Reaction Environment
Initial benzyl alcohol synthesis reactions were carried out under nitrogen flow. Thermal
decomposition of Fe(acac)3 or iron carboxylate salts are most commonly reported in literature as
using nitrogen or argon flow.51,131,143,144,195-198 The reaction N2-A2-24 produced nanoparticles
with 6.5 ± 1.2 nm crystallite sizes based on the Scherrer formula for calculating crystallite sizes
from line broadening of peaks in the XRD pattern shown in Figure 3.1. Characterization with
VSM and corrected by TGA revealed the Ms= 53.39 emu/g. DLS revealed a hydrodynamic
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diameter of 23.23 nm and a PDI of 0.351. This crystallite size is well below the desired 15-16
nm crystallite of ideal FeOx nanoparticles for RF induced hyperthermia. It should be noted that
there is not a clear relationship between crystallite and hydrodynamic sizes, but the primary goal
was to produce nanoparticles with the ideal crystallite size and low size distribution for
maximum RF heating. Benzyl alcohol can be oxidized to benzaldehyde and further oxidized to
benzoic acid at temperatures below the thermal decomposition temperatures as seen in glycol
syntheses of metal and metal oxide nanoparticles.53,120-122,199 Based on this information our
hypothesis was that by running the reaction open to air we could facilitate the production of
larger crystallite sizes. To investigate formation of nanoparticles at lower temperatures based on
the added oxidation mechanism, the reactions were monitored every minute while the reaction
was heated to its final temperature. This revealed that reactions open to air had reflux drips
starting at approximately 178°C and increasing as the temperature approached 205°C indicating
the formation of benzaldehyde (boiling point = 178.1°C).200 The oxidation of benzyl alcohol to
benzaldehyde suggests that a reduction of Fe(acac)3 may also be occurring at these temperatures.
The addition of a second mechanism of formation of monomers and nuclei starting at
temperatures below thermal decomposition could allow for better separation of nucleation and
growth phases leading to larger crystallite sizes.37 Additionally, the formation of monomers and
nuclei occurring at the lower temperatures due to an oxidation reduction mechanism occur when
the temperature ramp rate is still high which would also lead to larger separation of nucleation
and growth leading to larger crystallite sizes.37 Carrying out the reaction open to air (A2-24)
resulted in FeOx nanoparticles with 8.33 ± 0.393 nm crystallite sizes (Figure 3.1), Ms of 70.839
emu/g, hydrodynamic diameter of 13.64 and PDI of 0.703. This reaction is crucial as it
demonstrates the ability to produce larger crystallite sizes and more crystalline nanoparticles by
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only changing the reaction environment. The PDI value suggests a broad size distribution which
may be narrowed by altering the other reaction parameters. In an attempt to elucidate why larger
crystallites were formed the reaction color changes and corresponding temperatures were
recorded every minute as the temperature was initially increased. The thermal decomposition of
Fe(acac)3 depends on the solvent it is dissolved in, but is generally reported to occur around
170-180°C.201 As seen in Figure 3.6 the color change from dark red to black indicating
nanoparticle formation occurred at lower temperatures and earlier in the reaction when the
reaction was carried out under air (Figure 3.6B). The solution for reaction under nitrogen
remained dark red until 31 minutes in to the reaction at a temperature of 174.4°C and turned
completely black at 40 minutes. The solution for reaction open to air, however first started to
change colors after only 20 minutes at 169.4°C and became completely black after 30 minutes of
reaction. This corroborates the hypothesis that the presence of oxygen allows for the generation
of monomers and nuclei at lower temperatures and earlier in the reaction due to a possible
oxidation reduction mechanism.
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Figure 3.6. Heating curves for reaction of Fe(acac)3 in Benzyl Alcohol heated to 175°C under
nitrogen (A), and air (B). Heating curves for reaction containing FeCl2, NaOH, and Benzyl
Alcohol heated to 150°C under nitrogen flow (C), and air (D). For reactions under nitrogen the
initial and final color changes are indicated with a gold and black square. Likewise, the color
changes are indicated with a gold and black diamond for reactions open to air.

To verify that benzyl alcohol is reducing the iron precursor, Fe(acac)3 was replaced with glycol
reagents, FeCl2 and sodium hydroxide (NaOH).53,120,122,199 XRD confirmed that these reactions
carried out under nitrogen and air still produced FeOx (Figure 3.7) and further indicated that an
additional mechanism is responsible for the formation of FeOx nanoparticles in benzyl alcohol
since thermal decomposition did not occur in the FeCl2, NaOH, and benzyl alcohol reaction.
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Figure 3.7. XRD peak patterns for benzyl alcohol, FeCl2, and NaOH under nitrogen flow (blue),
and open to air (red) offset by 5000 intensity counts. NaCl was indicated by peaks at 32.5 and
46.2 angles. It was determined that the reaction under nitrogen and open to air contained 71%
and 77% NaCl respectively.

The reaction color and temperatures were also recorded for the FeCl2, NaOH, and benzyl alcohol
reactions carried out open to air and under nitrogen flow (Figure 3.6C and D). Reaction under
nitrogen flow first changed colors at 99.3°C and was completely black at 132.7°C, while the
reaction open to air had an initial color change at 90.8°C and was completely black at 127.7°C.
This further corroborates the hypothesis that the benzyl alcohol synthesis open to air produces
larger crystallite sizes by facilitating earlier generation of monomers and nuclei and thus a better
separation of nucleation and growth. Based on this mechanistic insight, the remaining synthesis
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reactions were primarily run open to air and reaction parameters were changed to gain larger
crystallite sizes and smaller size distributions.

3.3.3 Effect of Reaction Temperature
Increasing temperature of the reaction was hypothesized to further increase the crystallite
size based on recent reports that higher temperatures were required for sustained crystallite
growth.121,202 The heating mantle was replaced with a silicon oil bath to more efficiently control
the temperature. Additionally, the reflux of the benzyl alcohol solution was shown to start as low
as 178°C as benzaldehyde was most likely formed. Therefore, using the heating mantle to reach
reflux temperatures in air was most likely occurring at approximately 178°C and not at the
boiling point of benzyl alcohol (205°C).200 Increasing the temperature to 205°C was
hypothesized to further increase the crystallite size. Nitrogen reactions with varying reaction
temperatures were used as comparisons to reactions open to air to further elucidate the reaction
mechanisms occurring and to better determine other effects such as magnetization saturation
changes.
Nitrogen synthesis reaction temperatures were varied between 150-205°C and the
resultant nanoparticle properties are shown in Table 3.3. In addition to the reaction changing
color at later time points and at higher temperatures when compared to reactions open to air, the
nitrogen reaction did not contain reflux drips at 205°C. The absence of reflux drips suggests that
the oxidation and reduction of benzyl alcohol and Fe(acac)3 is not occurring when reacted under
nitrogen flow. Furthermore, this confirms that the primary mechanism of generation of
monomers and nuclei is due to thermal decomposition. Without reduction of Fe3+ to Fe2+ the
magnetite crystal structure is unlikely to form. This is validated by the lower magnetization
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saturation values of 48.54-57.69 emu/g exhibited by nanoparticles produced under nitrogen flow.
This result is in accordance with the lower magnetization saturation values of maghemite as
compared to magnetite in bulk and nanomaterials.203

Table 3.3. Effect of various temperatures in reactions under nitrogen flow on nanoparticle
properties.
Reaction
N2-A2-24
N2-A2-24(150)
N2-A2-24(175)
N2-A2-24(195)
N2-A2-24(205)

Magnetization
(emu/g)a
53.39
48.54*
57.69
57.09*
57.56*

RF Heating
([oC/min]/mg)b

Crystallite
size (nm)

Hydrodynamic
Diameter (nm)

PDIc

0.01
0.04
0.02
0.05

6.47 ± 1.17
5.65 ± 0.76
6.06 ± 0.52
6.3 ± 0.89
11.3 ± 0.73

23.23
13.02
11.51

0.351
0.372
0.306

38.48

0.152

a

mass unit indicates grams of FeOx nanoparticles corrected by TGA.
mass unit indicates milligrams of Fe determined by Prussian blue assay.
c
Polydispersity Index (PDI) determined by DLS.
*VSM data was corrected using 0.88 percent weight of sample
b

For the nitrogen syntheses the crystallite size only changed when the reaction reached 205°C,
however the magnetization was only 57.56 emu/g suggesting that mainly maghemite was
present. While larger nanoparticle sizes were obtainable by the nitrogen synthesis the
nanoparticles most likely consisted of the less magnetic maghemite crystal structure.
Higher magnetization saturation values and crystallite sizes were obtainable at lower
temperatures with the reactions open to air, as seen in Table 3.4. The larger magnetization
saturation values at lower temperatures strongly suggests the presence of magnetite and offers
additional evidence that a redox mechanism plays a significant role in the production of FeOx
nanoparticles. The size distribution as indicated by PDI was much lower for reactions at 205°C.
The trend of decreasing PDI as temperature increased was also seen for reactions under nitrogen
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flow; however the larger magnetization saturation values and crystallite sizes make the FeOx
nanoparticles synthesized open to air much more advantageous.

Table 3.4. Effect of various temperatures in reactions open to air on nanoparticle properties.
Reaction

Magnetization
(emu/g)a

RF Heating
([oC/min]/mg)b

Crystallite
size (nm)

A2-24
70.839
0.17
8.8 ± 0.61
A2-24(125)
A2-24(150)
55.50
0.06
6.2
A2-24(175)
70.91
0.14
8.9 ±1.39
A2-24(195)
74.32
0.18
8.1 ± 0.59
A2-24(205)
73.36*
2.76
14.1 ± 0.80
a
mass unit indicates grams of FeOx nanoparticles corrected by TGA.
b
mass unit indicates milligrams of Fe determined by Prussian blue assay.
c
Polydispersity Index (PDI) determined by DLS.
*VSM data was corrected using 0.925 percent weight of sample

Hydrodynamic
Diameter (nm)

PDIc

13.64
13.58
12.45
13.3
24.53

0.703
0.589
0.61
0.65
0.275

It should be noted that reaction A2-24 was most comparable to reactions A2-24(175) and A224(195) confirming that the heating mantle had inefficient control of temperature that may have
fluctuated between these temperatures. The larger PDI values of these reactions were attributed
to an overlap between thermal decomposition and redox of benzyl alcohol and Fe(acac)3.
Comparing the RF heating capabilities of FeOx nanoparticles produced by reactions under
nitrogen flow or open to air reveals drastically higher heating capabilities. This is attributed to
the larger crystallite sizes; however the RF heating may be limited by the lower magnetization
saturation values for nitrogen reactions. More specifically, the reaction open to air with
MS=70.91 emu/g had an RF heating rate almost three times as high as the largest crystallite FeOx
achieved with nitrogen reactions. The larger crystallite sizes for reactions open to air is explained
by the LaMer growth model, where reduction of Fe3+ to Fe2+ produces the first nuclei at lower
temperatures and then the reaction exhibits a large influx of new monomers as the reaction
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reaches higher temperatures where both thermal decomposition and redox reactions occur. This
large influx of monomers leads to a burst nucleation even and is quickly depleted to begin
growth on the nuclei. Since there are two “stages” where monomers and nuclei are formed there
is also a higher resultant size distribution, but this also leads to larger crystallite sizes. At 205°C
the temperature ramp rate is very high and passes through the beginning of the redox and thermal
decomposition mechanisms creating a large number of monomers which in turn causes a quicker
burst nucleation leading to smaller size distributions.
The effect of temperature on nanoparticle characteristics revealed several interesting
conclusions. Reactions open to air produce larger crystallite sizes at lower temperatures due to
the added redox mechanisms and lower temperature refluxing due to the formation of
benzaldehyde. Through modulation of the temperature the added redox mechanism of reactions
open to air can be taken exploited to more efficiently tune the crystallite size and size distribution
of nanoparticles. This is possible due to the better separation of nucleation and growth and burst
nucleation process that occurs in the reactions open to air.

3.3.4 Effect of Reaction Concentration
According to LaMer growth methodology the iron precursor concentration can also be
modulated to increase the production of monomers and further shorten the burst nucleation event
leading to larger crystallite sizes. Increasing reactant precursor concentrations has been reported
to increase the overall particle size.204 The LaMer growth model (Figure 3.8) is useful in
interpreting results of changing reaction parameters. The production of nanoparticles can be split
into three main sections including generation of monomers, self-nucleation, and growth. In the
benzyl alcohol reaction the monomers are generated from thermal decomposition and reduction
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of Fe(acac)3. When the concentration of monomers is sufficiently high, termed the concentration
minimum for nucleation (Cminnu), self-nucleation will begin. In the self-nucleation phase the
concentration of monomers will be rapidly depleted and will switch to the growth phase when
the concentration is decreased below the Cminnu.3,205 Theoretically the concentration of monomers
can approach but never reach the critical limiting supersaturation or the concentration maximum
of nucleation (Cmaxnu). This is because as the critical limiting supersaturation is approached the
rate of nucleation exponentially increases and will overcome even the largest rate of generation
of monomers.3,205,206 The rate of generation of monomers controls the maximum monomer
concentration that can be reached or how quickly the nucleation step will occur, since the
nucleation rate increases exponentially until it becomes effectively

Figure 3.8. LaMer growth model scheme, displaying the generation of monomers, selfnucleation, and growth phases. Adapted from 3.
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infinite at the critical limiting supersaturation concentration.3 The ramification of this is that
faster generation of monomers will lead to quicker “burst” nucleation events which will decrease
the size distribution of nuclei leading into the growth phase.3,205 The growth phase is controlled
by either diffusion of monomers to the surface of nuclei or reaction rate of monomers onto the
surface of nuclei depending on which process is rate limiting.207 Growth will continue until the
monomer concentration is depleted to the solubility concentration of monomers (CS).3,205 At this
point Ostwald ripening will occur where smaller nanoparticles are dissolved to grow on the
energetically favored larger nanoparticles.208,209 If the nanoparticles are monodisperse when
Ostwald ripening begins more polydisperse nanoparticles will be created. Alternatively if the
nanoparticles are polydisperse they will become more monodisperse by Ostwald ripening.
The effect of reaction concentration was investigated to further increase the crystallite
size of the FeOx nanoparticles. To investigate this parameter the Fe(acac)3 was increased from 2
grams to 4 and 6 grams in reactions (A2-24, A4-24 A6-24). However, this resulted in no
significant change in crystallite size for these reactions (Table 3.5).
Table 3.5. Effect of various concentrations of Fe(acac)3 on nanoparticle properties.
Reaction

Magnetization
(emu/g)a

RF Heating
([oC/min]/mg)b

Crystallite
size (nm)

Hydrodynamic
Diameter (nm)

PDIc

A2-24
A4-24
A6-24
A2-24(205)
A4-24(205)
A6-24(205)

70.84
68.99
68.25
73.36*
73.07*
69.93*

0.17
0.13
0.22
2.76
1.86
0.85

8.8 ± 0.61
8.3
7.9
14.1 ± 0.80
11.7 ± 0.73
8.2 ± 1.56

13.64
14.68
16.5
24.53
22.85
23.9

0.703
0.2
0.164
0.275
0.269
0.512

a

mass unit indicates grams of FeOx nanoparticles corrected by TGA.
mass unit indicates milligrams of Fe determined by Prussian blue assay.
c
Polydispersity Index (PDI) determined by DLS.
*VSM data was corrected using 0.925 percent weight of sample
b
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Interestingly, the hydrodynamic diameter increased (13.64 nm, 14.68 nm, and 16.5 nm) and the
size distribution decreased (PDI= 0.703, 0.2, 0.164) when the reactant concentration was
increased in agreement with the reported LaMer growth model.3,205,206 More specifically the
hydrodynamic size increased due to the growth phase switching from being limited by diffusion
to limited by reaction. When growth is limited by diffusion the monomers will have sufficient
time to react in the proper orientation which results in crystalline growth. However, when growth
is limited by reaction the monomers will not always orient in a way suitable for crystalline
growth, thus more amorphous growth will occur. With more amorphous growth the nanoparticles
will have larger nanoparticle sizes and smaller crystallite sizes. At these temperatures the
increase of concentration increases the generation of monomers resulting in more monodisperse
nanoparticles.
The same set of reactions was also investigated at 205°C to determine if the same trend
occurred when more precise temperature control was present. The higher temperature greatly
increases the generation of monomers leading to larger crystallite sizes as seen in the previous
section. Increased temperatures will also increase the rate of nucleation and the
diffusion/reaction growth mechanisms. Figure 3.9 depicts the theorized effect of increasing both
temperature and concentration on the LaMer growth model. It was thought that the combined
increase in temperature and concentration would result in even faster generation of monomers.
This is represented by a steeper slope in the generation of monomers phase. Interestingly,
increased concentration of Fe(acac)3 at 205°C resulted in a decreasing crystallite size (14.1 ±
0.80 nm to 11.7 ± 0.73 nm to 8.2 ± 1.56 nm) while the hydrodynamic diameter was constant. The
PDI was only increased when the concentration was increased to 6 g and is consistent with
growth limited by reaction leading to larger size distributions.207
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Figure 3.9. Proposed effect of increasing temperature and concentrations of precursor on LaMer
growth model (blue). The red curve represents the proposed effects of increasing either
temperature or concentration. The green curve represents the proposed effect of increasing both
temperature and concentration.

Based on the results of A6-24(205) an alternative explanation using LaMer growth
method was rationalized. In this reaction, the generation of monomers may have reached a limit
where further increases in temperature or precursor concentrations may not increase the rate of
monomer generation. Instead the nucleation event could possibly be prolonged if the rate of
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monomer generation has indeed reached a maximum. This theorized effect is shown in Figure
3.10 (green curve).

Figure 3.10. Proposed effect of increasing temperature and concentrations of precursor on
LaMer growth model (blue). The red curve represents the proposed effects of increasing both
temperature and concentration. The green curve represents the proposed effect of increasing both
temperature and concentration when a maximum generation of monomers has been reached
resulting in prolonged nucleation.

Prolonging the nucleation event would lead to broader size distributions, more nuclei, and
smaller particle sizes. More nuclei with a large concentration of monomers would lead to
69

increased amorphous growth due to growth limited by reaction. This theory is in accordance with
the results observed for A6-24(205) which has approximately the same hydrodynamic size (23.9
nm), but a much smaller crystallite size (8.2 ± 1.56 nm) and larger size distribution (PDI=
0.512).
Based on these results of increasing concentration of Fe(acac)3 and temperature, the
optimum starting amount of Fe(acac)3 for achieving the largest crystallite sizes is 2 g. The
combined increase in reaction temperature and iron precursor for benzyl alcohol synthesis can be
rationalized by the LaMer growth model where increasing temperature and/or precursor
concentration increases the rate of monomer generation. The largest crystallite size of 14.1 ±
0.80 was achieved in reaction A2-24(205). Since a potential limit was reached for rate of
monomer generation at these conditions a modified seed growth method was used in attempts to
further increase the crystallite size and decrease size distribution for maximum RF heating
potential.

3.3.5 Effect of Parameters: Modified Seed Growth
Seed growth methods have been used to further increase the size of nanoparticles, but
often require cooling or aging steps followed by washing and drying the nanoparticles to produce
a powder often referred to as “seeds”.129,210,211 Next, the seeds are re-dispersed in the solvent
with additional iron precursor prior to carrying out the reaction. A modified seed growth method
was developed in attempts to increase the crystallite size and decrease the size distribution to
produce optimum nanoparticle properties for RF hyperthermia. Instead of following traditional
seed growth methods the nanoparticle “seeds” are not washed and dried to a powder, but are kept
at elevated reaction temperatures and additional iron precursor (second addition) is added as a
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dry powder. This was done to keep the reaction at suitable temperatures for high rates of
monomer generation that will then nucleate and grow on the seeds.
The A2-24 reaction was used as the first half of the modified seed reaction to discern how
different temperatures and concentrations of second additions affect the resultant nanoparticle
properties. These reactions are listed in Table 3.6.

Table 3.6. Effect of various temperatures in the modified seed growth on nanoparticle properties.

Reaction
A2-24
A2-24(175)
A2-24(195)
A2-24(205)
A2-24_B2-24
A2-24_B2[cool addition]-24
A2-24(175)_B2-24(175)
A2-24(185)_B2-24(185)
A2-24(195)_B2-24(195)
A2-24(205)_B2-24(205)
a

Magnetization
(emu/g)a

RF Heating
([oC/min]/mg)b

Crystallite
size (nm)

Hydrodynamic
Diameter (nm)

PDIc

70.839
70.91
74.32
73.36
75.7
72.488
77.89
77.249
78.202
77.77

0.170
0.14
0.18
2.76
2.536
0.670
1.004
1.068
4.041
5.55

8.8 ± 0.61
8.9 ± 1.39
8.1 ± 0.59
14.1 ± 0.80
14.4 ± 2.42
9.5 ± 0.71
11.6 ± 1.01
11.2 ± 0.94
14.9 ± 0.74
19.5 ± 1.06

13.64
12.45
13.3
24.53
28.93
20.76
24.53
23.11
37.52
44.63

0.703
0.61
0.65
0.275
0.148
0.252
0.404
0.395
0.219
0.265

mass unit indicates grams of FeOx nanoparticles corrected by TGA.

b

mass unit indicates milligrams of Fe determined by Prussian blue assay.
Polydispersity Index (PDI) determined by DLS.
*VSM data was corrected using 0.925 percent weight of sample
c

The modified seed growth using the heating mantle (A2-24 and A2-24_B2-24) resulted in
larger crystallite size (8.8 ± 0.61 vs. 14.4 ± 2.42) and drastically reduced PDI values (0.703 vs.
0.148). Transmission electron microscopy (TEM) was used to directly image the morphology of
the FeOx nanoparticles (Figure 3.11).
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Figure 3.11. TEM bright field image A2-24_B2-24 nanoparticles dispersed with TMAOH.
Image J software determined an average particle diameter of 15.28 ± 2.21 nm.

The “hot” addition of iron precursor at the second addition step provides a burst nucleation event
producing nuclei that will be dissolved to grow on the thermodynamically favored larger seed
nanoparticles. This is also in accordance with Ostwald ripening resulting in a decrease in size
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distribution.208,209 Reaction A2-24_B2[cool addition]-24 was used to corroborate the “hot” addition
effect of lower size distribution by reducing the temperature to 30°C prior to the second addition
of Fe(acac)3. Indeed, the hot addition facilitates larger crystallite growth (14.4 ± 2.42 vs. 9.5 ±
0.71 nm) with lower size distribution (PDI= 0.148 vs. 0.252). More specifically, the hot addition
facilitates a faster generation rate of monomers.
Temperature was shown to play a significant role in increasing the crystallite size and
decreasing polydispersity for reactions without a seed growth step. Temperature was therefore
investigated to determine the effect in the modified seed growth. Reactions A2-24(175)_B224(175), A2-24(185)_B2-24(185), A2-24(195)_B2-24(195), and A2-24(205)_B2-24(205) were
carried out and their characteristics are shown in Table 3.6. A2-24(175)_B2-24(175) reaction
was used as the starting comparison point for temperature investigation. The crystallite size
changed from 11.6 ± 1.01 nm in reaction A2-24(175)_B2-24(175) to 11.2 ± 0.94 at 185°C, 14.9
± 0.74 at 195°C and 19.5 ± 1.06 at 205°C. The temperature at 185°C did not change the
crystallite size which is thought to be explained by insufficient increase in temperature to cause a
significant change in the nucleation event. The decrease in size distribution for the modified seed
growth at their respective temperatures was thought to be facilitated by the second addition of
iron precursor resulting in Ostwald ripening focusing the size distribution. Interestingly, the
modified seed growth reaction at 205°C had a crystallite size of 19.5 ± 1.06 and the highest RF
heating value 5.55 [oC/min]/mg even though the RF heating capabilities are theorized to
exponentially decay above 15-16 nm. The theoretic decrease in RF heating above 15-16 nm is
for superparamagnetic nanoparticles only, therefore the theoretic RF heating decrease may not be
seen as the nanoparticles above 15-16 nm are most likely switching to single domain particles.

73

Further analysis of the VSM hysteresis curve for A2-24(205)_B2-24(205) (Figure 3.12) reveals
some remnant magnetization indicating presence of single domain particles.

Figure 3.12. Hysteresis curve for reaction A2-24(205)_B2-24(205). Inset shows the remnant
magnetization and coercivity is non-zero.

Since the crystallite size determined by XRD is biased towards larger sizes, it is entirely possible
that the majority number population of nanoparticles have crystallite sizes closer to 15-16 nm.
Using the specific heat of water cH2O = 4.18

𝑊𝑠
𝑔𝐾

as a close approximation of the true specific heat
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of the nanoparticle solution, the SAR value was calculated to be 1,175.56
normalized using the H = 37.4
3.1127

𝑛𝐻𝑚2
𝑘𝑔

0.15-3.12

𝑘𝐴
𝑚

𝑊
𝑔

. The SAR value was

and f = 270 kHz of the coil used to calculate the ILP value of

. Commercially available synthetic ferrofluids are reported to have ILP values of

𝑛𝐻𝑚2 23
.
𝑘𝑔

Next, changes in iron precursor concentration effect in the modified seed growth method
were investigated. To do this both first and second additions of Fe(acac)3 were increased. It was
thought that the size distribution could be lowered while maintaining the larger crystallite sizes
achieved by increasing the temperature. Table 3.7 lists the reactions where concentration and
temperature were changed for the modified seed growth reactions.

Table 3.7. Effect of various Fe(acac)3 concentrations in the modified seed growth on
nanoparticle properties.
Reaction
A2-24(195)_B2-24(195)
A2-24(205)_B2-24(205)
A4-24(195)_B2-24(195)
A4-24(195)_B4-24(195)
A4-24(205)_B4-24(205)
A4-24(195)_B6-24(195)
A4-24(205)_B6-24(205)
A6-24(195)_B2-24(195)
A6-24(195)_B4-24(195)
A6-24(195)_B6-24(195)

Magnetization
(emu/g)a
78.202
77.77
75.12*
76.56*
73.76
76.09
84.57
72.27
73.29
75.1*

RF Heating
([oC/min]/mg)b
4.04
5.55
3.13
4.48
2.74
3.43
3.14
2.71
2.88
2.58

a

Crystallite
size (nm)
14.9 ± 0.74
19.5 ± 1.06
14.95 ± 2.03
13.4 ±1.61
12.4 ± 1.11
15.2 ± 1.50
15.3 ± 2.45
11.4 ± 1.25
12.9 ± 0.92
14.1 ±0.98

mass unit indicates grams of FeOx nanoparticles corrected by TGA.
mass unit indicates milligrams of Fe determined by Prussian blue assay.
c
Polydispersity Index (PDI) determined by DLS.
*VSM data was corrected using 0.925 percent weight of sample
b
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Hydrodynamic
Diameter (nm)
37.52
44.63
29.5
31.94
26.67
26.6
28.2
43.89
23.5
26.19

PDIc
0.219
0.265
0.36
0.121
0.146
0.112
0.14
0.305
0.176
0.231

Increasing the concentration of the first addition, A4-24(195)_B2-24(195), produced
nanoparticles with similar crystallite sizes of 14.95 ± 2.03 nm, but with a higher PDI value of
0.36. This is an important reaction as the RF heating rate was decreased even though the
crystallite size was very similar. This is most likely due to the larger PDI value. Increasing the
concentration at the second addition was thought to be crucial to utilize Ostwald ripening to
minimize the size distribution.208,209 When the second addition is lower than the first addition
there may not be sufficient added monomers to facilitate size distribution focusing and/or retain
crystalline growth. This can be seen when comparing reactions A4-24(195)_B2-24(195) and A424(195)_B4-24(195). In reaction A4-24(195)_B2-24(195) the second addition of only 2 g
resulted in more crystalline growth (14.95 ± 2.03 crystallite size and 29.5 nm hydrodynamic
size) compared to reaction A4-24(195)_B4-24(195) having more amorphous growth (13.4 ±1.61
crystallite size and 31.94 nm hydrodynamic size). The more amorphous growth is consistent with
the theory of growth limited by reaction. The lower PDI value of 0.121 for reaction A424(195)_B4-24(195) (compared to 0.36) most likely explains the higher measured RF heating
rate of 4.48 [oC/min]/mg. Size distribution narrowing by increasing the second addition
concentration can be explained by having a sufficiently high concentration of monomers where
both seeds and newly formed nanoparticles will have an equal number of monomers in their
diffusion layer.212 When this happens the smaller nanoparticles will grow at a faster rate and
“catch up” to the larger seed nanoparticles that are growing; this process reduces the surface
energy which is energetically favored.212,213 This means that when larger nanoparticles are
produced after the first addition a higher concentration of monomers is required to maintain
crystal growth and to reduce the size distribution. Even further reduction in size distribution with
more crystalline growth was observed for reaction A4-24(195)_B6-24(195). Similar trend is seen
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for reactions A6-24(195)_B4-24(195), and A6-24(195)_B6-24(195) when comparing to reaction
A6-24(195)_B2-24(195).

3.3.6 Examination of Radiofrequency Induced Heating Properties
All of the benzyl alcohol reactions were compiled into Table 3.8 to assess the effects of
nanoparticle characteristics and synthetic parameters on RF heating rate. Table 3.8 was sub
categorized by color with nitrogen reactions listed in blue and reactions open to air in green. This
color scheme coincides with the colors used in Figure 3.13 A-F to graphically compare the
nanoparticle characteristics. Several interesting trends can be seen in these comparisons.
First, the reactions open to air all had higher Ms values between 70-85 emu/g except for
reaction A2-24(150), whereas the nitrogen reactions were in the range of 48-58 emu/g, (Figure
3.13 A,C,E). Thus, the presence of air during the reaction leads to higher magnetization
saturation values and possibly magnetite instead of maghemite crystal structures. It is important
to point out the Ms value differences as the RF heating is highest for reactions open to air as seen
in Figure 3.13 E.
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Table 3.8. Effect of various Fe(acac)3 concentrations, temperatures, and reaction environment on
nanoparticle properties. Reactions are grouped by their reaction environment: nitrogen (blue) and
open to air (green).
Magnetization
RF Heating
Crystallite
Hydrodynamic
(emu/g)a
([oC/min]/mg)b
size (nm)
Diameter (nm)
N2-A2-24
53.39
6.47 ± 1.17
23.23
N2-A2-24(150)
48.54*
0.01
5.65 ± 0.76
13.02
N2-A2-24(175)
57.69
0.04
6.06 ± 0.52
11.51
N2-A2-24(195)
57.09*
0.02
6.3 ± 0.89
N2-A2-24(205)
57.56*
0.05
11.3 ± 0.73
38.48
A2-24
70.839
0.170
8.8 ±0.61
13.64
A2-24(125)
A2-24(150)
55.50
0.06
6.2
13.58
A2-24(175)
70.91
0.689
8.9 ±1.39
12.45
A2-24(195)
74.322
0.175
8.1 ± 0.59
13.3
A4-24
68.99
0.134
8.3
14.68
A6-24
68.25
0.219
7.9
16.5
A2-24(205)
73.09
2.76
14.1 ± 0.80
24.53
A4-24(205)
73.79
1.86
11.7 ± 0.73
22.85
A6-24(205)
71.19
0.85
8.2 ± 1.56
23.9
A2-24_B2-24
75.7
2.536
14.4 ± 2.42
28.93
A2-24_B2[cool addition]-24
72.488
0.670
9.5 ± 0.71
20.76
A2-24(175)_B2-24(175)
77.89
1.004
11.6 ± 1.01
24.53
A2-24(185)_B2-24(185)
77.249
1.068
11.2 ± 0.94
23.11
A2-24(195)_B2-24(195)
78.202
4.041
14.9 ± 0.74
37.52
A2-24(205)_B2-24(205)
77.77
5.55
19.5 ± 1.06
44.63
A4-24(195)_B2-24(195)
75.12*
3.13
14.95 ± 2.03
29.5
A4-24(195)_B4-24(195)
76.56*
4.48
13.4 ±1.61
31.94
A4-24(205)_B4-24(205)
73.76
2.74
12.4 ± 1.11
26.67
A4-24(195)_B6-24(195)
76.09
3.43
15.2 ± 1.50
26.6
A4-24(205)_B6-24(205)
84.57
3.14
15.3 ± 2.45
28.2
A6-24(195)_B2-24(195)
72.27
2.71
11.4 ± 1.25
43.89
A6-24(195)_B4-24(195)
73.29
2.88
12.9 ± 0.92
23.5
A6-24(195)_B6-24(195)
75.1*
2.58
14.1 ±0.98
26.19
A2-2_B2-24
76.1
0.211
9.3 ± 0.45
20.07
A2-2_B4-24
72.18
0.212
9.8 ± 1.33
17.72
A2-2_B6-24
75.56
0.639
10.5 ± 1.02
19.42
a
mass unit indicates grams of FeOx nanoparticles corrected by TGA.
b
mass unit indicates milligrams of Fe determined by Prussian blue assay.
c
Polydispersity Index (PDI) determined by DLS.
*VSM data was corrected using 0.925 and 0.88 percent weight of samples in air and under nitrogen
respectively
Reaction
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PDIc
0.351
0.372
0.306
0.152
0.703
0.589
0.61
0.65
0.2
0.164
0.275
0.269
0.512
0.148
0.252
0.404
0.395
0.219
0.265
0.36
0.121
0.146
0.112
0.14
0.305
0.176
0.231
0.373
0.304
0.368

Figure 3.13. Plots comparing nanoparticle properties with reactions under nitrogen and open to
air indicated by blue diamonds and green triangles respectively. (A, B) Plots of crystallite size
versus Ms and RF heating. (C, D) Plots of hydrodynamic diameter versus Ms and RF heating. (E)
Plot showing Ms versus RF heating. (F) Plot of polydispersity index versus RF heating.

Next, there is a strong trend between crystallite size and RF heating. This was expected
based on previously reported literature. Similarly there is a correlation between hydrodynamic
diameter and RF heating, however it is hard to determine if this is a real trend or just due to the
hydrodynamic diameter increasing as crystallite size increases. The linear correlation between
hydrodynamic diameter and crystallite size can be seen in Figure 3.14 B. There potentially exists
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an optimal crystallite to hydrodynamic size ratio for RF heating based on being able to provide
maximum heat loss to surrounding solution. Figure 3.14 A indicates no clear correlation
between crystallite size and size distribution. Therefore, the trend of increasing RF heating as
size distribution decreases is most likely real. Overall, the effect of crystallite size, hydrodynamic
diameter, and size distribution appear to have the most impact on RF heating.

Figure 3.14. Plots comparing PDI versus crystallite size (A) and hydrodynamic diameter versus
crystallite size (B) for reactions under nitrogen and open to air indicated by blue diamonds and
green triangles respectively.

Based on these initial comparisons JMP software was used to screen the effects and
determine which nanoparticle properties are significantly affecting RF heating. JMP software
was also used to further elucidate the reaction parameters that significantly affect nanoparticle
properties. All of the reactions open to air were used for effect screening. After determining
which nanoparticle properties significantly affect the RF heating rates, a model was created and
tested to determine its effectiveness in predicting RF heating based on nanoparticle properties.
Likewise, models were created to determine nanoparticle properties based on reaction
parameters.
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The effects of crystallite size, hydrodynamic diameter, PDI, magnetization saturation,
and ratio of crystallite size to hydrodynamic diameter determined by volume (Volume CS/HS)
on RF heating were analyzed for the seed growth syntheses listed in Table 3.9. The effect
screening table is shown in Figure 3.9. Analysis of variance determined that crystallite size, PDI,
and volume CS/HS were all significant (Table 3.11). Crystallite size had the most significant
effect on RF heating. A model was created using least squares and emphasis on effect leverage
of the significant nanoparticle properties to estimate the resultant RF heating. The ANOVA had a
significance of <0.0001 indicating that the 3 nanoparticle properties did have a significant effect
on the RF heating. The actual predicted fit plot is shown in Figure 3.15 and has an R2 value of
0.95. The parameter estimates (Table 3.12) were used to formulate Equation 17 to predict RF
heating, where CS and HD are crystallite size and hydrodynamic diameter. Crystallite size,
volume CS/HS, and PDI had prob>t values of <0.0001, 0.0002, and 0.0002 respectively.

Table 3.9. List of seed growth syntheses and nanoparticle properties used in the effect screening
and predicted model.

A2-24(175)_B2-24(175)
A2-24(185)_B2-24(185)
A2-24(195)_B2-24(195)
A6-24(195)_B2-24(195)
A2-24(205)_B2-24(205)
A6-24(195)_B4-24(195)
A6-24(195)_B6-24(195)
A4-24(195)_B2-24(195)
A4-24(195)_B4-24(195)
A4-24(195)_B6-24(195)
A4-24(205)_B6-24(205)
A4-24(205)_B4-24(205)
A2-24(205)_B2-24(205)

Crystallite
Size

Hydrodynamic
Diameter

11.4
13.2
15.2
11.8
19.4
13.7
14.9
17
14.6
16.1
14.4
14.1
17.8

24.53
23.11
37.52
43.89
44.63
23.5
26.19
29.5
31.94
26.6
28.2
26.67
43.92
81

PDI

Ms

0.404 77.89
0.395 77.249
0.219 78.202
0.305 72.27
0.265 77.77
0.176 73.29
0.231 75.10
0.36 75.12
0.121 76.56
0.112 76.09
0.14 84.57
0.146 73.76
0.19 75.59

RF
Heating

CS/HS

Volume
CS/HS

1.00
1.07
4.04
2.71
5.55
2.88
2.58
3.13
4.48
3.43
4.19
2.74
5.36

0.46
0.57
0.41
0.27
0.43
0.58
0.57
0.58
0.46
0.61
0.51
0.53
0.41

0.1
0.19
0.07
0.02
0.08
0.2
0.18
0.19
0.1
0.22
0.13
0.15
0.07

Table 3.10. Effect screening of crystallite size, hydrodynamic diameter, PDI, magnetization
saturation, and volume CS/HS on RF heating.

Figure 3.15. The actual vs predicted RF heating fit of the model of crystallite size, PDI, and
volume CS/HS on RF heating.
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Table 3.11. ANOVA results for the predicted model effect of significant nanoparticle properties
on RF heating.
Source

DF

Model
Error
C. Total

Sum of Mean
F
Squares Square Ratio
3

22.58684

9
12

1.085012
23.67185

7.52895

62.4514
Prob >
0.12056 F
<.0001

Table 3.12. Parameter estimates for the model fit least squares of significant nanoparticle
properties effecting RF heating.

Term
Intercept
Crystallite Size
VOLUME CS/HS
PDI

Estimate
-0.26799
0.423428
-9.93554
-6.01891

Std
Error
t Ratio Prob>|t|
0.816764
-0.33
0.7503
0.04583
9.24
<.0001
1.614326
-6.15
0.0002
1.016722
-5.92
0.0002

RF=-0.26799+(0.423428*CS)+(-9.93554*Volume CS/HS)+(-6.01891*PDI)

(17)

Table 3.13. Predicted and actual RF heating values.

Synthesis
A3-24(205)_B3-24(205)
A2.5-24(205)_B2.5-24(205)
A2-24_B2-24

RF Heating
Predicted
Actual
4.025245 3.037383
2.387036 2.481686
1.224124 1.092966

Using the properties of reactions A3-24(205)_B3-24(205), A2.5-24(205)_B2.5-24(205),
and A2-24_B2-24 the RF heating values were predicted using Equation 17 as shown in Table
3.13. The predicted RF heating values were in close agreement with measured RF heating values
for reactions A2.5-24(205)_B2.5-24(205), and A2-24_B2-24. The A3-24(205)_B3-24(205)
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predicted RF heating values were larger than the actual RF heating values (4.025245
(oC/min)/mg vs. 3.037383 (oC/min)/mg). It is speculated that the model is a good predictor of
the actual measured RF heating considering the large amount of compounding measurement
errors. Further reactions would increase the validity of the model and increase the efficiency in
predicting RF heating values.
Next, the reaction pararmeters of temperature, first addition, and second addition were
investigated to screen for effects on resulting nanoparticle properties. Only crystallite size, PDI,
and volume CS/HS were investigated as they were found to be the only significant predictors of
RF heating. The effect screening was unable to predict crystallite size, PDI, or volume CS/HS
with an acceptable R2 value. The effect screening identified a ‘null term’ indicating that there is
some additional factor influencing the nanoparticle properties besides temperature, first addition
amount, and second addition amount. Further investigation is needed to determine this additional
effect. However, it is speculated that this could be due to the reaction concentration affecting the
heating rate. Another possible explanation is that there is insufficient data regarding the
nanoparticle properties at 24 hours after the first addition to accurately determine how the second
addition affects the final resulting properties. Further analysis using the nanoparticle properties
after 24 hours of reaction as a starting point for predicting increase in crystallite size could reveal
the important parameter.
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Chapter 4: Surface Functionalization of Benzyl Alcohol
Synthesized Iron Oxide Nanoparticles

4.1 Experimental Section
4.1.1 Reagents, Materials, and Equipment
All chemicals and materials were used as received. Water (H2O) (Fisher Scientific, Optima ®
LC/MS grade), Tetramethylammonium hydroxide (TMAOH) solution (Alfa Aesar, 25% w/w
aq.), poly (vinyl alcohol) (Polysciences, Inc., MW ~6000, 80 mol% hydrolyzed), bromoacetic
acid (Alfa Aesar, 98+%), sodium hydroxide (NaOH) (Alfa Aesar, pearl, 97%), 70% ethanol
(EtOH) (Sigma Aldrich, 200 proof for molecular biology), ethanol (Pharmco-AAPER, 190 proof
ACS/USP

grade),

(3-Aminopropyl)trimethoxysilane

aminominopropyl)triethoxysilane

(APTES)

(Alfa

(APTS)
Aesar,

(Alfa

98%),

Aesar,

97%),

(3-

(3-Glycidyloxypropyl)

trimethoxysilane (GLYMO) (Acros Organics,98%), L-cysteine (Cys) (Alfa Aesar, 98+%), DLserine (Ser) (Alfa Aesar, 99%), DL-arginine (Arg) (Alfa Aesar, 98%), DL-lysine
monohydrochloride (Lys) (Alfa Aesar, 99%), DL-Threonine (Thr) (Alfa Aesar, 99%), glycine
(Gly) (Alfa Aesar, 99%), L-glutamine (Gln) (Sigma, ≥99%), L-(+)-asparagine (Asn) (Alfa Aesar,
99%), hydroxylamine HCl, citric acid, anhydrous (BDH, 99.5-100.5%), (S)-(-)-4-Amino-2-
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hydroxybutyric acid (SAHBA) (Aldrich Chemistry, 96%), γ-aminobutryic acid (ABA) (Sigma
Life Science ≥99%), ethylenediamine (EDA) (Acros Organics, 99+%, extra pure),
tetraethylenepentamine (TEPA) (Acros Organics, technical grade), hydrochloric acid (HCl)
(Fischer, OptimaTM, 32-35%), 0.2 μm filter (PALL Life Sciences, Acrodisc® Syringe Filter 0.2
μm Supor® Membrane Low Protein Binding), 30k, and 100k molecular weight cutoff (MWCO)
centrifuge filter (PALL Life Sciences, Macrosep® Advance Device), PD-10 desalting column
(GE Healthcare, Sephadex® G-25 medium), Fe inductively coupled plasma (ICP) standard (Alfa
Aesar, Iron, plasma standard solution, Specpure®, Fe 1000 µg/mL), hydrochloric acid solution
(HCl) (Electron Microscopy Sciences, 20%), potassium ferrocyanide aqueous solution (Prussian
Blue)

(Electron

Microscopy

Sciences,

20%),

S-2-(4-Aminobenzyl)-1,4,7,10-

tetraazacyclododecane tetraacetic acid (DOTA) (Macrocyclics),
Ethyl-3-(3-dimethylaminopropyl)carbodiimide

(EDC)

177

LuCl3 (Perkin Elmer), 1-

(Thermo

Scientific),

N-

hydroxysulfosuccinimide (S-NHS) (Thermo Scientific), β–mercaptoethanol (Sigma Aldrich),
ammonium hydroxide (Fisher Scientific, Optima grade), 0.25 M ammonium acetate , and 0.1 M
2-(N-morpholino)ethanesulfonic acid (MES) buffer containing 0.9% NaCl (Optima grade
NH4OH adjusted pH =6.4).

4.1.2 Synthesis of Carboxymethylated Polyvinyl Alcohol (CMPVA)
Polyvinyl alcohol (PVA) can be reacted with bromoacetic acid and base to synthesize
carboxymethylated polyvinyl alcohol (CMPVA) as previously reported.94,130 First, three different
solutions were made including: Solution A – 5 g of PVA dissolved in 50 mL of H2O, Solution B
– 5.324 g of sodium hydroxide (NaOH) dissolved in 25 mL of H2O, and Solution C – 11.575 g of
bromoacetic acid dissolved in 200 mL of 70% ethanol (EtOH). To Solution C 3.33 g of NaOH
86

was added slowly and stirred to dissolve. Solution A was set on a stirring hot plate and heated to
50°C with constant stirring prior to slow addition of Solution B. Next, a drop wise addition of
Solution C, to the mixed Solution A and B was carried out and reacted under a reflux condenser
for five hours to carboxymethylate the PVA. After carboxymethylation, the pH of the CMPVA
was measured and adjusted to approximately 6.0 with a 1 M solution of hydrochloric acid. The
CMPVA was then precipitated out of solution by addition of cold EtOH. The precipitated
CMPVA in cold EtOH was centrifuged at 3,000×g for 15 minutes (Thermo Scientific, Sorvall
Legend X1R centrifuge) to remove any unreacted chemicals. This process was repeated 3-6
times to fully wash the CMPVA. The washed CMPVA was then dried using a vacuum oven set
at 50°C for one week.

4.1.3 Surface Functionalization with CMPVA
To modify the surface with CMPVA, 40 mg of dry FeOx nanoparticles were sonicated
for 180 minutes in 2 mL of 0.0625%, 0.125%, 0.25%, or 0.5% w/w aqueous tetramethyl
ammonium hydroxide (TMAOH) solution. Dispersing the nanoparticles prior to addition of
surface functionalization ligands is crucial to efficiently surface functionalize individual
nanoparticles. During the entire surface functionalization procedure the nanoparticles were not
magnetically stirred to prevent possible aggregation due to magnetic fields causing additional
interparticle attraction. A 40 mg/mL CMPVA solution was made by dissolving dry CMPVA in
water with low heating and stirring. Next, 10 mL of the 40 mg/mL CMPVA solution was diluted
with 9.5 mL of H2O immediately prior to addition of 0.5 mL of the nanoparticle TMAOH
solution. This solution was sonicated for 180 minutes. The initial dilution of CMPVA was found
to aid in the nanoparticle surface functionalization. It is thought that surface functionalization is
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more efficient at lower concentrations of nanoparticles, which reduces the distance between
nanoparticles during CMPVA surface functionalization. The nanoparticle CMPVA solution was
allowed to sit for one week. In first attempts at surface functionalization with CMPVA the
nanoparticle CMPVA solution was allowed to sit for 2 weeks, however the particles initially
became clear at 1 week. Therefore, 1 week was chosen as the minimal amount of time, since
nanoparticles in CMPVA were still turbid at 24-48 hours.
Next, CMPVA-FeOx nanoparticles were washed using a 30k molecular weight cut-off
(MWCO) centrifugal filter spun at 4,000×g to remove excess CMPVA and any residual
TMAOH. This centrifuge process also concentrated the nanoparticle solution. This concentrated
solution was transferred to a clean vial and sonicated briefly (15 minutes) to aid in proper redispersion. Further clean-up was carried out using a disposable PD-10 desalting column that was
equilibrated with H2O. This step was used to remove non-functionalized or aggregated
nanoparticles as well as any remaining TMAOH. The desalting column diluted the sample
slightly, so an additional 30k centrifuge filter was spun at 4,000×g for one hour. A 0.2 µm sterile
filter was used in a biosafety laminar flow hood to sterilize the CMPVA-FeOx nanoparticles and
remove any CMPVA-FeOx clusters larger than 200 nm.

4.1.4 Surface Functionalization with APTS or APTES
Surface functionalization with APTS or APTES was performed by adding 10 mg of dry
FeOx nanoparticles to a 0.125% TMAOH solution. This was sonicated for 30 minutes to disperse
the nanoparticles. Prior to addition of APTS or APTES the nanoparticle TMAOH solution was
diluted with 8 mL of H2O and vortexed briefly (10 seconds). Immediately after dilution, either
1.78

mL

of

(3-Aminopropyl)trimethoxysilane
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(APTS)

or

2.38

mL

(3-

aminominopropyl)triethoxysilane (APTES) was added dropwise followed by a quick 10 second
vortex spin. The surface modification reaction was magnetically stirred at 60°C for one hour.
The solution pH was adjusted to about 7.4 with 32-35% hydrochloric acid (HCl) solution.
Magnetic separation for 1 hour was used to pull out partially, incompletely, or aggregated
surface functionalized nanoparticles. The remaining clear honey colored top solution was 0.2 μm
filtered to remove any large APTS or APTES nanoparticles as well as any excess reacted APTS
or APTES that may clog up the centrifuge filter. This solution was then washed 3-5 times with
H2O in a 30k MWCO centrifuge filter spun at 4,000rpm for 10 minutes in a swing bucket
centrifuge. In the final wash step the solution was concentrated to 1.5 mL and the pH was
readjusted to about 7.4. Sterile filtration with a 0.2 μm filter in a biosafety laminar flow hood
was used to obtain the final sterile surface functionalized product.

4.1.5 Surface Functionalization with GLYMO and Base Catalyzed
Epoxide Ring Opening with Nucleophiles
The surface functionalization process with GLYMO started with adding 10 mg of dry
FeOx nanoparticles to 10 mL of 0.125% TMAOH solution. The nanoparticle TMAOH solution
was sonicated for 30 minutes to fully disperse the nanoparticles. This solution was then further
diluted upon addition of 8 mL of H2O prior to addition of 2.25 mL of 3-Glycidyloxypropyl
trimethoxysilane (GLYMO) (0.0114 mol). It is essential that the GLYMO be added all at once
rather than dropwise to facilitate efficient surface modification. Following the GLYMO addition,
the solution was vortexed for 10 seconds and then magnetically stirred and heated at 60°C for 1
hour. After approximately 15 minutes of reaction the solution changed colors from a clear brown
solution to a muddy brown solution. This indicated surface modification with GLYMO, as the
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terminal epoxy groups should render the nanoparticles unstable at the high pH. The three
membered epoxy ring was opened through a base catalyzed reaction with addition of a
nucleophile. This reaction could have been acid-catalyzed, but this was not done as low pH could
start to dissolve the surface of the FeOx nanoparticles. Additional base (1.6 mL of 25%
TMAOH) was added immediately prior to addition of 1:1 molar ratio of the following
nucleophiles: glycine (Gly) (0.86 g), DL-serine (Ser) (1.2g), γ-aminobutyric acid (ABA) (1.18
g), or (S)-(-)-4-amino-2hydroxybutyric acid (SAHBA) (1.36 g), L-cysteine (Cys) (1.38 g), DLlysine-monohydrochloride (Lys) (2.08 g), L-glutamine (Gln) (1.67 g), DL-arginine (Arg) (1.86
g), L-(+)-asparagine (Asn) (1.51 g), DL-Threonine (Thr) (1.36 g), hydroxylamine (0.79 g) or
citric acid, anhydrous (2.19 g). Ethylenediamine (EDA) (0.763 mL) or tetraethylenepentamine
(TEPA) (2.18 mL) were also used, but no additional TMAOH base was added as these chemical
compounds are inherently basic. The reaction was continued at 60°C with magnetic stirring for 1
hour. At this point the reaction was removed from heat and the pH was adjusted with 32-35%
HCl to a pH of about 7.4. As a first cleanup step any nanoparticles that were not stable were
magnetically separated for 1 hour. Only the top clear honey colored stable solution of
nanoparticles was removed and subjected to a 0.2 μm filter. Next, the particles were washed with
water 3-5 times in a 30k molecular weight cutoff (MWCO) centrifuge filter spinning at 4,000
rpm for 10 minutes. The final wash was spun down to approximately 3 mL and the solution was
then subjected to a disposable PD-10 desalting column equilibrated with water or PBS. As a final
step the nanoparticles pH was checked and adjusted to 7.4 and then sterilized with a 0.2 μm filter
in a biosafety laminar flow hood to obtain the final product.
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4.1.6 EDC Coupling DOTA Chelate and Radiolabeling
The SAHBA-FeOx and CMPVA-FeOx nanoparticles were linked to DOTA metal chelate
by EDC coupling reaction. First, 500 µL of SAHBA-FeOx or CMPVA-FeOx were mixed with
500 µL of 0.1 M MES buffer (NH4OH adjusted pH=6.4). Next, 100 mg of EDC was dissolved in
500 µL Ultra H2O and 100 mg of S-NHS was dissolved in 500 µL Ultra H2O. Activation of the
carboxyl groups was performed by addition of 100 µL of EDC solution. The activated carboxyl
groups were stabilized by addition of 100 µL of the S-NHS solution. After 10 mins 2 µL of β–
mercaptoethanol was added. In 100 µL of Ultra grade H2O 2 mg of DOTA was dissolved and
then added to the FeOx in MES buffer to form an amide bond between the terminal amine on the
DOTA chelate and the activated carboxyl groups of SAHBA-FeOx or CMPVA-FeOx. The
reaction was allowed to react for 1.5 hours, before quenching with 100 µL of 0.275 M
hydroxylamine. The resultant DOTA-SAHBA-FeOx or DOTA-CMPVA-FeOx were buffered
exchange with a PD-10 column equilibrated with ammonium acetate.
Radiolabeling with

177

Lu was performed by adding 40 µL of

177

LuCl3 (~10 mCi) and 20

µL of NH4OH to the DOTA-SAHBA-FeOx or DOTA-CMPVA-FeOx in ammonium acetate.
The maximum beta energy of
MeV. The

177

chelation of

177

Lu is 0.497 MeV (79%), but the average beta energy is 0.13

Lu also has two gamma energies at 208 keV (11%) and 113 keV (6.4%). The

177

Lu by DOTA was carried out at 40°C in a silicon oil bath overnight. The silicon

oil bath was magnetically stirred. An MCX column was used to remove any free
177

Lu-DOTA-SAHBA-FeOx or

buffer exchange

177

177

Lu from

Lu-DOTA-CMPVA-FeOx. A PD-10 column was used to

Lu-DOTA-SAHBA-FeOx or

DPBS and to remove any free
SAHBA-FeOx or

177

177

177

177

Lu-DOTA-CMPVA-FeOx into non-sterile

Lu-DOTA or DOTA chelate. The ‘washed’

177

Lu-DOTA-

Lu-DOTA-CMPVA-FeOx were then concentrated using a 3k MWCO
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centrifuge filter spinning at 4,000 rpm in a swing bucket centrifuge for 10 minutes. The final
product was obtained by 0.2 µm filtering in a sterile laminar flow hood.

4.2 Characterization Techniques
4.2.1 Fourier Transform Infrared (FTIR) Attenuated Total Reflectance
(ATR) Spectroscopy
Fourier transform infrared (FTIR) attenuated total reflectance (ATR) spectroscopy is
paramount when analyzing the chemistry of colloid surfaces such as surface functionalized FeOx
nanoparticles.214 The ability to analyze the surface functionalization in the aqueous environment
is advantageous as it prevents the possibility of altering the surface functionalization during
drying steps or removal from the aqueous environment.214 The attenuated total reflectance
utilizes the properties of an internal reflectance element (IRE) with a high refractive index. These
properties allow for the interface between the IRE and sample to be probed with infrared
radiation. When the infrared radiation interacts with the interface an evanescent wave will
penetrate slightly into the sample and absorb resulting in an absorption spectrum.214 The depth of
penetration (dp) depends on the incident wavelength (λ), refractive index of IRE (n1), refractive
index of sample (n2), and angle of incidence (θ) (Equation 18).214
d𝑝 =

𝜆
𝑛 2
2𝜋𝑛1 √sin2 𝜃−( 2 )

(18)

𝑛1

When the infrared light interacts with the surface of the sample, after passing through the IRE,
the created perpendicular standing wave becomes ‘attenuated’ if the sample absorbs the infrared
light.214 The refractive wave will lose some energy and is termed ‘attenuated total reflectance’.214
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FTIR-ATR spectroscopy was performed on a Thermo Scientific Nicolet 6700 equipped
with a smart iTR for ATR to analyze liquid or dry samples. Single bounce ATR was used to
examine all samples placed on the diamond crystal. The ATR system used has a penetration
depth of 2.03 μm at an incident wavelength of 1000 cm-1, an incident wavelength angle of 42º,
and a refractive index of 2.4.

4.2.2 X-ray Photoelectron Spectroscopy (XPS)
X-ray photoelectron spectroscopy (XPS) was performed on a Thermo Scientific
ESCALAB 250 spectrometer using a monochromatic Al Kα X-ray source (1486.6 eV). External
and internal flood guns were utilized to account for the organic coatings with charge
composition. Sample preparation involved pressing nitrogen dried samples onto a strip of indium
foil and attachment to the sample holder with double-sided adhesive carbon tape. CasaXPS
software was used to analyze all data. Adventitious carbon at 284.8 eV was used to correct the
observed binding energies.

4.2.3 High-Performance Liquid Chromatography (HPLC)
High-performance liquid chromatography (HPLC) was performed using a Waters isocratic
HPLC system, equipped with UV-VIS absorbance and radioactivity (Bioscan) detectors to
determine the radiochemical purity of radiolabeled FeOx nanoparticles eluted from a size
exclusion-gel permeation chromatography column. The buffer used was 90% 50 mM ammonium
acetate and 10% methanol. Aqueous samples were loaded before DOTA coupling to FeOx, after
radiolabeling and MCX column, and after PD-10 column wash steps.

93

4.3 CMPVA Discussion
4.3.1 Surface Functionalization and Optimization for Biostability
The following naming system was used to keep track of the different types of surface
functionalizations. The abbreviation of the respective surface functionalization precedes ‘FeOx’
and is separated by a hyphen. For example, carboxymethylated polyvinyl alcohol surface
functionalized FeOx nanoparticles are referred to as ‘CMPVA-FeOx’. Any additional
modifications to the surface functionalization will precede the surface functionalization
abbreviation and will also be separated by a hyphen.
Carboxymethylated polyvinyl alcohol (CMPVA) was used to provide colloidal and
biological stability as well as providing terminal carboxyl groups for future conjugation.
Optimization of this process is beneficial to facilitate higher yield, better biological stability, and
increased biofunctionalization potential. The carboxyl groups on CMPVA polymer interact
strongly with the surface iron atoms of FeOx nanoparticles and create a hydrophilic surface due
to terminal carboxyl and hydroxyl groups.94 Therefore, it is important to optimize the surface
functionalization process to ensure that an adequate number of carboxyl groups interact with the
FeOx surface and a sufficient number of carboxyl groups are oriented outward to provide
solution stability and sites for further conjugation. Optimization is especially important to
determine how to effectively surface functionalize differently sized nanoparticles as even small
changes in nanoparticle size will have drastic differences in surface area to volume ratio for a
given gram amount of material. Several parameters were investigated to determine how to best
adjust reaction parameters to functionalize varying nanoparticle sizes.
First, the carboxymethylation of polyvinyl alcohol was confirmed by FTIR-ATR
spectroscopy of CMPVA. The spectrum from FTIR-ATR of CMPVA is shown in Figure 4.1.
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Figure 4.1. The FTIR spectra shown as % transmittance vs wavenumber is shown with polyvinyl
alcohol in blue, and carboxymethylated polyvinyl alcohol in red. Peaks at 1640, 1583 and 1417
indicate the presence of carboxylate anion and the peak at 1089 cm-1 indicates the ether group.
Polyvinyl acetate presence was indicated by peak at 1730 cm-1. The disappearance of the 1730
cm-1 peak and appearance of peaks at 1600 and 1417 cm-1 are indicative of acetate groups being
replaced by carboxylate ion groups in CMPVA.

Peaks at 1640 and 1417 cm-1 are indicative of asymmetrical C=O stretching mode for
carboxylate ion and the peak at 1089 cm-1 indicates asymmetrical stretching of C-O-C
respectively.215 Typically the surface functionalization of FeOx nanoparticles with CMPVA
involves a difficult phase transfer process to establish aqueous colloidal stability. The as
synthesized nanoparticles were stable in organic solutions such as chloroform and were
transferred to an aqueous 1.5% TMAOH solution by mixing overnight. The dry FeOx
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nanoparticles produced by the modified seed growth method in benzyl alcohol were uniquely
able to be dispersed in TMAOH directly and without the use of organic solutions such as
chloroform. This is one large advantage to using the benzyl alcohol synthesized nanoparticles.
The previously reported CMPVA surface functionalization methods did not provide long term
colloidal stability in PBS, tissue culture medium, or other biologically relevant medium. It was
thought that the previous methods had been optimized for their particular FeOx nanoparticle
synthesis and certain factors may influence the efficiency of surface modification including pH,
nanoparticle diameter, base concentration, and number of polymer per nanoparticle. These
factors were investigated in an attempt to improve surface functionalization efficiency.
The concentration of TMAOH used was first investigated as the initial step is to disperse
the nanoparticles in a TMAOH solution. It is advantageous to have well dispersed nanoparticles
to properly surface functionalize individual nanoparticles and thus limit the amount of bridging
or coating of aggregated nanoparticles. Low and high concentrations of base can lead to
insufficient nanoparticle separation. Several concentrations (0.0625%, 0.125%, 0.25%, and 0.5%
w/w TMAOH) were used to disperse the nanoparticles (20 mg/mL; 40:1 CMPVA to FeOx mass
ratio). FeOx nanoparticles in these TMAOH solutions were analyzed with DLS to determine
differences in hydrodynamic diameter and dispersion of nanoparticles. The hydrodynamic
diameters were similar (26.42 ± 1.31 nm) as well as the PDI values throughout the different
TMAOH concentrations as shown in Table 4.1. At each step in the surface functionalization
procedure and wash steps DLS was performed. This provided an easy way to analyze the initial
base concentration effect on efficiency of surface functionalization.
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Table 4.1. Initial hydrodynamic diameters and PDI values for various v/v % concentration of
TMAOH.
% TMAOH

Hydrodynamic
Diameter (nm)

PDIa

0.0625

25.99

0.38

0.125

29.96

0.363

0.25

23.61

0.39

0.5

26.12

0.41

a

Polydispersity Index (PDI) determined by DLS.

The results from the DLS investigation are shown in Figure 4.2. Aliquots were taken from four
time points throughout the surface functionalization procedure and were labelled steps 1-4.
Aliquots were taken before 30k MWCO centrifuge filter (step 1), after 30k MWCO centrifuge
filter (step 2), and first (step 3) and second (step 4) fractions of elution from disposable PD-10
desalting column. Large hydrodynamic diameters indicate possible bridging between
nanoparticles and/or functionalizing an aggregation of nanoparticles. Large PDI values indicate
large size distributions which are indicative of multiple size populations and/or aggregation. As
can be seen with the 0.0625% TMAOH nanoparticle solution the PDI value was 0.51 and only
5% of nanoparticles were not above 1000 nm (Figure 4.2 A). This is in accordance with the
visual observation that the solution became turbid and had visible aggregation and precipitation
after CMPVA was introduced. It was not surprising that subsequent steps 2-4 also contained
large hydrodynamic diameters and PDI values.
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Figure 4.2. DLS hydrodynamic size measurements at 4 steps throughout the surface
functionalization process with CMPVA based on several TMAOH concentrations. The
concentrations of TMAOH used were (A) 0.0625% TMAOH, (B) 0.125% TMAOH, (C) 0.25%
TMAOH, and (D) 0.5%. The four steps when aliquots were taken are listed in order: before and
after a 30k MWCO centrifuge filter and 1st and 2nd elution fractions from a PD-10 desalting
column. Small, medium, and large hydrodynamic diameters correspond to inadequately
functionalized (red), adequately functionalized (blue), or aggregated nanoparticles (green).

To investigate if the pH after addition of CMPVA was sufficient in maintaining dispersion,
samples of CMPVA only and FeOx nanoparticles containing CMPVA were titrated with
TMAOH. The pH changes upon addition of 6.25% TMAOH to solutions of CMPVA only and
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FeOx nanoparticles containing CMPVA are shown in Figure 4.3. Identical reaction
concentrations of CMPVA and nanoparticles were used when titrating with 6.25% TMAOH.

Figure 4.3. Solutions of CMPVA (blue) and FeOx nanoparticles with CMPVA (red) titrated
with 6.25% TMAOH. Several markers indicate solution pH when TMAOH concentrations used
in the DLS study were reached.

A pH above 8.5 was deemed necessary to maintain a dispersion of nanoparticles for efficient
surface functionalization with CMPVA. It was concluded that 0.0625% TMAOH offered a
sufficiently high pH to initially disperse the nanoparticles, but the nanoparticles quickly
aggregated due to a pH drop upon addition of CMPVA. As can be seen in Figure 4.3 the pH of
nanoparticles with CMPVA at 0.0625% drops below 8.5 to a pH of 6.89. Next, the pH changes at
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the 0.5% TMAOH solution in Figure 4.3 revealed that the 0.5% TMAOH concentration
provided dispersion for the functionalization with CMPVA (steps 1 and 2 in Figure 4.2 D),
however after elution from the PD-10 desalting column (steps 3 and 4 in Figure 4.2 D) it is
apparent that removal of TMAOH by the desalting column resulted in the nanoparticles
aggregating and crashing out of solution. This instability was further confirmed by a large
amount of crashed nanoparticles on the PD-10 column and the large percentage by volume
(>90%) with hydrodynamic diameters exceeding 1000 nm. The crashed nanoparticles on the PD10 column were most likely stabilized by TMAOH only since nanoparticles dispersed in
TMAOH only completely crashed when loaded on to a PD-10 desalting column. All of these
observations and results leads to the interpretation that the high concentration of TMAOH
prevented an adequate exchange of TMAOH with CMPVA. A high concentration gradient of
TMAOH results in retention of more TMAOH than CMPVA resulting in TMAOH molecules
being more likely to re-interact with the FeOx surface. While the 0.5% TMAOH solution
resulted in mainly unstable nanoparticles there was a small population of 188.8 and 173.7 nm
hydrodynamic diameter nanoparticles that were attributed to ‘inadequately functionalized’
CMPVA surface functionalized nanoparticles. They were termed this because they displayed
aggregation and loss of colloidal stability over time. It is thought that the removal of TMAOH
led to reordering of the CMPVA on FeOx nanoparticles leading to bridging and aggregation.
This exemplifies the importance of the PD-10 desalting column step to increase the long term
stability and separate a stable population. While the 0.5% TMAOH solution resulted in surface
functionalization of a small population of nanoparticles, this concentration did not produce the
desired long term stability.
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The 0.125% and 0.25% TMAOH FeOx nanoparticle solutions resulted in stable CMPVA
surface functionalized nanoparticles. There were crucial differences that can be seen after elution
from the PD-10 desalting column (step 3- Figure 4.2 C). It can be seen that 20% of the
population of the 0.25% TMAOH nanoparticle solution is inadequately functionalized. Similar to
the 0.5% TMAOH step 3 and 4, the removal of TMAOH from the 0.25% TMAOH nanoparticle
solution revealed that there was a population that was not fully functionalized and would lead to
aggregation through bridging and/or reordering of CMPVA polymers. Interestingly, when the
TMAOH was removed in steps 3 and 4 for the 0.125% TMAOH nanoparticles solution the
population shifted from a 50:50 population of adequately to inadequately functionalized
nanoparticles to 100% adequately surface functionalized nanoparticles. Additionally, the PDI
values for 0.125% and 0.25% TMAOH nanoparticles solutions were 0.169 and 0.163
respectively indicating small size distributions and minimal aggregation or crashing. Since,
0.125% TMAOH nanoparticle solution had a larger initial population of adequately CMPVA
surface functionalized nanoparticles (step 1) it resulted in a higher overall yield. Of the four
TMAOH concentrations tested the 0.125% was chosen as the best concentration for CMPVA
surface functionalization.
Subsequently, the above conditions were tested on a different size of nanoparticles to
determine the methods applicability. Reaction A2-24_B2-24 nanoparticles (used in TMAOH
concentration study) had a crystallite size of 12.8 nm and a hydrodynamic diameter of 28.9 nm.
Nanoparticles produced by reaction A2-24(195)_B2-24(195) were chosen as they had a
crystallite size of 15.2 nm and a hydrodynamic diameter of 37.5 nm. First, the same surface
functionalization conditions and methods as above were tested on the larger nanoparticles (20
mg/mL CMPVA, 0.125% TMAOH, and same mass ratio of CMPVA to nanoparticles). This
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method did indeed functionalize the surface with CMPVA; however the final product’s
hydrodynamic size was 310.97 ± 51 nm which resulted in aggregation and precipitation.
Additionally, this size is too large to be sterile filtered and is therefore less applicable regardless
of stability. The large resultant hydrodynamic diameter was thought to be a result of excessive
CMPVA concentration leading to higher chances of crosslinking or bridging of multiple
nanoparticles. The same mass amount of smaller nanoparticles contains a greater number of total
nanoparticles and a larger total surface area which greatly offsets the ratio of CMPVA to
nanoparticles. An approximate ratio of number of CMPVA molecules to number of FeOx
nanoparticles or total surface area was calculated. The nanoparticles were treated as spheres as
TEM confirmed spherical nanoparticle morphology. The surface area and volume of a sphere
were used to simplify the calculations. The density of magnetite (5.17 g/cm3) was used when
determining the number of nanoparticles in 10 mg of sample by mass. The total number of
nanoparticles and surface area of one nanoparticle were used to determine the total surface area
of 10 mg of nanoparticles. The 400 mg of CMPVA, used to functionalize the surface of A224_B2-24 nanoparticles, equates to 66.67 μmoles or 4.015×1019 of 6,000 molecular weight
CMPVA. The surface area, volume and mass of one nanoparticle are shown in Table 4.2 to
illustrate the large differences of particle properties with small changes in the diameter of
nanoparticles.
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Table 4.2. Values of nanoparticle properties calculated using crystallite and hydrodynamic
diameter.
Crystallite
Volume SA
Mass of
diameter (nm)
(m^3)
(m^2)
SA/V 1 NP (g)
12.8 1.10E-24 5.15E-16
0.47 5.68E-18
15.2 1.84E-24 7.26E-16
0.39 9.51E-18
Hydrodynamic
Diameter (nm)
28.9 1.26E-23 2.62E-15
0.21 6.53E-17
37.5 2.76E-23 4.42E-15
0.16 1.43E-16

The total number and total surface area of nanoparticles in 10 mg sample are shown in Table
4.3. These ratios were used to determine the amount of CMPVA to use for the investigation of
surface functionalizing larger nanoparticles by matching the ratios used in the TMAOH
optimization for CMPVA surface functionalization.

Table 4.3. Total number and surface area of nanoparticles in 10 mg are shown based on different
crystallite and hydrodynamic diameters. The ratio of the number of CMPVA molecules to both
nanoparticles and total surface area are also shown.
Crystallite
# of NP in
SA in 10 mg
#of
# of
diameter (nm)
10 mg
(m^2)
CMPVA:NP CMPVA:SA
12.8
1.76E+15
9.07E-01
2.28E+04
4.43E+19
15.2
1.05E+15
7.64E-01
3.82E+04
5.26E+19
Hydrodynamic
Diameter (nm)
28.9
1.53E+14
4.02E-01
2.62E+05
1.00E+20
37.5
7.01E+13
3.09E-01
5.73E+05
1.30E+20

Based on the ratios calculated it was determined that when the crystallite size increased from
12.8 to 15.2 nm the CMPVA concentration should be 11.9 mg/mL. Likewise, based on
hydrodynamic diameter increase from 28.9 to 37.5 nm the CMPVA concentration should be 9.15
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mg/mL. When the CMPVA concentration was adjusted based on surface area it was determined
that 16.8 mg/mL and 15.4 mg/mL be used respective of calculations using crystallite or
hydrodynamic diameter. It should be noted that the original article94 used slightly different
crystallite (15 nm instead of 15.2 nm) and hydrodynamic diameter (30 nm instead of 28.9 nm
and 37 nm instead of 37.5 nm) values which resulted in calculating 12.4 mg/mL and 10.7 mg/mL
CMPVA concentration based on total number of particles for crystallite and hydrodynamic size
respectively and 17.1 mg/mL and 16.2 mg/mL based on total surface area for crystallite and
hydrodynamic size respectively. Since, hydrodynamic diameter is larger than the particle size
and crystallite size is smaller than the particle size the values were averaged. Optimally 2.28×10 4
CMPVA molecules should be used for every one nanoparticle or 4.43×10 19 CMPVA molecules
should be used based on the total surface area of 10 mg. Using the same mass amount of A224(195)_B2-24(195) nanoparticles the above averaged values were used to determine if
calculations based on total number or total surface area is more accurate. Two surface
functionalization attempts with 11.6 mg/mL and 16.7 mg/mL of CMPVA (values from original
article that were tested) were used in place of 20 mg/mL CMPVA originally used. Aliquots of
the two surface functionalizations were taken before and after a 30k MWCO centrifuge filter and
from 3 elution fractions from a PD-10 desalting column to compare the efficiency (Figure 4.4).
It was determined that adjusting the CMPVA concentration based on number of nanoparticles
(11.6 mg/mL of CMPVA) lead to more efficient functionalization of nanoparticles.
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Figure 4.4. DLS hydrodynamic size measurements based on volume for different CMPVA
concentrations based on total number of nanoparticles (A) (11.5 mg/mL CMPVA) or surface
area (B) (16.6 mg/mL) in 10 mg of FeOx nanoparticles at various steps in the clean-up process.
Depending on the hydrodynamic size the volume population of nanoparticles was labelled as
either functionalized (blue), partially functionalized (red), or aggregated (green) nanoparticles.
The four steps when aliquots were taken are listed in order: before and after a 30k MWCO
centrifuge filter and 1st and 2nd elution fractions from a PD-10 desalting column.

The resultant CMPVA nanoparticles had an average hydrodynamic size of 199.97 ± 34.04 nm
(50%) and 54.79 ± 24.53 nm (50%) with a PDI of 0.206 (Figure 4.4). The hydrodynamic size of
A2-24(195)_B2-24(195) CMPVA nanoparticles is slightly larger than the A2-24_B2-24
CMPVA nanoparticles, but they were stable in various media. This was expected since A224(195)_B2-24(195) nanoparticles had a larger crystallite and hydrodynamic size before
CMPVA surface functionalization. The CMPVA surface functionalization based on surface area
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had a majority of nanoparticles with large hydrodynamic diameters (approaching 1000 nm). This
suggests that the nanoparticles were aggregating due to a high concentration of CMPVA.
CMPVA surface functionalization of A4-24(195)_B6-24(195) nanoparticles for broad
stability assessment was carried out with some minor modifications to the CMPVA surface
functionalization method. These modifications were used as they more closely resemble the
surface modification procedure of APTS, APTES, and GLYMO that were used in the stability
assessment. The initial dispersion of nanoparticles in TMAOH solution was only sonicated for
30 minutes prior to addition of CMPVA solution. The time allotted for CMPVA modification of
the surface was 24 hours instead of 1 week. FTIR-ATR was used to confirm successful surface
functionalization with CMPVA. Figure 4.5 displays the FTIR-ATR spectra of bare FeOx
nanoparticles and water. The normalized FTIR-ATR spectra of CMPVA nanoparticles with
water subtracted out is shown in Figure 4.6. FTIR-ATR was carried out on CMPVA-FeOx in
solution to discern the functional groups without potentially altering the functional groups which
may have occurred by drying nanoparticles to a fine powder prior to FTIR characterization. In
Figure 4.6 the C-H stretching vibrations, asymmetrical C=O stretching mode for dimerized
saturated carboxylic acids, and asymmetrical stretching of C-O-C are indicated respectively by
the existence of peaks at 2940, 1716, and 1092 cm-1. The 2940 cm-1 peak can be attributed to CH stretching vibrations of the carbon chain in CMPVA instead of the very strong and broad O-H
stretching vibrations due to subtraction of water from the spectra.
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Figure 4.5. FTIR-ATR spectra of A) FeOx nanoparticles and B) water.
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Figure 4.6. Normalized FTIR-ATR spectra of CMPVA-FeOx aqueous solution with water
subtracted.

DLS was also used to confirm modification of FeOx nanoparticles with CMPVA (Figure
4.7). Interestingly, the shorter sonication time used to disperse nanoparticles and shorter
CMPVA reaction time reduced the resultant hydrodynamic size to 91.6±20.53 (100%) with a
PDI value of 0.148±0.015. This is important as this is the upper limit of the “optimal size” of
nanoparticles to avoid opsoinzation and clearance from the body, and to facilitate more passive
targeting. Zeta potential further corroborated the presence of CMPVA on FeOx nanoparticles. A
negative zeta potential indicated carboxylic acid groups at pH=7.4 (Figure 4.8).

Figure 4.7. DLS hydrodynamic diameter by volume percentage for CMPVA-FeOx.
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Figure 4.8. Zeta potential measurement of CMPVA -FeOx.

4.4 Silane Surface Functionalization of Iron Oxide Nanoparticles
FeOx nanoparticles (A4-24(195)_B6-24(195)) were surface functionalized with three
silane ligands including GLYMO, APTS, and APTES. These silane surface functionalizations
are used in many applications including corrosion protection,216-218 adhesive durability,219
semiconductor coatings,220-223 and surface passivation224 and are well characterized and
understood for bulk materials. GLYMO was chosen because the epoxy ring can be easily opened
with a base catalyzed reaction involving nucleophilic ligands to provide a multitude of surface
functionalizations with different properties. This epoxy ring opening can be base or acid
catalyzed allowing for rapid alterations in the surface chemistry such as charge and terminal
functional groups present. These alterations however will have significant effects on the stability
in different buffers and medium. Therefore investigate how different ligands affect the stability
in different aqueous stability will provide a better understanding of how the stability can be
tailored by choice of ligands. APTS-FeOx and APTES-FeOx were used as comparison surface
functionalizations in the stability assessment as they are a commonly used in literature to surface
functionalize nanoparticles for aqueous stability.225,226 Hydrolysis and condensation of APTS,
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APTES, and GLYMO to the surface of FeOx nanoparticle results in a silica-like shell or network
surrounding the FeOx nanoparticle. However, the inherent solubility and rate of hydrolysis of
each silane notably affects the resultant surface functionalization efficiency.150 The solubility
difference of APTS and APTES compared to GLYMO determined how the silanes were added to
the nanoparticle solution. A slow drop-wise addition of APTS and APTES was required for
efficient surface functionalization. APTS and APTES are most soluble at pH~10 in water.
Therefore when adding these silanes to the TMAOH nanoparticle solution (high pH), a quick
addition could lead to a high local concentration of the silanes and a nucleation event preventing
efficient condensation on the surface of the FeOx nanoparticles. Upon titration to pH 7.4 with
HCl the terminal amine groups of APTS-FeOx and APTES-FeOx provided sufficient colloidal
stability and were ready for subsequent wash and purification steps.
In contrast, GLYMO is highly soluble at pH=5.3. The complete and rapid addition of
GLYMO facilitates the generation of an emulsion-like suspension where the GLYMO ligands
will interact with the FeOx and condense to the surface in the proper orientation. The
condensation can be visibly seen as the clear brown TMAOH nanoparticle solution changes to a
“muddy brown” color after 10-15 minutes of reaction. This color change is the result of the
alteration of solubility of the nanoparticles due to the terminal epoxy groups of the GLYMO
shifting the nanoparticle stability to lower pH. At this point addition of extra TMAOH base and
nucleophiles were used to open the epoxy ring to provide aqueous stability. Addition of a
nucleophile at the high pH resulted in an immediate color change from “muddy brown” to clear
brown indicating the successful base-catalyzed epoxy ring opening. This color change was not
always indicative of aqueous stability as the addition of Lys, Arg, Cys, Thr, Asn, Gln,
hydroxylamine, or citric acid did not result in colloidal stability once the pH was adjusted to 7.4.
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Only Gly, Ser, EDA, TEPA, ABA or SAHBA proved to provide sufficient colloidal stability at
pH=7.4. Figure 4.9 is a visual comparison of sufficient colloidal stability provided by Gly and
Ser at pH=7.4, even in the presence of a rare earth magnet, and the unstable and precipitated
solutions of Lys, Gln, Arg, and Cys.

Figure 4.9. Visual aqueous stability assessment at pH=7.4 in presence of a magnet of several
nucleophilic ligands used to open the GLYMO epoxy ring. Aqueous stability was indicated by a
clear brown top solution as seen in Gly-FeOx and Ser-FeOx. From left to right: Lys-FeOx, GlnFeOx, Gly-FeOx, Ser-FeOx, Arg-FeOx, and Cys-FeOx.
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The instability in a magnetic field is critical in identifying unstable nanoparticles and is used as
the first step in the washing and purification process. Bridging and aggregation due to inefficient
electrostatic repulsion or steric hindrance is the most likely cause of the aggregation seen in
GLYMO-FeOx nanoparticles modified with Lys, Arg, Cys, Thr, Asn, Gln, hydroxylamine, or
citric acid.
The APTS-FeOx, APTES-FeOx, and GLYMO-FeOx nanoparticles were all washed,
purified, and sterilized after pH titration and magnetic separation of unstable nanoparticles. This
process was also used for CMPVA nanoparticles used in the stability investigation. The PD-10
desalting column was not used for additional cleanup of APTS-FeOx or APTES-FeOx
nanoparticles as these nanoparticles crashed on the column during the elution step. The reasoning
behind this is that APTS and APTES surface functionalizations require specific counter-ion salts
for stability and the size exclusion PD-10 column swiftly separates the ions from the much larger
nanoparticles. The rapid removal of the counter-ions required for stability results in aggregation
and instability as the nanoparticles move through the PD-10 column. Additional 30k MWCO
centrifuge filter wash steps were applied in lieu of the PD-10 column to further remove excess
APTS and APTES and as a buffer exchange step. The sterilization with a 0.2 μm sterile filter in a
sterile bio-safety laminar flow hood was the last step of the wash, purification, and sterilization
process.
Characterization with FTIR, XPS, and DLS was used to confirm the addition of APTS,
APTES, and GLYMO to the surface of FeOx nanoparticles. The normalized FTIR-ATR spectra
for APTS-FeOx and APTES-FeOx with water removed are displayed in Figure 4.10. The
normalized FTIR-ATR spectra for GLYMO-FeOx and further modified with Gly, Ser, EDA,
TEPA, ABA, and SAHBA with water removed are shown in Figure 4.11-13. When the
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GLYMO-FeOx terminal epoxy ring is opened and modified with a nucleophile the nanoparticle
is named without the GLYMO. For example, ‘Ser-FeOx’ refers to the terminal epoxy ring
opening of GLYMO-FeOx with Ser. The primary identifying peaks of respective surface
functionalizations are listed in Table 4.4. There are several silane containing peaks
corresponding to SiO-H, Si-O-Si, and Si-O-H stretches that were present at approximately 1100
cm-1, 1058 cm-1, and 918 cm-1 respectively.227-230 Each of the silanes contained a C-H
stretching doublet from the propyl group that absorbs at 2930 cm-1 and 2860 cm-1.227,228 The
terminal amine group of APTS-FeOx and APTES-FeOx nanoparticles had peaks indicative of NH stretching vibration, weak asymmetrical NH3+ bending, and symmetrical NH3+ bending at
3420 cm-1, 1660-1610 and 1550-1485 cm-1 respectively.215,227,228 A combined asymmetric NH3+
bending vibration and torsional oscillation was present in APTS-FeOx, APTES-FeOx, EDAFeOx, and TEPA-FeOx nanoparticles at peaks of 2222-2000 cm-1.215

113

Figure 4.10. FTIR-ATR spectra with normalized percent transmittance for A) APTS-FeOx and
B) APTES-FeOx with water subtracted.
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Figure 4.11. FTIR-ATR spectra with normalized percent transmittance for A) Gly-FeOx and B)
Ser-FeOx with water subtracted.
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Figure 4.12. FTIR-ATR spectra with normalized percent transmittance for A) EDA-FeOx and
B) TEPA-FeOx with water subtracted.
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Figure 4.13. FTIR-ATR spectra with normalized percent transmittance for A) ABA-FeOx and
B) SAHBA-FeOx with water subtracted.

Epoxy ring opening by respective nucleophiles was confirmed by the absence of the “12 micron
band” peak at 750-840 cm-1 and ring breathing frequency for the epoxide group at 1250 cm-1.215
FTIR-ATR spectra comparison of GLYMO-FeOx and SAHBA-FeOx demonstrate the epoxy
ring opening (Figure 4.14). The epoxy ring peaks are absence in all GLYMO nanoparticle
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functionalizations after the addition of the nucleophilic ligand (Figure 4.11-13 and Table 4.4).
In Figure 4.14 it is important to note the appearance of peaks at 1581 and 1416 cm-1
corresponding to the terminal carboxylate anion which indicates that the amine group of SAHBA
opened the epoxy ring.215

Figure 4.14. Normalized FTIR-ATR spectrum of GLYMO-FeOx (blue line) and SAHBA-FeOx
(red line). Epoxy ring opening with SAHBA is indicated by disappearance of peaks at 1250 and
740-850 cm-1 and appearance of peaks at 1581 and 1416 cm-1.
Table 4.4. List of identifying FTIR-ATR peaks surface functionalized FeOx nanoparticles.
Peak Description and
Wavenumber (cm-1)
N-H stretching
3420
C-H stretching 2930
doublet, propyl 2860
group
Asymmetric
2222-2000
NH3+ bending
vibration
and
torsional
oscillation
Carboxylate
1650-1550
Anion
1400
Epoxy
Ring 1250
Breathing
Frequency
CO2 stretching/ 1320-1000
C-O stretch
SiO-H
1100
Si-O-Si
1058
Si-O-H
918
12 micron band
840-750

APTSFeOx
3455
2965
2892

APTESFeOx
3422
2930
2846

EDAFeOx
3422
2964
2898

TEPAFeOx
3421
2964
2864

2100

2095

2205

2152

1118
917

917

GlyFeOx
3422
2916
2870

SerFeOx
3421
2939
2858

ABAFeOx
3422
2920
2879

SAHBAFeOx
3421
2941
2880

1614
1400

1616
1400

1558
1405

1581
1416

1201

1201

1201

1201

1201

1201

1101
1057
916

1101
1057
917

1110
1057
911

1100
1058
916

1100
1058
916

1101
1060
917
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XPS was first used to characterize the non-surface functionalized nanoparticles. Highresolution Fe 3p XPS characterization of A4-24(195)_B6-24(195) nanoparticles (Figure 4.15)
was used to determine the amount of magnetite and maghemite present. High-resolution Fe 2p
XPS spectrum is not suitable to distinguish between magnetite and maghemite crystal structures
due to multiple satellite peaks and broad line widths.231,232 The Fe 3p peak was deconvoluted into
three peaks at 53.119 eV, 55.195 eV, and 56.279 eV. The 53.119 eV peak was attributed to Fe2+
ions.232 The 55.195 and 56.279 eV were attributed to Fe3+ ions.231,232 Pure magnetite will consist
of a 1:2 Fe2+ to Fe3+ ratio, but experimentally it was determined to be 0.52.231,232 Since the ratio
of Fe2+ to Fe3+ was 3:96 it was concluded that the sample contained a mixture of magnetite and
maghemite as maghemite contains no Fe2+ ions. Using the experimentally determined Fe2+ to
Fe3+ ratio of 0.52 for pure magnetite it was estimated that the sample with a ratio of 3:96
contained approximately 8.86% magnetite and 91.14% maghemite.

Figure 4.15. High-resolution Fe 3p XPS spectrum of FeOx nanoparticles without surface
modification.
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XPS was also used to further verify surface functionalization and confirm epoxy ring opening.
Non-surface functionalized FeOx nanoparticles are shown in Figure 4.16.The FeOx
nanoparticles XPS N 1s and Si 2p spectra (not shown) revealed no peaks were present providing
confirmation that peaks in these spectra of APTS-FeOx, Gly-FeOx, and Ser-FeOx are due to
their respective surface functionalization’s.

Figure 4.16. XPS survey spectrum, and high resolution Fe 2p, and O 1s spectra of FeOx
nanoparticles without surface modification.

Analyzing the XPS survey scan of the APTS-FeOx (Figure 4.17) revealed presence of
iron, oxygen, carbon, silicon, and nitrogen as expected for successful surface functionalization.
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Further analysis of the high-resolution Si 2p spectrum revealed the presence of Si-C and Si-O
bonds from the deconvulted peaks positioned at 102.038 eV, and 104.732 eV.233 This confirms
the presence of the APTS and the successful hydrolysis of the silane. However, to confirm
successful silanization with the FeOx nanoparticles analysis of the high-resolution O 1s spectrum
is required. The O 1s peak was deconvulted into four peaks at 529.803 eV, 530.424 eV, 531.573
eV, and 532.573 eV binding energies. The peaks at 530.424 eV, 531.573 eV are most likely due
to impurities from benzyl alcohol, benzaldehyde, or even acetylacetonate. The peaks at 529.803
eV and 532.573 eV correspond to Fe-O and Si-O binding energies.231,234 These peaks confirm the
successful silanization of APTS to FeOx nanoparticles. The high-resolution N 1s spectrum was
next analyzed to further determine the APTS is modifying the surface as expected. Indeed, the N
1s doublet peak was deconvulted into three peaks at 399.323 eV, 400.245 eV, and 401.328 eV
binding energies indicating N-C, -NH2, and –NH3+ respectively.234 The high-resolution C 1s
spectrum was used to further confirm that the attachment of the APTS to FeOx is occurring
through the Si-O-Fe rather than a NHCO bond. A NHCO bond would appear in the C 1s
spectrum with binding energy of 292 eV.233 The only peaks deconvulted from the C 1s spectrum
were 284.988 eV, 286.197 eV, and 288.291 eV corresponding to C-C/C-H bonds, C-O/C-N, and
carbon impurities.233,235
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Figure 4.17. XPS high-resolution Si 2p, N 1s, and O 1s spectra of APTS-FeOx nanoparticles.

Gly-FeOx and Ser-FeOx were investigated with XPS to confirm successful GLYMO
silanization and attachment to FeOx and successful epoxy ring opening by the amine in Gly and
Ser. Ser-FeOx had similar silane peaks to APTS as expected and are shown in the highresolution Si 2p, N 1s, and O 1s spectra (Figure 4.18). In the high-resolution Si 2p spectrum the
peak can be deconvulted into 102.484 and 103.1781 eV binding energy peaks corresponding to
Si-C and Si-O bonds in GLYMO. Next, the O 1s spectrum was analyzed and the main peak
deconvoluted into four peaks at 529.617, 530.987, 532.067, and 532.651 eV binding energies.
The 529.617 eV binding energy peak is attributed to the oxygen in Fe3O4.231 The 530.987 and
532.651 eV binding energies are attributed to the carboxylic acid of Ser. The epoxy ring opening
with Ser through the amine rather than the carboxylic acid is confirmed by absence of a 533.13
eV binding energy peak.236 Analysis of the high-resolution N 1s spectrum revealed three
deconvulted peaks at binding energies of 399.589 eV, 401.354 eV, and 402.851 eV
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corresponding to N-C, NH2, and NH2+, respectively.237 The N 1s spectrum further corroborates
the amine opening of the epoxide ring as expected.

Figure 4.18. XPS high-resolution Si 2p, N 1s, and O 1s spectra of Ser-FeOx nanoparticles.

Figure 4.19. XPS high-resolution Si 2p, N 1s, and O 1s spectra of Ser-FeOx nanoparticles.
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The Gly-FeOx high resolution XPS spectra (Figure 4.19) was in close agreement with
the Ser-FeOx XPS spectra as expected. The high-resolution Si 2p spectrum revealed Si-O and
SiO2 peaks at 102.412 and 102.98 eV binding energies from the GLYMO. The high-resolution O
1s spectrum also revealed a Fe-O bond at 529.591 eV. The Si-O, and carboxylic acid oxygen
bonds from glycine were observed at 532.42 eV, and 531.148 eV and 532.682 eV
respectively.238 The high-resolution N 1s spectrum further established the amine group opened
the GLYMO epoxy ring, indicated by 399.589, 401.354, and 402.851 eV binding energy
corresponding to N-C, NH2, and NH2+.237
DLS is an invaluable characterization technique to determine the properties of the surface
modified nanoparticles in solution. The efficiency of surface functionalization was assessed by
hydrodynamic diameter, polydispersity index (PDI), and zeta potential (ζ), listed in Table 4.5.
The DLS size measurements and zeta potential measurements for each surface functionalization
are shown in Figures 4.21-23. The hydrodynamic diameter change for each surface
functionalization

as

compared

to

TMAOH

nanoparticles

depends

on

the

surface

functionalization. Possible aggregation was revealed in some of the surface functionalizations
which contained a small volume fraction of larger hydrodynamic diameters. The small
hydrodynamic diameter of APTS-FeOx (17.83±7.628 (99.9%)) compared to the hydrodynamic
diameters of APTES-FeOx (92.15±17.77 (71.4%) and 332.5±58.37 (28.6%)) suggests that APTS
is most likely more stable than APTES. APTES has a 7 fold slower hydrolysis rate than APTS
which most likely resulted in some incomplete or insufficient surface functionalization; this is
supported by the second larger hydrodynamic diameter population for APTES. 150
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Table 4.5. DLS measurements of hydrodynamic diameter, polydispersity index, and Zeta
potential for surface functionalized FeOx nanoparticles.
Surface
Functionalization
TMAOH-FeOx
APTS-FeOx
APTES-FeOx
EDA-FeOx
TEPA-FeOx
Gly-FeOx
Ser-FeOx
ABA-FeOx
SAHBA-FeOx
CMPVA-FeOx

Hydrodynamic
Diameter (nm)
26.6±7.795 (100%)
17.83±7.628 (99.9%)
92.15±17.77 (71.4%)
332.5±58.37 (28.6%)
35.56±11.09 (99.9%)
193.2±41.47 (0.1%)
38.12±9.959 (100%)
29.13±12.67 (100%)
34.63±6.5 (82.3%)
110.3±32.88 (17.7%)
29.56±5.713 (93)
114.2±37.97 (7%)
25.59±6.269 (99.2%)
126.7±36.98 (0.8%)
91.6±20.53 (100%)

Polydispersity Index Zeta Potential
(PDI)
(mV)
0.112
0.317
21.5±1.33
0.386
21.1±1.94
0.221

46.4±13.1

0.150
0.228
0.219

41.2±19.7
-22.4±5.8
-20.2±11.2

0.372

-21.8±5.09

0.269

-29.2±14

0.148

-19.2±0.936

(ζ)

Figure 4.20. DLS measurements based on volume percent for A) APTS-FeOx and B) APTESFeOx.

125

Remarkably, there was a range of hydrodynamic diameters and PDI values for GLYMO
nanoparticles. While the differences are subtle they are more than likely due to small changes in
size of the added nucleophile, formation of differing water solvation shell sizes, and/or magnetic
separation selecting a particular size. Despite the differences in hydrodynamic size and PDI
values these GLYMO functionalized nanoparticles produced a stable colloid at biologically
relevant pH.

Figure 4.21. DLS measurements based on volume percent for A) Gly-FeOx and B) Ser-FeOx.
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Figure 4.22. DLS measurements based on volume percent for A) ABA-FeOx and B) SAHBAFeOx.

Figure 4.23. DLS measurements based on volume percent for A) EDA-FeOx and B) TEPAFeOx.
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DLS was next used to measure the zeta potential which can be useful in predicting cellular
interactions. The zeta potential measurements are shown in Figures 4.24-27. The presence of
terminal carboxylate groups in Gly-FeOx, Ser-FeOx, ABA-FeOx, SAHBA-FeOx and CMPVA
nanoparticles resulted in negative zeta potentials. The negative zeta potentials due to terminal
carboxyl groups is expected as the amine groups of these molecules are much better nucleophiles
than alcohol groups or water and will open the epoxy ring much more efficiently.239 SAHBAFeOx had the most negative zeta potential of -29.2 mV. The chemically similar ligands SAHBA
and Ser differ in the carbon chain length and position of the alcohol group in relation to the
carboxylic acid group. This is important as the OH group in SAHBA is closer to the electron
withdrawing group of the carboxylic acid thus lowering the pKa resulting in a more negative zeta
potential at pH of 7.4. Large negative or positive zeta potentials have been reported as an
indicator of colloidal stability, but may not always indicate stability in biologically relevant
medium that cannot be easily measured using DLS.
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Figure 4.24. Zeta potential measurement of A) Gly-FeOx and B) Ser-FeOx nanoparticles.

Figure 4.25. Zeta potential measurement of A) ABA-FeOx and B) SAHBA-FeOx nanoparticles.
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The APTS-FeOx, APTES-FeOx, EDA-FeOx, and TEPA-FeOx nanoparticles all had positive
zeta potentials as expected (Figure 4.26 and 4.27). This was due to the terminal protonated
amine groups at pH of 7.4. The APTS-FeOx and APTES-FeOx nanoparticles were expected to
have the same final surface functionalization despite different starting ligands. This was further
corroborated by the similar zeta potentials measured. The EDA-FeOx and TEPA-FeOx
nanoparticles had zeta potentials twice as large as APTS-FeOx /APTES-FeOx which resulted
from the larger amount of primary and secondary amines present in EDA-FeOx and TEPA-FeOx
nanoparticles as compared to APTS-FeOx and APTES-FeOx nanoparticles. Additionally, the pH
titration to 7.4 for EDA-FeOx and TEPA-FeOx nanoparticles required more HCl than the APTSFeOx and APTES-FeOx nanoparticles, further substantiating the zeta potential differences.

Figure 4.26. Zeta potential measurement of A) APTS-FeOx and B) APTES-FeOx.
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Figure 4.27. Zeta potential measurement of A) EDA-FeOx and B) TEPA-FeOx.

4.5 Stability Assessment in Different Biologically Relevant Medium
The stability assessment of the surface functionalized FeOx nanoparticles is vital in
predicting how efficiently they can be used in biological applications. By testing the stability in
several biologically relevant medium a better understanding of biological effects such as cellular
uptake, biodistribution, and retention can be accomplished. The surface functionalization
methods were chosen to provide biological stability and allow for further conjugation potential
via 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) coupling. More specifically, APTS
and APTES were chosen as they are commonly used surface functionalizations with reported
aqueous stability provided by terminal amines. The CMPVA surface functionalization was used
as it was shown to have stability in a wide range of biological media. GLYMO surface
functionalizations were chosen as they provided a convenient and rapid way to modify the
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surface with a nucleophile. The benefit of the GLYMO method is that a variety of nucleophiles
can be used to tailor the stability to specific applications. Several amino acids were used in
attempts to provide a variety of terminal groups granting a “bio-stealth” like property and EDA
and TEPA were chosen to produce an amine terminal functionalization that would be a good
comparison to APTS and APTES functionalizations. While a variety of tested amino acids and
compounds were unsuccessful in providing stability after magnetic extraction and purification
steps, Gly-FeOx and Ser-FeOx had very promising initial stabilities. Thus, ABA and SAHBA
were chosen as they are chemically and structurally similar to Gly and Ser respectively. In a
recent study increasing chain length of multidentate block copolymers were shown to positively
affect the stability of FeOx nanoparticles in PBS.240 ABA contains a slightly longer carbon chain
than glycine. SAHBA differs from Ser as it contains a slightly longer carbon chain and the
alcohol group is closer in proximity to the carboxylic acid group. With the alcohol closer to the
carboxylic acid it is thought that stability would be improved by increasing the electrostatic
repulsion between nanoparticles by producing a more negative zeta potential.
Water, 1x PBS, 0.5x PBS, 0.9% NaCl, CSF, CM, and HS were used to determine the
stability and investigate potential causes of instability of the different surface functionalizations.
Visual assessment of the surface functionalized FeOx nanoparticles at various time points were
used in place of DLS measurements as not all solutions can be easily measured using DLS
techniques. Visual assessment was broken into three categories: clear solution, cloudy solution,
and precipitated/crashed solution representing stability, partial stability, and complete instability
respectively. The stability was monitored at several time points from initial dispersion to 2 weeks
in test medium. Table 4.6 summarizes the times at which each surface functionalized
nanoparticle first showed signs of instability (cloudy or precipitation). Upon initial inspection all
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surface functionalized nanoparticles were stable in all media except EDA-FeOx and TEPAFeOx. Both of these became cloudy in cell medium and HS immediately.

Table 4.6. List of first signs of instability of various surface functionalized FeOx nanoparticles;
indicated by a cloudy or precipitated solution.
H2O
APTS-FeOx
APTES-FeOx
EDA-FeOx
TEPA-FeOx
Gly-FeOx
Ser-FeOx
ABA-FeOx
SAHBA-FeOx
CMPVA-FeOx

1x PBS

0.5x PBS

2 hours
2 hours

2 hours
2 hours

0.9%
NaCl
2 hours

CSF

CM

2 hours
2 hours

48 hours
24 hours
2 hours
2 hours
2 weeks*
2 weeks**
2 weeks*
2 weeks**
2 weeks**

1 week

HS

24 hours
24 hours
2 hours
24 hours
2 weeks
2 weeks

*Small amount of precipitation may be due to cell medium sitting at room temperature
**Very small amount of precipitation which may be due to cell medium sitting at room
temperature

Visual inspection of nanoparticles in water revealed that even at 1 month time (Figure
4.28) all surface functionalizations were clear and stable. This is important to note as stability in
water does not necessarily indicate stability in the biological media of interest. PBS was
investigated as it is a very commonly used biological buffer. All nanoparticles except APTSFeOx and APTES-FeOx were soluble in 1x PBS at 2 weeks. APTS-FeOx and APTES-FeOx
showed initial aggregation at 2 hours and were completely precipitated out of solution at 24
hours.
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Figure 4.28. Time study of surface functionalized FeOx nanoparticle stability in water (H2O)
and 1x phosphate buffered saline (PBS). Clear, cloudy, or aggregated precipitations indicate
stable, partially stable, or complete instability respectively.
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Assessment of stability in 0.5x PBS and 0.9% NaCl (Figure 4.29) solutions were chosen
to ascertain if the phosphate ions or concentration of sodium and chloride counter ions caused
the instability in 1x PBS for APTS-FeOx and APTES-FeOx. Interestingly, APTS-FeOx and
APTES-FeOx had the same stability in 0.5x PBS, but APTES-FeOx was instable in 0.9% NaCl.
This suggests that the phosphate ions are causing instability in APTS-FeOx. Analysis of the DLS
data (Table 4.5) shows that APTES-FeOx has a much larger hydrodynamic size (92.15±17.77
nm (71.4%) and 332.5±58.37 nm (28.6%)) as compared to APTS-FeOx (17.83±7.628 nm
(99.9%)). This difference in size and the inability to 0.2 μm sterile filter APTS-FeOx or APTESFeOx solutions after several days prompted further investigation. To further investigate the
difference in stability the hydrodynamic size was analyzed in water at two time points. The data
(Figure 4.30) shows a hydrodynamic diameter increase over time for both APTS-FeOx and
APTES-FeOx, but the extent of increase suggests that APTES-FeOx aggregates at a much faster
rate than APTS-FeOx. This suggests that the APTES-FeOx may not have completely formed a
silane shell and may be reorienting and forming a silane shell around multiple nanoparticles.
Alternatively, a re-hydrolyzation process leading to improper silane shell reforming could also
be occurring leading to larger hydrodynamic sizes and instability. The APTES-FeOx is able to
maintain stability in water even with changes in hydrodynamic size, but the addition of salts
causes complete precipitation. These results suggests that APTS-FeOx and APTES-FeOx may
appear clear and stable in some solutions, but are susceptible to re-hydrolysis and aggregation
over time.
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Figure 4.29. Time study of surface functionalized FeOx nanoparticle stability in 0.5x PBS and
0.9% sodium chloride (saline). Clear, cloudy, or aggregated precipitations indicate stable,
partially stable, or complete instability respectively.
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Figure 4.30. DLS hydrodynamic size measurements of APTS-FeOx (A) or APTES-FeOx (B)
after 1 (Top) and 12 days (Bottom).
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CSF stability is important to investigate for the application of FeOx nanoparticles for the
treatment of glioblastoma multiforme (GBM). CSF is a close representation of the environment
that the nanoparticles would be subjected to in treatment of brain tumors. In Figure 4.31 it can
be seen that APTS-FeOx and APTES-FeOx first show signs of instability at 2 hours and at 24
hours are completely crashed out of solution. TEPA-FeOx showed a small amount of
precipitation at 1 week indicating partial instability. Instability at these short time periods limits
their applicability in delivering time sensitive brachytherapy. Additionally, the instability could
prohibit blood circulation and/or uptake.

Figure 4.31. Time study of surface functionalized FeOx nanoparticle stability in artificial
cerebral spinal fluid (CSF). Clear, cloudy, or aggregated precipitations indicate stable, partially
stable, or complete instability respectively.

In vitro investigations of FeOx nanoparticles are often performed using complete cell
medium containing FBS. Similarly, in vivo administered FeOx nanoparticles in humans will
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have some degree of interaction with HS. The proteins contained in the respective serum can
have varying degrees of interaction with the nanoparticles and therefore affect the stability. Thus,
stability assessments in these media are imperative and are shown in Figure 4.32. Protein
coronas can form around nanoparticles when introduced to media containing serum which will
directly and substantially affect cellular interactions.241 Interestingly, EDA-FeOx and TEPAFeOx nanoparticles instantaneously became cloudy upon introduction to CM or HS and were
approaching complete precipitation at 2 hours. The other positive zeta potential surface
functionalizations, APTS-FeOx and APTES-FeOx, also displayed aggregation signs early. At 48
hours for APTS-FeOx and 24 hours for APTES-FeOx aggregation and precipitation began. The
negative surface functionalized nanoparticles showed small amounts of precipitation for GlyFeOx and Ser-FeOx and very small amounts of precipitation for ABA-FeOx, SAHBA-FeOx, and
FeOx at 2 weeks. Analyzing the HS stability revealed that only APTS-FeOx, SAHBA-FeOx,
and CMPVA-FeOx retained stability at 2 weeks. The stability was very similar in CM and HS
for APTES-FeOx, EDA-FeOx, TEPA-FeOx, and Ser-FeOx suggesting that the FBS in CM was
the cause of instability. Gly-FeOx was instable at 24 hours in HS and only showed small
amounts of instability at 2 weeks in CM suggesting that the higher concentration of serum in HS
as compared to CM resulted in the different stabilities.
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Figure 4.32. Time study of surface functionalized FeOx nanoparticle stability in cell medium
(CM) and human serum (HS). Clear, cloudy, or aggregated precipitations indicate stable,
partially stable, or complete instability respectively.
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Interesting stability information can be established when comparing the differences of
stability in PBS, CM, and HS. With regards to APTS-FeOx the instability can be attributed to
phosphate ions rather than serum proteins as the APTS-FeOx nanoparticles remained stable in
HS at 2 weeks. The differences between positive and negative zeta potential surface
functionalizations are striking. The larger degree of instability of positive surface
functionalizations as compared to negative surface functionalizations seen in CM and HS offers
some substantiation to claims of higher cellular uptake values recorded for cationic amine group
functionalizations. However, the increased uptake recorded may be due to crashed cationic
surface functionalizations and not true uptake or internalization.
DLS investigation of APTS-FeOx, APTES-FeOx, EDA-FeOx, and TEPA-FeOx in water
was assessed after 12 days to determine if any changes were occurring that were not visually
seen. The hydrodynamic size after twelve days in water for APTS-FeOx and APTES-FeOx is
shown in Figures 4.30; EDA-FeOx and TEPA-FeOx is shown in Figure 4.33 and 4.34. APTSFeOx nanoparticles increased from 17.83±7.628 nm (99.9%) to 122.1±37.45 nm (95.7%) and
5326±699.2 nm (4.3%) where APTES increased to 674.7±85.2 nm (100%) (Figure 4.30). EDAFeOx and TEPA-FeOx surface functionalized nanoparticles measured hydrodynamic diameters
were 35.56 ±11.09 nm (99.9%) and 38.12±9.959 nm (100%) respectively. After 12 days EDAFeOx and TEPA-FeOx surface functionalized nanoparticles measured hydrodynamic diameters
were 27.82±11.01 nm (100%) and 29.52±9.047nm (100%). This is crucial as it clearly shows
that the silane on the EDA-FeOx and TEPA-FeOx nanoparticles does not alter overtime whereas
the APTS silane does alter over time resulting in larger hydrodynamic diameters.
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Figure 4.33. Dynamic light scattering hydrodynamic diameter measurement by volume for
EDA-FeOx nanoparticles (A) and EDA-FeOx nanoparticles 12 days later (B).

Figure 4.34. Dynamic light scattering hydrodynamic diameter measurement by volume for
TEPA-FeOx nanoparticles (A) and TEPA-FeOx nanoparticles 12 days later (B).
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The long term stability was analyzed at 3 weeks, 1 month and 5 months (Figure 4.35 and
4.36). The stability at 1 month was deemed sufficient for initial stability assessment. The 5
month time point may not be an accurate representation of long term stability as there was some
volume changes observed in a few of the microcentrifuge tubes most likely due to evaporation.
The volume changes do not seem to be related to media and are considered an effect of random
inefficient sealing of microcentrifuge tubes which resulted in only some of the samples
evaporating. Regardless, the 5 month analysis is helpful in visualizing instability that may have
been present and unseen at earlier time points. For water the first signs of instability were seen at
5 months for APTES-FeOx and very small amounts of precipitation in Gly-FeOx, and Ser-FeOx.
There was some small amount of precipitation at 5 months in 1x PBS for Gly-FeOx, and SerFeOx, but not 0.5x PBS. At 5 months the first and small signs of instability in CSF were
observed for Gly-FeOx, Ser-FeOx, ABA-FeOx, and CMPVA-FeOx.
In conclusion, CMPVA-FeOx, Ser-FeOx, ABA-FeOx, and SAHBA-FeOx demonstrated
broad stability at 1 week. The CMPVA-FeOx and SAHBA-FeOx nanoparticles only had
minimal precipitation in CM at 2 weeks, but were otherwise stable up to 5 months with the
exception of some CMPVA-FeOx precipitation in CSF. Overall, SAHBA-FeOx had the best and
broadest solution stability even at 5 months. It is thought that the longer carbon chain and the
alcohol being in closer proximity to the carboxylate group in SAHBA provided the best
electrosteric stability of the surface functionalizations tested. Furthermore, this investigation
suggests that the presence of both hydroxyl and carboxyl groups appear to provide the best and
broadest stability as seen in CMPVA-FeOx and SAHBA-FeOx. The different media revealed
that the concentration of salt, sugar, and protein can have dramatic effects on the stability. More
specifically, water or PBS stability is not indicative of stability in all biologically relevant media.
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These two surface functionalizations have relatively large differences in hydrodynamic size, but
similar broad stability and zeta potentials. They will potentially be very useful in determining
differences in biological effects based on size.

Figure 4.35. Time study of surface functionalized FeOx nanoparticle stability in water, 1x PBS,
and 0.5x PBS at 3 weeks, 4 weeks, and 5 months. Clear, cloudy, or aggregated precipitations
indicate stable, partially stable, or complete instability respectively.
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Figure 4.36. Time study of surface functionalized FeOx nanoparticle stability in 0.9% NaCl,
CSF, CM, and HS at 3 weeks, 4 weeks, and 5 months. Clear, cloudy, or aggregated precipitations
indicate stable, partially stable, or complete instability respectively.
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4.6 Iron Oxide Nanoplatform: Confirming Conjugation Potential
with a Radiotherapeutic
The surface functionalizations were chosen not only to provide biological stability, but to
also provide additional conjugation potential. To demonstrate their conjugation potential a metal
chelate, DOTA, was conjugated to SAHBA-FeOx and CMPVA-FeOx nanoparticles. DOTA can
chelate Lutetium-177 (177Lu), primarily a beta emitter that has been used to treat GBM in
preclinical murine orthotopic xenograft models.48 It can also be easily monitored due to a
relatively small amount of gamma emmision.48 Successful attachment of the DOTA chelate and
radiolabeling with 177Lu will demonstrate these FeOx surface functionalized nanoparticles ability
to act as a nanoplatform for additional radiotherapeutics. SAHBA-FeOx and CMPVA-FeOx
were

chosen

as

they

showed

the

best

stability

results.

1-Ethyl-3-(3-

dimethylaminopropyl)carbodiimide (EDC) is a water soluble carbodiimide used for the coupling
reaction of carboxyl and amine groups to form an amide bond.93 N-hydroxysulfosuccinimide (SNHS) is used to increase the efficiency of the carboxyl and primary amine coupling reaction.93
High-performance liquid chromatography (HPLC) was used to confirm successful EDC
coupling of the DOTA chelate and determine the radiochemical purity of radiolabeled

177

Lu-

DOTA-SAHBA-FeOx. The HPLC elution profiles of SAHBA-FeOx measured by UV-VIS
absorbance at 254 nm and radioactivity detectors are shown in Figure 4.37. This was done to
establish the time at which SAHBA-FeOx nanoparticles elute and confirm no radioactivity is
present. Next, EDC coupling of the DOTA chelate to the SAHBA-FeOx was performed and then
radiolabeled with

177

column, specifically

Lu. HPLC was used after removal of free metal cations with an MCX

177

Lu. Dose calibrator measurements of

177

Lu-DOTA-SAHBA-FeOx after

MCX column indicated a 52.4% chelation yield. The absorbance results in Figure 4.38 show
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additional peaks at approximately 12.05 and 21.9 mins corresponding to free

177

Lu-DOTA, and

ammonium hydroxide buffer, respectively. The radioactivity peak (Figure 4.38) centered at
approximately 9.18 mins overlaps with the absorbance at 254 nm peak (~8.49 mins) indicating
successful radiolabeling of DOTA-SAHBA-FeOx nanoparticles with

177

Lu. It should be noted

that the HPLC radioactivity elution time is slightly delayed due to the time required for the
elution to reach the radioactivity counter. The radioactivity peak at 12.33 mins represents free
177

Lu-DOTA.

Figure 4.37. HPLC elution profiles of SAHBA-FeOx nanoparticles. The absorbance at 254 nm
(top) and radioactivity counts (bottom) are shown.
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Figure 4.38. HPLC elution profiles of

177

Lu-DOTA-SAHBA-FeOx post MCX column elution.

The normalized absorbance at 254 nm (top) and radioactivity counts (bottom) are shown.

To remove the remaining free

177

Lu-DOTA, and DOTA, a PD-10 size exclusion column was

used. Dose calibrator measurements of

177

Lu-DOTA-SAHBA-FeOx after PD-10 column

indicated a 14.5% synthetic radiochemical yield. The absorbance at 254 nm in Figure 4.39 only
contains one peak centered at approximately 8.6 mins confirming the successful removal of
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remaining free

177

Lu-DOTA, and DOTA chelate by the PD-10 column. Furthermore, the

presence of only one radioactivity peak at 8.79 mins confirms the removal of free 177Lu-DOTA.

Figure 4.39.

HPLC elution profiles of

177

Lu-DOTA-SAHBA-FeOx post MCX and PD-10

column elution. The absorbance at 254 nm (top) and radioactivity counts (bottom) are shown.

Next, an HPLC study was used to determine the radiochemical stability of the
nanoplatform when subjected to RF hyperthermia. This investigation is essential in determining
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the ability of the nanoparticles to deliver both hyperthermia and brachytherapy. The
radiochemical stability was assessed for 177Lu-DOTA-SAHBA-FeOx after 0, 15, and 45 minutes
of RF heating. If the

177

Lu is released from the DOTA chelate or

177

Lu-DOTA is released from

the nanoparticle after RF heating there could be a reduction in the treatment dose in the region of
interest and potential radiation damage to normal tissue in other regions. Additionally, free 177Lu
has been shown to incorporate in bone which could limit the amount of activity that can be safely
used in treatment, due to radiation sensitivity of bone marrow.242,243 The HPLC separated
absorbance spectrum for 0, 10, and 15 minutes of RF heating is shown in Figure 4.40. The
HPLC integrated peak areas at approximately 8.3-11.4 mins and 12.03-14.01 mins correspond to
177

Lu-DOTA-SAHBA-FeOx and

177

Lu-DOTA respectively. Changes in integrated peak areas

were used to assess the heat stability after 15 and 45 minutes of RF heating (Figure 4.41). The
integrated peak ratios of

177

Lu-DOTA-SAHBA-FeOx to

177

Lu-DOTA were 97.2% to 2.8%,

97.2% to 2.8%, and 97.6% to 2.4% for 0, 10 and 15 minutes of RF heating. No significant
increases in integrated peak areas for radioactivity were observed after 15 or 45 minutes of RF
heating, confirming the heat stability of 177Lu-DOTA-SAHBA-FeOx.
Furthermore, gamma counting was used to determine if any
heating. To accomplish this, the

177

177

Lu was released after

Lu-DOTA-SAHBA-FeOx nanoparticles were passed through

a MCX column after RF heating and the MCX column was gamma counted after elution of the
177

Lu-DOTA-SAHBA-FeOx. The gamma counts per minute of the MCX columns for RF heating

177

Lu-DOTA-SAHBA-FeOx 0, 10, and 15 mins were 120,686 cpm, 117,373 cpm, and 118,275

cpm respectively. The MCX column can remove

177

FeOx as the MCX column more strongly binds

Lu from the stable

177

Lu-DOTA-SAHBA-

Lu. This result shows clearly that no

significant amount of 177Lu was released upon RF heating.
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Figure 4.40. HPLC elution profiles absorbance at 245 nm of
product after T0, T15, and T45 minutes of RF heating.
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177

Lu-DOTA-SAHBA-FeOx final

Figure 4.41. HPLC elution profiles radioactivity counts of
product after T0, T15, and T45 minutes of RF heating.
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177

Lu-DOTA-SAHBA-FeOx final

HPLC absorbance and radioactivity analysis confirmed the successful conjugation of
DOTA metal chelate and radiolabeling with 177Lu to SAHBA-FeOx and CMPVA-FeOx. Greater
than 97% radiochemical purity was obtainable with the cleanup methods used. Additionally, no
significant amount of 177Lu or 177Lu-DOTA was released from 177Lu-DOTA-SAHBA-FeOx
nanoparticles after RF heating. These results demonstrate the possibility of expanding the
conjugation to include combinations of other radiotherapeutics, chemotherapeutics, and/or
diagnostic agents by utilizing EDC coupling.
In this chapter the synthesized nanoparticles were easily surface functionalized without
the need for difficult phase transfer methods. For surface functionalization with CMPVA, an
optimal 0.125% TMAOH concentration was determined. Furthermore, it was determined that for
different nanoparticle sizes the methods are best modified by changing the amount of surface
functionalization ligand relative to the number of nanoparticles. The CMPVA surface
functionalization methods were successfully used to produce APTS-FeOx, APTES-FeOx, and
GLYMO-FeOx. The GLYMO-FeOx nanoparticles proved to be very beneficial as the terminal
epoxy ring could be modified with a variety of nucleophiles to provide different biological
stability properties. FeOx nanoparticle surface functionalizations were verified through FTIRATR, XPS, and/or DLS characterization. Stability investigations revealed that SAHBA-FeOx
had the best and broadest stability in different biologically relevant media. The SAHBA-FeOx
and CMPVA-FeOx demonstrated further conjugation potential via the EDC coupling of DOTA
metal chelate and radiolabeling with 177Lu. This produces a theranostic FeOx nanoparticle that
can potentially provide radiotherapy and hyperthermia, with MRI capability.
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Chapter 5: Biological Testing of Surface Functionalized Iron
Oxide Nanoparticles

5.1 Experimental Section
5.1.1 Reagents, Materials, and Equipment
T75 flask (Greiner Bio-One, CELLSTAR®, red filter cap, sterile), Dulbecco’s phosphate
buffered saline (DPBS) (Corning, cellgro, without calcium and magnesium, sterile), 0.25%
trypsin solution (Hyclone), handheld automated cell counter (Millipore, Scepter™), 6-well plate
(Greiner Gio-One, Cellstar®), 96-well plates (Greiner Bio-One, Cellstar®), artificial cerebral
spinal fluid (CSF) (Harvard Apparatus, artificial), human serum (HS) (Bioreclamation, LLC),
modified DMEM/F-12 medium (Hyclone, 0.1 µm sterile filtered) containing 10% fetal bovine
serum (FBS) (Seradigm, ultimate grade, triple 0.1 µm sterile filtered), 1% antibiotic/antimycotic
solution (Hyclone, 10,000 U/mL Penicillin G, 10,000 µg/mL Streptomycin, 25 µg/mL
Amphotericin B, 0.2 µm filtered), Cell LyticTM M lysis buffer (Sigma), cell proliferation reagent
WST-1 (Roche)
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5.1.2 Tissue Culture and Cellular Uptake Studies
For biological testing, M059K, GBM-6, or U87MG (AmericanType Culture Collection)
cell lines were incubated at 37°C and 5% CO2 in either T75 or T25 flasks containing complete
cell medium. Upon reaching ~80% confluence the cells were washed with Dulbecco’s phosphate
buffered saline (DPBS) and trypsinised with 0.25% trypsin solution to passage or split the cells
into additional culture flasks. A handheld automated cell counter was used to determine the
concentration of cells. Cells were diluted to a concentration of 75,000 cells/mL of culture
medium prior to plating 2 mL in each well of a 6-well plate. The cells were allowed to attach
overnight (~16 hours). Cellular uptake was determined by adding 200 μL of surface
functionalized nanoparticles (250 μg/mL). After 4 hours of uptake the cell medium was aliquoted
(500 μL), followed by aspiration of the remaining medium. Next, cells were washed three times
with DPBS. Cells were lifted in approximately 1.5 mL of DPBS and transferred to a
microcentrifuge tube. Cells were centrifuged at 13,000 rpm for 7 minutes to pellet the cells. The
supernatant was discarded and 30 μL of Cell LyticTM M lysis buffer was added and sonicated for
15 minutes. To dissolve the nanoparticles and cells 2.14 μL of 70% nitric acid was added and
heated in a heat block at 90°C for 1 hour. A 30 μL aliquot of the collected cell media with 2.14
μL of 70% nitric acid was also heated at 90°C for 1 hour. Prussian blue assay was used to
determine the amount of iron. The concentration of cells and amount of iron were used to
calculate the cell uptake in units of iron per cell.

5.1.3 WST-1 Cell Proliferation Assays
Cytotoxicity was assessed by a WST-1 cell proliferation assay in a 96-well format. The
cells were diluted to a concentration of 25,000 cells/mL of cell medium and 100 μL (2,500 cells)
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were plated in each well (n=7). After attaching overnight, 10 μL of PBS control or surface
functionalized nanoparticles (250 μg/mL) was added to each well on two 96-wells plates to
assess proliferation at 24 and 48 hours. Cell medium was aspirated at 24 or 48 hours and 110 μL
of cell proliferation reagent WST-1 in cell medium (500 μL in 5 mL of cell media) was added to
each well. The cells were incubated at 37°C and 5% CO2. At 30, 60, 90, and 120 minutes the 96well plate was shaken for 60 seconds in a plate reader equipped with UV-VIS. UV-VIS was
measured at 440 nm with a reference at 620 nm.
A half maximal inhibitory concentration (IC50) was also determined using a WST-1 assay
similar to the cytotoxicity methods above. A 10x DMEM-FBS solution was created by
dissolving 1.56 g of DMEM powder (HyClone Laboratories Inc., DME/F -12 1:1+2.5 mM L
glutamine, +15 mM HEPES buffer, -sodium bicarbonate) and 0.2438 g of sodium bicarbonate
(NaHCO3) (Sigma, 99.5%) in 10 mL of Ultra H2O. This solution was 0.1 µm sterile filtered in a
sterile biological laminar flow hood. Next, 9 mL of the 10x DMEM solution was mixed with 9
mL of sterile 10x FBS to obtain a 5x DMEM-FBS solution. To 120 µL of the 5x DMEM-FBS
solution a total of 540 µL of SAHBA-FeOx nanoparticles (~2,200 µg of Fe/mL) and water was
added to create 81.81%, 75%, 65.909%, 50%,40%, 20%, 10%, and 0% (1769, 1555, 1179, 944,
472, and 236 µg of Fe/mL) treatment concentrations. After plating 2,500 cells in 100 μL in each
well of a 96-well plate the cells were allowed to attach overnight, the medium was then aspirated
and then treated with 110 μL of SAHBA-FeOx DMEM-FBS solutions. After 24 hours of
treatment, the WST-1 cell proliferation assay was completed as stated above. The resulting cell
proliferation values were analyzed in Microsoft Excel with Solver add-in to fit a non-linear IC50
curve. Solver was used to minimize the sum of squares of the predicted y-values from Equation
19, where A, B, C and D constants are the maximum point, slope of the middle section of the
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curve, point of inflection, and minimum point respectively. The IC50 was determined by
rearranging Equation 19 to formulate Equation 20.
𝑦=𝐷+

(𝐴−𝐷)

(19)

𝑥 𝐵
𝐶

1+( )

1

𝑥=𝐶 ×

(𝐴−𝑦) (𝐵)
[(𝑦−𝐷)]

(20)

5.1.4 Colony Forming Cell Assay of RF Hyperthermia treated M059K Cells
M059K cells were harvested from a T75 culture flask and counted. Next, 800,000 cells
were transferred to a 15 mL conical tube and centrifuged at 1,500 rpm for 5 minutes to pellet the
cells. The cells were re-dispersed in 1 mL of cell medium and added to 4 mL of cell medium in a
T25 culture flask. Overnight incubation allowed time for the cells to attach. CMPVA
nanoparticle treatment or PBS control (250 μL) was added to respective T25 flask and placed
back in the incubator for 24 hours. After 24 hour incubation the cells were harvested with 1 mL
of trypsin and quenching with 3 mL of cell medium. Next, three 500 μL aliquots of PBS control
and six 500 μL CMPVA nanoparticle treatments were added to microcentrifuge tubes. For the
PBS control an additional 150 μL of cell medium was added (no particle control group). Three of
the CMPVA nanoparticle treatment aliquots received 150 μL of cell medium (particle group) and
three received 150 μL of extra CMPVA nanoparticles (~325 µg of iron) in cell medium (extra
particle group). Each treatment group was then heated in a water bath at 37°C for one minute
prior to RF heating for 0, 10 or 15 minutes at 200.2 A, and 1287 W, in a coil tuned to ~270 kHz.
The colony assay performed by diluting each treatment to 150 cells/mL and plating 300 cells (2
mL) on 6-well plates in triplicate. Cell colonies were stained with crystal violet dye and counted
at 2 weeks.
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5.1.5 U87MG Glioblastoma Tumor Implantation
The in vivo mice investigations were conducted according to protocols sanctioned by the
McGuire VAMC institutional animal care and use committee (IACUC# 01748). For tumor
implantation, female athymic nude-Foxn1nu mice (Harlan Laboratories) were first anesthetized
with isoflurane (3% knockdown, 2% maintenance in oxygen). Next, the mice were positioned in
a stereotactic frame (David Kopf Instruments). A drill was positioned after a midline incision to
drill a 0.7 mm burr hole at a position 0.5 mm anterior to the bregma and 2 mm laterally to the
right. Next, a microinjection pump (Bioanalytical Systems) equipped with a 25 µL Hamilton
syringe and a 28 gauge removable needle was positioned at a depth of 4.0 mm into the brain
(measured from the surface of the skull). The syringe was loaded with 5 µL of PBS containing 5
x 104 U87MG cells per µL. The cell suspension was infused at a constant rate of 0.2 µL per
minute for a period of 10 minutes resulting in deposition of 1 x 105 cells. After infusion, sterile
bone wax was utilized to seal the burr hole and the midline incision was sutured. After sufficient
recovery time, the animals were returned to the vivarium.

5.1.6 Radioactivity Dose Preparation and Survival Study
CMPVA-FeOx or SAHBA-FeOx were further conjugated to DOTA chelate via EDC
coupling, radiolabeled with

177

Lu, washed, purified, and sterilized as described in section 4.1.6.

Additionally, DOTA chelate only was also radiolabeled to serve as a treatment group. The
radioactivity was measured by gamma well counting and dose calibrator. The radioactivity was
matched for

177

Lu-DOTA,

177

Lu-DOTA-SAHBA-FeOx, and

177

Lu-DOTA-CMPVA-FeOx by

dilution with PBS, SAHBA-FeOx, and CMPVA-FeOx respectively. SAHBA-FeOx and
CMPVA-FeOx nanoparticles were used for dilution in order to retain a similar concentration of
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nanoparticles to the SAHBA-FeOx treatment group. Additionally, three radioactivity
concentrations were prepared for each treatment in sterile microcentrifgue tubes to account for
177

Lu radioactive decay (half-life= 6.7 days) over the three days required for surgical procedures

and infusion of 40 mice (15, 15, 10 mice for days 1, 2, and 3 respectively). More specifically, the
three concentrations were required to allow for a constant infusion volume of 10 µL in order to
deliver the same radioactive dosage to the mice. The U87MG survival study consisted of 40 mice
randomized into five treatment groups (n=8) including PBS control, SAHBA FeOx,
DOTA,

177

Lu-DOTA-SAHBA-FeOx, and

177

Lu-

177

Lu-DOTA-CMPVA-FeOx. All radiolabeled

treatment groups were planned to receive approximately 10 µCi of
SAHBA-FeOx, or

177

Lu-DOTA-CMPVA-FeOx.

177

Lu-DOTA,

177

Lu-DOTA-

For CED the mice were placed into a

stereotactic frame and a midline incision was made to reveal the burr hole. After removal of bone
wax the microinjection needle was centered stereotactically on the burr hole and lowered to a
depth of 4 mm to hit the center of the tumor. Next, CED of the treatment groups was performed
at 0.2 µL/min flow rate for 50 minutes to deliver a total volume of 10 µL. A rodent study of
CED with aqueous infusion using a 28-gauge needle was proven to provide effective CED.244
For further verification a 0.6% agarose gel (1.5 mL in microcentrifuge tube) was also infused
with 10 µL of each treatment to determine average activity delivered at time of infusion.
Survival studies were conducted by weight measurements of mice daily in order to follow the
disease progression. Mice were weighed on the day of infusion and a loss of body weight was
used as a surrogate end point for death. Mice were euthanized when body weight was reduced to
80% of maximum weight. Euthanasia was performed by CO2 asphyxiation.
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5.1.7 Statistical Analysis
Where appropriate, values are mean ± standard error. Cell survival and cell uptake
treatment groups are compared to the control group using analysis of variance (ANOVA) and
Dunnett two-sided post hoc test with a 0.05 significance level. ANOVA Tukey honest significant
difference (HSD) post hoc test with a 0.05 significance level was used to compare between
individual treatment groups. The in vivo survival study data was analyzed using a Mantel-Cox
log rank test for pair-wise comparisons. IBM SPSS Statistics 22 software was used to perform all
statistical analysis.

5.2 Cellular Uptake, Proliferation, and IC50 Investigations
The cellular uptake of APTS-FeOx, APTES-FeOx, CMPVA-FeOx, and Gly-FeOx, SerFeOx, EDA-FeOx, TEPA-FeOx, ABA-FeOx, and SAHBA-FeOx at 4 hours is shown in Figure
5.1 as percent uptake and picograms (pg) of iron per cell. The cellular uptake method used in this
study was not able to discern between internalized nanoparticles or surface adsorbed
nanoparticles, but did allow for comparison between differences in surface functionalized
nanoparticles. Upon first analysis the uptake of EDA-FeOx and TEPA-FeOx appear to have by
far the best cellular uptake with uptake calculated to be 96.2 ± 8.8 pg of iron/cell and 71.7 ± 20.6
% uptake for EDA-FeOx and 99.2 ± 32.7 pg of iron/cell and 41.3 ± 9.0 % uptake for TEPAFeOx. ANOVA Tukey HDC post-hoc test revealed that both EDA-FeOx and TEPA-FeOx were
statistically different than the PBS control (p<0.001) (Appendix - Tables A1-5). Positive zeta
charge may indeed increase interaction with the surface of the cells, but it was determined that
the high cellular uptake is a false indication of the true cellular uptake for two reasons. First,
there is a known cell medium instability that could lead to precipitation on the surface of cells.
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Second, visual clumping of EDA-FeOx and TEPA-FeOx could be seen during incubation with
cells in the cell uptake study. This result is important as it illustrates, rather dramatically, the
potential for artificially high cellular uptake due to instability upon introduction into cell
medium. Both of these GLYMO surface functionalizations appeared stable in water, 1x PBS,
0.5x PBS, and 0.9% NaCl for more than 2 weeks, but were significantly precipitated after only 2
hours in cell medium. Therefore, the stability of nanoparticles to be used in biological
applications must be carefully evaluated and considered when reporting high cell uptake. The
other positive zeta potential surface functionalizations, APTS-FeOx and APTES-FeOx, resulted
in higher cell uptake values compared to the negative surface functionalizations. However,
ANOVA Tukey HSD post hoc test revealed only significant differences between APTS-FeOx or
APTES-FeOx and either EDA-FeOx or TEPA-FeOx.
Cellular uptake studies with APTS-FeOx or APTES-FeOx that was not prepared
immediately prior to testing resulted in larger cellular uptakes further corroborating the
connection between instability/size and cellular uptake seen in EDA-FeOx and TEPA-FeOx
uptake. More specifically given time the APTS-FeOx and APTES-FeOx formed larger
aggregates due to rehydrolyzing or restructuring causing increased instability and cellular uptake.
Examining the negative zeta potential surface functionalizations reveals similar uptake values
within the range of 0.19-0.46% uptake or 0.65-1.41 pg of iron per cell. All five of the tested
anionic surface functionalizations had strikingly similar stabilities. The similar stability and
terminal group chemistry results in similar measured cellular uptake values. Remarkably, the
SAHBA-FeOx nanoparticles, which were stable in a wide array of media, had the lowest uptake
(0.65±0.06 pg of iron per cell, 0.19±0.03% uptake). However, ANOVA Tukey HSD post-hoc
tests (Appendix – Tables 1-5) CMPVA-FeOx, Gly-FeOx, Ser-FeOx, ABA-FeOx, and SAHBA-
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FeOx SAHBA-FeOx were only statistically different when compared to EDA-FeOx or TEPAFeOx. More studies may reveal a significant link between better stability and lower cellular
uptake. Future reports linking only positive zeta potential to higher cellular uptake may need to
be reported as lower stability resulting in higher cell uptake.

Figure 5.1. GBM-6 cellular uptake results for surface functionalized FeOx nanoparticles;
reported in units of percent uptake (purple) or pg of iron/cell (blue). EDA-FeOx and TEPA-FeOx
uptake values are included in the inset figure with a larger y-axis.

Initial toxicity was investigated in terms of proliferation using a WST-1 cell proliferation
assay at 24 and 48 hours. The results are shown in Figure 5.2. TEPA-FeOx had significant
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(ANOVA Tukey HSD post-hoc test) difference in proliferation as compared to the control at
both 24 and 48 hours (Appendix – Tables A6-12). This was expected due to the high degree of
instability in cell medium at short time points and the large amount of cell uptake. Larger
amounts of cell uptake may be preventing essential cellular processes leading to the observed
toxicity and decreased proliferation rates. Interestingly the EDA-FeOx only showed decreases in
cell proliferation at 48 hours even though the nanoparticles were instable in cell medium and had
large amounts of cell uptake. Further analysis of WST-1 with ANOVA Tukey and Dunnett twosided post-hoc tests (Appendix – Table A6-12) only indicated a significant reduction in cell
proliferation, compared to the PBS control, at 24 hours for TEPA-FeOx nanoparticles and at 48
hours for EDA-FeOx and TEPA-FeOx nanoparticles.

Figure 5.2. Effect of surface functionalized nanoparticles on cell proliferation at 24 (blue) and
48 (purple) hours.
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The half maximal inhibitory concentration (IC50) of SAHBA-FeOx was determined by
WST-1 and cell titer blue cell proliferation assays at 24 hours using several concentrations of
SAHBA-FeOx in U87 cells. The results from both assays are shown in Figure 5.3. The nonlinear curve was fitted using Microsoft Excel Solver add-in by minimizing the sum of squares of
Equation 19 predicted y-values. Due to increased cell proliferation at the lowest concentration
of SAHBA-FeOx the curve was solved without the 0 SAHBA-FeOx concentration data point.
The A, B, C, and D constant values were found to be 120.0642, 5.838533, 53.19202, and
24.84344 respectively when minimizing the sum of squares. The sum of squares was minimized
to 12.59 or 112.77 for WST-1 and cell titer blue respectively. Using Equation 20 it was found
that the IC50 at 24 hours of treatment with SAHBA-FeOx was 1495.91 or 1320.38 µg/mL for
2,500 U87 cells plated 24 hours prior to treatment based on WST-1 and cell titer blue
respectively. The difference in percent control of cell viability for the two cell proliferation
assays is thought to be due to determination via absorbance (WST-1) or fluorescence (cell titer
blue) measurements. Due to the color of the iron oxide solutions it is thought that there could be
some overlap in the WST-1 UV-VIS absorbance measurements resulting in higher cell viability
as compared to the PBS control. Therefore, the cell titer blue fluorescent based assay is more
likely indicative of the true cell viability. However, we also see an increase in cell viability as
compared to the PBS control for both assays at low concentrations suggesting that the FeOx
nanoparticle treatment may be increasing cell viability. Further investigation is needed to
comment further.
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Figure 5.3. Effect of varying concentrations of SAHBA-FeOx on cell proliferation at 24 hours
based on WST-1 (green) and cell titer blue (blue) assays used to determine IC50. The IC50 trend
line is shown in black with open circles representing estimated y-values.

5.3 Effect of Hyperthermia on Cell Proliferation
WST-1 cell proliferation assay was also used to investigate potential differences of RF
induced hyperthermia. M059K glioblastoma cells were selected for initial in vitro hyperthermia
studies to verify the FeOx nanoparticles could be used to kill glioblastoma cells by delivering
sufficient hyperthermia. The CMPVA surface functionalized A2-24_B2-24 nanoparticles were
used due to their well-studied surface functionalization and low polydispersity. The cellular
uptake (Figure 5.4) revealed that the M059K cells had an uptake value of 0.2 µg of Fe per
100,000 cells when treated with 2.18 mg/mL iron concentration of CMPVA nanoparticles. Extra
CMPVA nanoparticles were added after 24 hours of uptake prior to cell heating as a positive
control and to ensure an adequate concentration of nanoparticles to demonstrate RF
hyperthermia. An additional ~325 µg of iron was added for the extra nanoparticles group
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resulting in 99.94% of ‘external’ and 0.06% ‘internal’ nanoparticles (0.2 µg/325.2 µg). With
such a large excess of ‘external’ nanoparticles the extra nanoparticles group was considered a
mixture with a dominant percent of ‘external’ heating and the particle group was considered only
‘internal’ heating.245,246

Figure 5.4. M059J cell uptake of CMPVA-FeOx (red) and PBS control (Blue) at 24 hours in
terms of µg of iron (A), percent uptake (B), and pg of Fe/cell (C).

The results of the in vitro hyperthermia experiment are shown in Figure 5.5. Analysis of
the ‘no heat’ treatment (Figure 5.5. top (blue)) for PBS control, nanoparticles, and extra
nanoparticles, revealed no significant differences in cell proliferation further corroborating no
significant toxicity of CMPVA nanoparticles (Appendix –Tables A13-16 statistical analysis
results).
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Figure 5.5. RF hyperthermia effect on M059K survival as determined by colony assay. (Top) No
particle (blue), particle (red), and extra particle (green) treatment groups survival are shown at 0,
10 and 15 minutes with a * indicating a significant difference determined by ANOVA and
Dunnett two-sided post-hoc tests with a 0.05 significance level. (Bottom) The corresponding
treatments measured RF hyperthermia over 15 minutes with dashed lines indicating 10 and 15
minutes of heating.

The PBS control showed no changes in cell proliferation after exposure to RF AC magnetic field
for 10 and 15 minutes. The RF heating of the PBS control (Figure 5.5. bottom, blue line) was
measured and did not have significant deviation from 37°C. The RF hyperthermia of the
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nanoparticle and extra nanoparticle treatments had measurable and significant lowering of cell
proliferation at 10 minutes. Interestingly, the decreases of cell proliferation were seen in both
treatments with different temperature measurements (Figure 5.5, bottom). Even though the
temperature only reached 38.5°C after ten minutes of RF heating (red line) it had similar cell
killing as compared to the extra particle group (green line) with a temperature increase to 47.1°C.
Analyzing the 15 minutes heating revealed that both nanoparticle and extra nanoparticle
treatments had significant cell killing when compared to the PBS control treatment. At first
glance, the extra nanoparticle group at 15 minutes appears to have additional cell killing, but was
not found to be significant based on ANOVA Tukey HSD post hoc test (Appendix – Tables
A13-16). At 15 minutes the extra nanoparticle group temperatures entered the thermal ablation
range at 48.4°C, where the nanoparticle group only reached 39.1°C. It should be noted that
repeating the experiment with additional replicates (higher N) could elucidate significant
differences that is expected for the larger temperature differences. However, these results were
sufficient to demonstrate glioblastoma cell killing via RF induced hyperthermia and revealed
potential vast differences based on ‘internal’ and ‘external’ hyperthermia.

5.4 Survival Study- Iron Oxide nanoparticle

177

Lu Brachytherapy

Investigation
The efficacy of FeOx nanoparticles in providing brachytherapy was investigated for
177

Lu-DOTA-SAHBA-FeOx and

177

Lu-DOTA-CMPVA-FeOx nanoparticles. These two surface

functionalized nanoparticles were chosen due to their similar broad and long term stability
characteristics, and differences in surface functionalization size. It was hypothesized that the
smaller size of

177

Lu-DOTA-SAHBA-FeOx could facilitate better distribution within the tumor.
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In order to test this hypothesis an in vivo survival study using a murine orthotopic xenograft
model of glioblastoma multiforme (U87MG) was used. Radiolabeling SAHBA-FeOx and
CMPVA-FeOx nanoparticles with 177Lu was confirmed with HPLC absorbance and radioactivity
measurements (Figures 5.6 and 5.7). The overlap of peaks in the 254 nm absorbance and
radioactivity spectra at the same elution time confirms the successful radiolabel chelation
product for both

177

Lu-DOTA-SAHBA-FeOx and

177

Lu-DOTA-CMPVA-FeOx nanoparticles.

The radioactivity counts are shifted slightly to longer elution times due to delay in time required
to travel from elution to the eSatin radioactivity counter. Dose calibrator measurements were
used to determine the chelation yield, and synthetic radiochemical yield. After washing with the
MCX column the chelation yield was estimated to be 64%, 54.9%, and 83.6% yield for
DOTA-SAHBA-FeOx,

177

Lu-DOTA-CMPVA-FeOx, and

177

177

Lu-

Lu-DOTA respectively. The

synthetic radiochemical yield, after PD-10 wash, was estimated to be 23.6% for

177

Lu-DOTA-

SAHBA-FeOx and 14.2% for 177Lu-DOTA-CMPVA-FeOx. The 177Lu-DOTA was not run on the
PD-10 column due to inability to visualize the progression through the PD-10 column and collect
only the 177Lu-DOTA.
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Figure 5.6. HPLC of

177

Lu-DOTA-SAHBA-FeOx final product. The absorbance at 254 nm

(top) and radioactivity counts (bottom) are shown.
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Figure 5.7. HPLC of

177

Lu-DOTA-CMPVA-FeOx final product. The absorbance at 254 nm

(top) and radioactivity counts (bottom) are shown.

Agarose gels were also infused with 177Lu-DOTA, 177Lu-DOTA-SAHBA-FeOx, or 177LuDOTA-CMPVA-FeOx in order to determine the average infused

177

Lu activity. Gamma well

counting and back decaying of agarose gels revealed an average infused
0.03, 8.59 ± 0.20, and 9.10 ± 0.37 µCi for

177

Lu-DOTA,
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177

177

Lu activity of 9.72 ±

Lu-DOTA-SAHBA-FeOx, or

177

Lu-

DOTA-CMPVA-FeOx respectively. The survival curves for PBS, SAHBA-FeOx,
177

Lu-DOTA-SAHBA-FeOx and

177

177

Lu-DOTA,

Lu-DOTA-CMPVA-FeOx in vivo treatments are shown in

Figure 5.8. The pair-wise comparison of a log rank Mantel-Cox test revealed differences in
survival between the five treatment groups (Appendix - Tables A17 and A18). The FeOx
control treatment was significantly different than 177Lu-DOTA control (significance = 0.000), but
was not significantly different from the PBS control (significance = 0.058). A larger survival
study may elucidate a significant difference between the SAHBA-FeOx and PBS and

177

Lu-

DOTA control groups. The difference between SAHBA-FeOx and 177Lu-DOTA is speculated to
be a combination of two factors. First, there is evidence from WST-1 cell proliferation assays
that SAHBA-FeOx may potentially increase cell proliferation which could translate to increased
tumor growth rate and reduced survival time. Second,

177

Lu-DOTA may possibly have a small

positive effect on survival, however no significant difference was found between

177

Lu-DOTA

and PBS treatment at this dose level. A significant difference was revealed between the three
controls and
controls and

177

Lu-DOTA-SAHBA-FeOx (significance 0.000), as well as between the three

177

Lu-DOTA-CMPVA-FeOx (significance 0.000). These results confirm the

effective brachytherapy deliver by

177

Lu-DOTA-SAHBA-FeOx and

FeOx. There was no significant difference between

177

177

Lu-DOTA-CMPVA-

Lu-DOTA-SAHBA-FeOx and

DOTA-SAHBA-FeOx. This is not surprising as only one mouse in the
FeOx lived 37 more days than the last surviving

177

177

177

Lu-

Lu-DOTA-SAHBA-

Lu-DOTA-CMPVA-FeOx mouse. Since one

mouse is representative of 12.5% of the population, a larger study will be necessary to determine
if this is a real effect on number of long term survivors between 177Lu-DOTA-SAHBA-FeOx and
177

Lu-DOTA-CMPVA-FeOx nanoparticle treatments due to differences in hydrodynamic

diameters or surface chemistry. Additionally, further studies such as biodistribution and retention
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investigations are needed to confirm no biological differences between

177

Lu-DOTA-SAHBA-

FeOx and 177Lu-DOTA-CMPVA-FeOx.

Figure 5.8. Survival study using murine orthotopic xenograft model of glioblastoma multiforme
(U87MG) treated with PBS (Black), FeOx (Blue), 177Lu-DOTA (Purple), 177Lu-DOTA-SAHBAFeOx (Red), and

177

Lu-DOTA-CMPVA-FeOx (Green). Significantly different treatment groups

from control are indicated by a * as determined by ANOVA and Dunnett two-sided post hoc test
at a 0.05 significance level.
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Chapter 6: Conclusion

6.1 Conclusion
The first goal of this dissertation was to synthesize FeOx nanoparticles via an innovative
and optimizable benzyl alcohol modified seed growth to obtain ideal nanoparticle properties for
increased RF induced magnetic hyperthermia treatment of cancer. This was achieved by
investigating reaction environment, precursor concentration, and temperature effects on resultant
nanoparticle properties.
1. Carrying out the reaction in the presence of air instead of under nitrogen flow provided
an additional mechanism of nucleation and growth besides the thermal decomposition.
This added oxidation of benzyl alcohol to benzaldehyde mechanism allowed for
reduction of Fe(acac)3 facilitating possible synthesis of magnetite and synthesizing
nanoparticles with larger crystallite sizes by better separation of nucleation and growth.
This was in accordance with reflux occurring just above benzaldehyde’s boiling point
(178.1°C).
2. Increasing the Fe(acac)3 concentration and/or temperature results were explained by the
LaMer growth and Ostwald ripening methods. These increases result in increased
monomer generation leading to faster burst nucleation events (reaching higher rates of
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nucleation) and a better separation of nucleation and growth leading to larger crystallite
sizes and smaller size distributions. The mixed reaction-diffusion limited growth
processes and Ostwald ripening were used to explain the differences in amorphous vs.
crystallite growth and increasing or decreasing size distributions respectively. There
appears to be a limit of monomer generation based on increasing concentration and
temperature that result in a prolonged nucleation event leading to larger size distributions,
amorphous growth, and smaller crystallite sizes.
3. The modified seed growth aided in obtaining larger crystallite sizes that were more
crystalline and had a lower size distribution. Nanoparticles produced by the modified
seed growth methods resulted in some of the largest RF heating values.
4. The best RF magnetic heating values were obtained for reaction A2-24(205)_B2-24(205)
which has a crystallite size of 19.5 ± 1.06 nm and a PDI of 0.265. The SAR and ILP
values (SAR = 1,175.56 W/g and ILP = 3.113

𝑛𝐻𝑚2
𝑘𝑔

) are comparable to some of the best

commercially available ferrofluids.
5. JMP software was able to model the nanoparticle properties effect on RF heating. The
determined equation for predicting RF heating could reasonably predict the RF heating
properties based on the significant nanoparticle properties of crystallite size, PDI, and
volume CS/HS.

The second goal was to design a surface functionalization method that can provide true
colloidal and biological stability and is easily conjugated with additional targeting ligands,
chemotherapeutics, or radiotherapeutics.
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1. The GLYMO surface functionalization process provided a simple method that could be
tuned with a wide array of nucleophiles to obtain broad biological stability.
2. SAHBA-FeOx and CMPVA-FeOx had the best and broadest stability of the surface
functionalizations tested. Both surface functionalizations proved stable in water, PBS,
saline, CSF, complete cell medium, and human serum. SAHBA-FeOx had the best
overall stability even at 5 months.
3. Further conjugation potential was proven by EDC coupling a DOTA chelate and
radiolabeling with 177Lu. HPLC verified the EDC coupling and radiolabeling process was
successful.

The

EDC

coupling

can

be

used

to

attach

chemotherapeutics,

radiotherapeutics, and/or diagnostics containing a primary amine or carboxyl group.

The final goal was to initially investigate biological effects of iron oxide nanoparticles on cell
proliferation and uptake, as well as investigate initial in vitro effect of hyperthermia and in vivo
brachytherapy delivery.
1. The surface functionalized iron oxide nanoparticles, with the exception of EDA-FeOx
and TEPA-FeOx, were shown to not significantly affect the cell proliferation indicating
no toxicity.
2. Cellular uptake measurements revealed that proper stability in water or PBS and cell
medium or other relevant medium is essential to measuring accurate cellular uptake. The
EDA-FeOx and TEPA-FeOx nanoparticles were not stable in cell medium which resulted
in false indication of high cellular uptake values. Furthermore, statistical analysis
between positive (APTS-FeOx and APTES-FeOx) and negative (CMPVA-FeOx, GlyFeOx, Ser-FeOx, ABA-FeOx, and SAHBA-FeOx) nanoparticles revealed no statistically
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significant differences in cellular uptake. This finding is not in agreement with literature
reporting’s of increased cellular uptake for positive surface charged nanoparticles.
3. Cell colony assay revealed that RF heating with surface functionalized FeOx
nanoparticles could be used to effectively kill cells. Furthermore, there is evidence
suggesting that cell killing can be obtained without large increases in solution
temperature which would be highly beneficial for RF hyperthermia applications.
4. Survival studies of murine orthotopic xenograft model of glioblastoma multiforme
177

(U87MG) treated with PBS, FeOx,
177

Lu-DOTA-CMPVA-FeOx

Lu-DOTA,

showed

that

177

Lu-DOTA-SAHBA-FeOx, and

SAHBA-FeOx

and

CMPVA-FeOx

nanoparticles can be effectively used to delivery brachytherapy via CED.

The investigation into the benzyl alcohol modified seed growth synthetic parameters and
JMP analysis revealed important nucleation and growth mechanism. This lead to the ability to
optimize synthesis to produce optimal nanoparticle characteristics for RF induced magnetic
hyperthermia. The GLYMO surface functionalization process proved to be a facile method with
tunable colloidal/biological stability and is directly applicable to biomedical applications
including hyperthermia and brachytherapy delivery. Researching the material synthesis, surface
functionalization, and biological testing proved to be a more directly applicable approach to
furthering iron oxide nanoparticles to the clinic for RF induced magnetic hyperthermia.
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Appendix

Table A1. Descriptives for cell uptake study based on pg of Fe per cell values.

Gly-FeOx
Ser-FeOx
EDA-FeOx
TEPA-FeOx
ABA-FeOx
SAHBA-FeOx
CMPVA-FeOx
APTS-FeOx
APTES-FeOx
Total

N

Mean

9
9
9
9
9
9
9
9
9
81

1.2770
1.3263
96.1587
99.2303
1.4106
.6539
1.3357
3.4168
2.3539
23.0181

Std.
Deviation
.67894
.23690
10.06934
35.11813
.53743
.12100
1.09110
.87460
.54045
41.81012

Std. Error

.22631
.07897
3.35645
11.70604
.17914
.04033
.36370
.29153
.18015
4.64557

95% Confidence Interval for
Minimum Maximum
Mean
Lower Bound
Upper Bound
.7551
1.7989
.55
2.50
1.1442
1.5084
.92
1.66
88.4187
103.8987
79.92
107.98
72.2361
126.2245
62.38
153.77
.9975
1.8237
.83
2.50
.5609
.7469
.52
.88
.4970
2.1744
.34
3.05
2.7445
4.0891
2.10
4.60
1.9385
2.7694
1.45
3.05
13.7732
32.2631
.34
153.77

Table A2. Descriptives for cell uptake study based on percent uptake values.

Gly-FeOx
Ser-FeOx
EDA-FeOx
TEPA-FeOx
ABA-FeOx
SAHBA-FeOx
CMPVA-FeOx
APTS-FeOx
APTES-FeOx
Total

N

Mean

9
9
9
9
9
9
9
9
9
81

.4615
.3511
71.7294
41.2559
.4271
.1937
.4079
.9150
.5237
12.9184

Std.
Deviation
.14989
.06166
21.95533
9.61316
.14410
.04216
.32337
.16723
.13339
25.67111

Std. Error

.04996
.02055
7.31844
3.20439
.04803
.01405
.10779
.05574
.04446
2.85235

95% Confidence Interval for
Minimum Maximum
Mean
Lower Bound
Upper Bound
.3463
.5767
.24
.67
.3037
.3985
.25
.44
54.8531
88.6058
42.23
95.81
33.8666
48.6452
33.31
55.85
.3164
.5379
.28
.70
.1613
.2261
.14
.27
.1593
.6565
.11
.91
.7865
1.0436
.63
1.08
.4212
.6263
.38
.79
7.2420
18.5947
.11
95.81
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Table A3. ANOVA values for cell uptake studies.
Sum of Squares
Between Groups
pg

Mean Square

129144.970
10701.945

8
72

139846.915

80

Within Groups

48123.297
4597.189

8
72

Total

52720.486

80

Within Groups
Total
Between Groups

Percent

df

F

Sig.

16143.121
148.638

108.607

.000

6015.412
63.850

94.212

.000

Table A4. Tukey HSD post-hoc tests results for cell uptake study based on pg of Fe per cell
values.
(I) Treatment

Gly-FeOx

Ser-FeOx

EDA-FeOx

TEPA-FeOx

ABA-FeOx

(J) Treatment
Ser-FeOx
EDA-FeOx
TEPA-FeOx
ABA-FeOx
SAHBA-FeOx
CMPVA-FeOx
APTS-FeOx
APTES-FeOx
Gly-FeOx
EDA-FeOx
TEPA-FeOx
ABA-FeOx
SAHBA-FeOx
CMPVA-FeOx
APTS-FeOx
APTES-FeOx
Gly-FeOx
Ser-FeOx
TEPA-FeOx
ABA-FeOx
SAHBA-FeOx
CMPVA-FeOx
APTS-FeOx
APTES-FeOx
Gly-FeOx
Ser-FeOx
EDA-FeOx
ABA-FeOx
SAHBA-FeOx
CMPVA-FeOx
APTS-FeOx
APTES-FeOx
Gly-FeOx
Ser-FeOx

Mean Difference
(I-J)

Std. Error

-.04928
-94.88166*
-97.95332*
-.13355
.62308
-.05872
-2.13980
-1.07693
.04928
-94.83238*
-97.90404*
-.08427
.67236
-.00944
-2.09053
-1.02765
94.88166*
94.83238*
-3.07166
94.74811*
95.50474*
94.82294*
92.74185*
93.80473*
97.95332*
97.90404*
3.07166
97.81977*
98.57640*
97.89460*
95.81351*
96.87639*
.13355
.08427

5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
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Sig.
1.000
.000
.000
1.000
1.000
1.000
1.000
1.000
1.000
.000
.000
1.000
1.000
1.000
1.000
1.000
.000
.000
1.000
.000
.000
.000
.000
.000
.000
.000
1.000
.000
.000
.000
.000
.000
1.000
1.000

95% Confidence Interval
Lower Bound
Upper Bound
-18.4292
18.3306
-113.2615
-76.5018
-116.3332
-79.5734
-18.5134
18.2463
-17.7568
19.0030
-18.4386
18.3212
-20.5197
16.2401
-19.4568
17.3030
-18.3306
18.4292
-113.2123
-76.4525
-116.2839
-79.5242
-18.4642
18.2956
-17.7075
19.0522
-18.3893
18.3704
-20.4704
16.2894
-19.4075
17.3522
76.5018
113.2615
76.4525
113.2123
-21.4516
15.3082
76.3682
113.1280
77.1248
113.8846
76.4430
113.2028
74.3620
111.1217
75.4248
112.1846
79.5734
116.3332
79.5242
116.2839
-15.3082
21.4516
79.4399
116.1997
80.1965
116.9563
79.5147
116.2745
77.4336
114.1934
78.4965
115.2563
-18.2463
18.5134
-18.2956
18.4642

SAHBA-FeOx

CMPVA-FeOx

APTS-FeOx

APTES-FeOx

EDA-FeOx
TEPA-FeOx
SAHBA-FeOx
CMPVA-FeOx
APTS-FeOx
APTES-FeOx
Gly-FeOx
Ser-FeOx
EDA-FeOx
TEPA-FeOx
ABA-FeOx
CMPVA-FeOx
APTS-FeOx
APTES-FeOx
Gly-FeOx
Ser-FeOx
EDA-FeOx
TEPA-FeOx
ABA-FeOx
SAHBA-FeOx
APTS-FeOx
APTES-FeOx
Gly-FeOx
Ser-FeOx
EDA-FeOx
TEPA-FeOx
ABA-FeOx
SAHBA-FeOx
CMPVA-FeOx
APTES-FeOx
Gly-FeOx
Ser-FeOx
EDA-FeOx
TEPA-FeOx
ABA-FeOx
SAHBA-FeOx
CMPVA-FeOx
APTS-FeOx

-94.74811*
-97.81977*
.75663
.07483
-2.00625
-.94338
-.62308
-.67236
-95.50474*
-98.57640*
-.75663
-.68180
-2.76289
-1.70001
.05872
.00944
-94.82294*
-97.89460*
-.07483
.68180
-2.08109
-1.01821
2.13980
2.09053
-92.74185*
-95.81351*
2.00625
2.76289
2.08109
1.06288
1.07693
1.02765
-93.80473*
-96.87639*
.94338
1.70001
1.01821
-1.06288

5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723
5.74723

.000
.000
1.000
1.000
1.000
1.000
1.000
1.000
.000
.000
1.000
1.000
1.000
1.000
1.000
1.000
.000
.000
1.000
1.000
1.000
1.000
1.000
1.000
.000
.000
1.000
1.000
1.000
1.000
1.000
1.000
.000
.000
1.000
1.000
1.000
1.000

-113.1280
-116.1997
-17.6233
-18.3051
-20.3861
-19.3233
-19.0030
-19.0522
-113.8846
-116.9563
-19.1365
-19.0617
-21.1428
-20.0799
-18.3212
-18.3704
-113.2028
-116.2745
-18.4547
-17.6981
-20.4610
-19.3981
-16.2401
-16.2894
-111.1217
-114.1934
-16.3736
-15.6170
-16.2988
-17.3170
-17.3030
-17.3522
-112.1846
-115.2563
-17.4365
-16.6799
-17.3617
-19.4428

-76.3682
-79.4399
19.1365
18.4547
16.3736
17.4365
17.7568
17.7075
-77.1248
-80.1965
17.6233
17.6981
15.6170
16.6799
18.4386
18.3893
-76.4430
-79.5147
18.3051
19.0617
16.2988
17.3617
20.5197
20.4704
-74.3620
-77.4336
20.3861
21.1428
20.4610
19.4428
19.4568
19.4075
-75.4248
-78.4965
19.3233
20.0799
19.3981
17.3170

*. The mean difference is significant at the 0.05 level.

Table A5. Tukey HSD post-hoc tests results for cell uptake study based on percent uptake
values.
(I) Treatment

(J) Treatment

Gly-FeOx

Ser-FeOx
EDA-FeOx
TEPA-FeOx
ABA-FeOx
SAHBA-FeOx
CMPVA-FeOx

Mean Difference
(I-J)

Std. Error

.11041
-71.26792*
-40.79442*
.03437
.26779
.05358

3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
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Sig.
1.000
.000
.000
1.000
1.000
1.000

95% Confidence Interval
Lower Bound
Upper Bound
-11.9360
12.1568
-83.3143
-59.2215
-52.8408
-28.7480
-12.0120
12.0808
-11.7786
12.3142
-11.9928
12.1000

Ser-FeOx

EDA-FeOx

TEPA-FeOx

ABA-FeOx

SAHBA-FeOx

CMPVA-FeOx

APTS-FeOx

APTS-FeOx
APTES-FeOx
Gly-FeOx
EDA-FeOx
TEPA-FeOx
ABA-FeOx
SAHBA-FeOx
CMPVA-FeOx
APTS-FeOx
APTES-FeOx
Gly-FeOx
Ser-FeOx
TEPA-FeOx
ABA-FeOx
SAHBA-FeOx
CMPVA-FeOx
APTS-FeOx
APTES-FeOx
Gly-FeOx
Ser-FeOx
EDA-FeOx
ABA-FeOx
SAHBA-FeOx
CMPVA-FeOx
APTS-FeOx
APTES-FeOx
Gly-FeOx
Ser-FeOx
EDA-FeOx
TEPA-FeOx
SAHBA-FeOx
CMPVA-FeOx
APTS-FeOx
APTES-FeOx
Gly-FeOx
Ser-FeOx
EDA-FeOx
TEPA-FeOx
ABA-FeOx
CMPVA-FeOx
APTS-FeOx
APTES-FeOx
Gly-FeOx
Ser-FeOx
EDA-FeOx
TEPA-FeOx
ABA-FeOx
SAHBA-FeOx
APTS-FeOx
APTES-FeOx
Gly-FeOx
Ser-FeOx
EDA-FeOx
TEPA-FeOx
ABA-FeOx
SAHBA-FeOx

-.45355
-.06224
-.11041
-71.37834*
-40.90483*
-.07604
.15738
-.05683
-.56396
-.17265
71.26792*
71.37834*
30.47351*
71.30229*
71.53571*
71.32151*
70.81438*
71.20569*
40.79442*
40.90483*
-30.47351*
40.82879*
41.06220*
40.84800*
40.34087*
40.73218*
-.03437
.07604
-71.30229*
-40.82879*
.23342
.01921
-.48792
-.09661
-.26779
-.15738
-71.53571*
-41.06220*
-.23342
-.21420
-.72133
-.33002
-.05358
.05683
-71.32151*
-40.84800*
-.01921
.21420
-.50713
-.11582
.45355
.56396
-70.81438*
-40.34087*
.48792
.72133

3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
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1.000
1.000
1.000
.000
.000
1.000
1.000
1.000
1.000
1.000
.000
.000
.000
.000
.000
.000
.000
.000
.000
.000
.000
.000
.000
.000
.000
.000
1.000
1.000
.000
.000
1.000
1.000
1.000
1.000
1.000
1.000
.000
.000
1.000
1.000
1.000
1.000
1.000
1.000
.000
.000
1.000
1.000
1.000
1.000
1.000
1.000
.000
.000
1.000
1.000

-12.5000
-12.1086
-12.1568
-83.4247
-52.9512
-12.1225
-11.8890
-12.1032
-12.6104
-12.2191
59.2215
59.3319
18.4271
59.2559
59.4893
59.2751
58.7680
59.1593
28.7480
28.8584
-42.5199
28.7824
29.0158
28.8016
28.2945
28.6858
-12.0808
-11.9704
-83.3487
-52.8752
-11.8130
-12.0272
-12.5343
-12.1430
-12.3142
-12.2038
-83.5821
-53.1086
-12.2798
-12.2606
-12.7677
-12.3764
-12.1000
-11.9896
-83.3679
-52.8944
-12.0656
-11.8322
-12.5535
-12.1622
-11.5929
-11.4825
-82.8608
-52.3873
-11.5585
-11.3251

11.5929
11.9842
11.9360
-59.3319
-28.8584
11.9704
12.2038
11.9896
11.4825
11.8738
83.3143
83.4247
42.5199
83.3487
83.5821
83.3679
82.8608
83.2521
52.8408
52.9512
-18.4271
52.8752
53.1086
52.8944
52.3873
52.7786
12.0120
12.1225
-59.2559
-28.7824
12.2798
12.0656
11.5585
11.9498
11.7786
11.8890
-59.4893
-29.0158
11.8130
11.8322
11.3251
11.7164
11.9928
12.1032
-59.2751
-28.8016
12.0272
12.2606
11.5393
11.9306
12.5000
12.6104
-58.7680
-28.2945
12.5343
12.7677

APTES-FeOx

CMPVA-FeOx
APTES-FeOx
Gly-FeOx
Ser-FeOx
EDA-FeOx
TEPA-FeOx
ABA-FeOx
SAHBA-FeOx
CMPVA-FeOx
APTS-FeOx

.50713
.39131
.06224
.17265
-71.20569*
-40.73218*
.09661
.33002
.11582
-.39131

3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681
3.76681

1.000
1.000
1.000
1.000
.000
.000
1.000
1.000
1.000
1.000

-11.5393
-11.6551
-11.9842
-11.8738
-83.2521
-52.7786
-11.9498
-11.7164
-11.9306
-12.4377

12.5535
12.4377
12.1086
12.2191
-59.1593
-28.6858
12.1430
12.3764
12.1622
11.6551

*. The mean difference is significant at the 0.05 level.

Table A6. Descriptives for WST-1 cell proliferation assay at 24 hours.

PBS
Gly-FeOx
Ser-FeOx
EDA-FeOx
TEPA-FeOx
ABA-FeOx
SAHBA-FeOx
CMPVA-FeOx
APTS-FeOx
APTES-FeOx
Total

N

Mean

6
6
6
6
6
6
5
6
4
4
55

100.0000
103.9668
103.6124
104.1469
7.4513
102.0611
109.1063
97.3286
96.1010
99.5506
91.6280

Std.
Deviation

Std. Error

3.11791
2.43660
4.09556
4.57737
1.03709
2.10804
3.50315
3.54828
17.67964
35.46892
31.46880

1.27288
.99474
1.67200
1.86870
.42339
.86061
1.56666
1.44858
8.83982
17.73446
4.24325

95% Confidence Interval for
Mean
Lower Bound Upper Bound
96.7280
103.2720
101.4097
106.5238
99.3143
107.9104
99.3432
108.9505
6.3629
8.5397
99.8488
104.2733
104.7565
113.4560
93.6049
101.0523
67.9688
124.2333
43.1117
155.9896
83.1208
100.1352

Minimum

Maximum

95.67
100.27
98.29
98.71
6.27
98.78
103.93
92.98
69.67
47.06
6.27

104.30
107.10
109.01
112.01
9.16
104.45
111.86
102.38
106.72
122.74
122.74

Minimum

Maximum

74.86
79.07
67.57
56.20
7.34
73.24
84.81
92.62
100.92
80.71
7.34

114.99
118.77
123.76
82.92
10.16
114.86
107.05
102.96
118.97
103.41
123.76

Table A7. Descriptives for WST-1 cell proliferation assay at 48 hours.

PBS
Gly-FeOx
Ser-FeOx
EDA-FeOx
TEPA-FeOx
ABA-FeOx
SAHBA-FeOx
CMPVA-FeOx
APTS-FeOx
APTES-FeOx
Total

N

Mean

4
4
5
6
6
5
4
6
6
6
52

100.0000
101.8516
97.7795
65.8497
8.4482
90.8483
94.9261
98.2567
108.2573
96.7339
84.5293

Std.
Deviation

Std.
Error

17.95642
18.16914
20.18831
9.11565
.97988
18.15668
9.50615
3.55627
6.61101
8.62068
31.97574

8.97821
9.08457
9.02849
3.72145
.40003
8.11991
4.75308
1.45184
2.69893
3.51938
4.43424

95% Confidence Interval for
Mean
Lower Bound
Upper Bound
71.4273
128.5727
72.9404
130.7627
72.7124
122.8466
56.2834
75.4160
7.4198
9.4765
68.3038
113.3928
79.7997
110.0525
94.5246
101.9888
101.3194
115.1951
87.6871
105.7808
75.6272
93.4314

Table A8. ANOVA values for cell proliferation WST-1 assay at 24 and 48 hours.
Sum of Squares

df
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Mean Square

F

Sig.

Between Groups
Proliferation24

Proliferation48

Within Groups

48357.024
5118.400

9
45

Total

53475.424

54

Between Groups
Within Groups

45893.541
6251.304

9
42

Total

52144.845

51

5373.003
113.742

47.238

.000

5099.282
148.841

34.260

.000

Table A9. Tukey HSD post-hoc tests results for WST-1 cell proliferation assay at 24 hours.
(I) Treatment

PBS

Gly-FeOx

Ser-FeOx

EDA-FeOx

TEPA-FeOx

(J) Treatment

Gly-FeOx
Ser-FeOx
EDA-FeOx
TEPA-FeOx
ABA-FeOx
SAHBA-FeOx
CMPVA-FeOx
APTS-FeOx
APTES-FeOx
PBS
Ser-FeOx
EDA-FeOx
TEPA-FeOx
ABA-FeOx
SAHBA-FeOx
CMPVA-FeOx
APTS-FeOx
APTES-FeOx
PBS
Gly-FeOx
EDA-FeOx
TEPA-FeOx
ABA-FeOx
SAHBA-FeOx
CMPVA-FeOx
APTS-FeOx
APTES-FeOx
PBS
Gly-FeOx
Ser-FeOx
TEPA-FeOx
ABA-FeOx
SAHBA-FeOx
CMPVA-FeOx
APTS-FeOx
APTES-FeOx
PBS
Gly-FeOx

Mean

Std.

Difference

Error

(I-J)
-3.96677
-3.61236
-4.14688
92.54869*
-2.06109
-9.10628
2.67141
3.89897
.44937
3.96677
.35441
-.18011
96.51546*
1.90567
-5.13951
6.63818
7.86573
4.41613
3.61236
-.35441
-.53452
96.16105*
1.55127
-5.49392
6.28377
7.51133
4.06172
4.14688
.18011
.53452
96.69557*
2.08578
-4.95940
6.81829
8.04584
4.59624
-92.54869*
-96.51546*

6.15744
6.15744
6.15744
6.15744
6.15744
6.45798
6.15744
6.88423
6.88423
6.15744
6.15744
6.15744
6.15744
6.15744
6.45798
6.15744
6.88423
6.88423
6.15744
6.15744
6.15744
6.15744
6.15744
6.45798
6.15744
6.88423
6.88423
6.15744
6.15744
6.15744
6.15744
6.15744
6.45798
6.15744
6.88423
6.88423
6.15744
6.15744
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Sig.

95% Confidence Interval
Lower Bound

1.000
1.000
1.000
.000
1.000
.918
1.000
1.000
1.000
1.000
1.000
1.000
.000
1.000
.998
.984
.977
1.000
1.000
1.000
1.000
.000
1.000
.997
.989
.983
1.000
1.000
1.000
1.000
.000
1.000
.999
.981
.973
1.000
.000
.000

-24.4520
-24.0976
-24.6321
72.0635
-22.5463
-30.5914
-17.8138
-19.0042
-22.4538
-16.5185
-20.1308
-20.6653
76.0302
-18.5796
-26.6246
-13.8471
-15.0375
-18.4871
-16.8729
-20.8396
-21.0198
75.6758
-18.9340
-26.9790
-14.2015
-15.3919
-18.8415
-16.3384
-20.3051
-19.9507
76.2103
-18.3995
-26.4445
-13.6670
-14.8573
-18.3069
-113.0339
-117.0007

Upper Bound
16.5185
16.8729
16.3384
113.0339
18.4241
12.3788
23.1567
26.8022
23.3526
24.4520
20.8396
20.3051
117.0007
22.3909
16.3456
27.1234
30.7689
27.3193
24.0976
20.1308
19.9507
116.6463
22.0365
15.9912
26.7690
30.4145
26.9649
24.6321
20.6653
21.0198
117.1808
22.5710
16.5257
27.3035
30.9490
27.4994
-72.0635
-76.0302

ABA-FeOx

SAHBA-FeOx

CMPVA-FeOx

APTS-FeOx

APTES-FeOx

Ser-FeOx
EDA-FeOx
ABA-FeOx
SAHBA-FeOx
CMPVA-FeOx
APTS-FeOx
APTES-FeOx
PBS
Gly-FeOx
Ser-FeOx
EDA-FeOx
TEPA-FeOx
SAHBA-FeOx
CMPVA-FeOx
APTS-FeOx
APTES-FeOx
PBS
Gly-FeOx
Ser-FeOx
EDA-FeOx
TEPA-FeOx
ABA-FeOx
CMPVA-FeOx
APTS-FeOx
APTES-FeOx
PBS
Gly-FeOx
Ser-FeOx
EDA-FeOx
TEPA-FeOx
ABA-FeOx
SAHBA-FeOx
APTS-FeOx
APTES-FeOx
PBS
Gly-FeOx
Ser-FeOx
EDA-FeOx
TEPA-FeOx
ABA-FeOx
SAHBA-FeOx
CMPVA-FeOx
APTES-FeOx
PBS
Gly-FeOx
Ser-FeOx
EDA-FeOx
TEPA-FeOx
ABA-FeOx
SAHBA-FeOx
CMPVA-FeOx
APTS-FeOx

-96.16105*
-96.69557*
-94.60979*
-101.65497*
-89.87728*
-88.64973*
-92.09933*
2.06109
-1.90567
-1.55127
-2.08578
94.60979*
-7.04519
4.73250
5.96006
2.51046
9.10628
5.13951
5.49392
4.95940
101.65497*
7.04519
11.77769
13.00525
9.55565
-2.67141
-6.63818
-6.28377
-6.81829
89.87728*
-4.73250
-11.77769
1.22756
-2.22204
-3.89897
-7.86573
-7.51133
-8.04584
88.64973*
-5.96006
-13.00525
-1.22756
-3.44960
-.44937
-4.41613
-4.06172
-4.59624
92.09933*
-2.51046
-9.55565
2.22204
3.44960

6.15744
6.15744
6.15744
6.45798
6.15744
6.88423
6.88423
6.15744
6.15744
6.15744
6.15744
6.15744
6.45798
6.15744
6.88423
6.88423
6.45798
6.45798
6.45798
6.45798
6.45798
6.45798
6.45798
7.15430
7.15430
6.15744
6.15744
6.15744
6.15744
6.15744
6.15744
6.45798
6.88423
6.88423
6.88423
6.88423
6.88423
6.88423
6.88423
6.88423
7.15430
6.88423
7.54129
6.88423
6.88423
6.88423
6.88423
6.88423
6.88423
7.15430
6.88423
7.54129

*. The mean difference is significant at the 0.05 level.

205

.000
.000
.000
.000
.000
.000
.000
1.000
1.000
1.000
1.000
.000
.983
.999
.997
1.000
.918
.998
.997
.999
.000
.983
.717
.721
.940
1.000
.984
.989
.981
.000
.999
.717
1.000
1.000
1.000
.977
.983
.973
.000
.997
.721
1.000
1.000
1.000
1.000
1.000
1.000
.000
1.000
.940
1.000
1.000

-116.6463
-117.1808
-115.0950
-123.1401
-110.3625
-111.5529
-115.0025
-18.4241
-22.3909
-22.0365
-22.5710
74.1245
-28.5303
-15.7527
-16.9431
-20.3927
-12.3788
-16.3456
-15.9912
-16.5257
80.1699
-14.4399
-9.7074
-10.7964
-14.2461
-23.1567
-27.1234
-26.7690
-27.3035
69.3920
-25.2177
-33.2628
-21.6756
-25.1252
-26.8022
-30.7689
-30.4145
-30.9490
65.7465
-28.8633
-36.8069
-24.1307
-28.5388
-23.3526
-27.3193
-26.9649
-27.4994
69.1961
-25.4137
-33.3573
-20.6811
-21.6396

-75.6758
-76.2103
-74.1245
-80.1699
-69.3920
-65.7465
-69.1961
22.5463
18.5796
18.9340
18.3995
115.0950
14.4399
25.2177
28.8633
25.4137
30.5914
26.6246
26.9790
26.4445
123.1401
28.5303
33.2628
36.8069
33.3573
17.8138
13.8471
14.2015
13.6670
110.3625
15.7527
9.7074
24.1307
20.6811
19.0042
15.0375
15.3919
14.8573
111.5529
16.9431
10.7964
21.6756
21.6396
22.4538
18.4871
18.8415
18.3069
115.0025
20.3927
14.2461
25.1252
28.5388

Table A10. Dunnett two-sided post-hoc tests results for WST-1 cell proliferation assay at 24
hours.
(I) Treatment

(J)
Treatment

Mean
Std.
Sig.
95% Confidence Interval
Difference
Error
Lower Bound
Upper Bound
(I-J)
Gly-FeOx
PBS
3.96677 6.15744
.994
-13.3274
21.2609
Ser-FeOx
PBS
3.61236 6.15744
.997
-13.6818
20.9065
EDA-FeOx
PBS
4.14688 6.15744
.991
-13.1473
21.4410
TEPA-FeOx
PBS
-92.54869* 6.15744
.000
-109.8428
-75.2546
ABA-FeOx
PBS
2.06109 6.15744 1.000
-15.2331
19.3552
SAHBA-FeOx PBS
9.10628 6.45798
.658
-9.0320
27.2445
CMPVA-FeOx PBS
-2.67141 6.15744 1.000
-19.9656
14.6227
APTS-FeOx
PBS
-3.89897 6.88423
.997
-23.2344
15.4365
APTES-FeOx
PBS
-.44937 6.88423 1.000
-19.7848
18.8861
b. Dunnett t-tests treat one group as a control, and compare all other groups against it.

Table A11. Tukey HSD post-hoc tests results for WST-1 cell proliferation assay at 48 hours.
(I) Treatment

(J) Treatment

Mean

Std. Error

Sig.

Difference (IJ)

PBS

Gly-FeOx

Ser-FeOx

EDA-FeOx

Gly-FeOx
Ser-FeOx
EDA-FeOx
TEPA-FeOx
ABA-FeOx
SAHBA-FeOx
CMPVA-FeOx
APTS-FeOx
APTES-FeOx
PBS
Ser-FeOx
EDA-FeOx
TEPA-FeOx
ABA-FeOx
SAHBA-FeOx
CMPVA-FeOx
APTS-FeOx
APTES-FeOx
PBS
Gly-FeOx
EDA-FeOx
TEPA-FeOx
ABA-FeOx
SAHBA-FeOx
CMPVA-FeOx
APTS-FeOx
APTES-FeOx
PBS

-1.85159
2.22047
34.15028*
91.55184*
9.15172
5.07392
1.74330
-8.25726
3.26608
1.85159
4.07205
36.00187*
93.40343*
11.00330
6.92551
3.59489
-6.40567
5.11766
-2.22047
-4.07205
31.92981*
89.33137*
6.93125
2.85345
-.47716
-10.47773
1.04561
-34.15028*

8.62672
8.18402
7.87508
7.87508
8.18402
8.62672
7.87508
7.87508
7.87508
8.62672
8.18402
7.87508
7.87508
8.18402
8.62672
7.87508
7.87508
7.87508
8.18402
8.18402
7.38748
7.38748
7.71597
8.18402
7.38748
7.38748
7.38748
7.87508
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1.000
1.000
.003
.000
.980
1.000
1.000
.987
1.000
1.000
1.000
.002
.000
.937
.998
1.000
.998
1.000
1.000
1.000
.003
.000
.996
1.000
1.000
.915
1.000
.003

95% Confidence Interval
Lower

Upper

Bound
-30.6548
-25.1046
7.8567
65.2582
-18.1734
-23.7293
-24.5503
-34.5509
-23.0275
-26.9516
-23.2531
9.7083
67.1098
-16.3218
-21.8777
-22.6987
-32.6993
-21.1759
-29.5456
-31.3972
7.2642
64.6658
-18.8311
-24.4717
-25.1428
-35.1433
-23.6200
-60.4439

Bound
26.9516
29.5456
60.4439
117.8454
36.4768
33.8771
28.0369
18.0363
29.5597
30.6548
31.3972
62.2955
119.6970
38.3284
35.7287
29.8885
19.8879
31.4113
25.1046
23.2531
56.5954
113.9970
32.6936
30.1786
24.1884
14.1879
25.7112
-7.8567

TEPA-FeOx

ABA-FeOx

SAHBA-FeOx

CMPVA-FeOx

APTS-FeOx

APTES-FeOx

Gly-FeOx
Ser-FeOx
TEPA-FeOx
ABA-FeOx
SAHBA-FeOx
CMPVA-FeOx
APTS-FeOx
APTES-FeOx
PBS
Gly-FeOx
Ser-FeOx
EDA-FeOx
ABA-FeOx
SAHBA-FeOx
CMPVA-FeOx
APTS-FeOx
APTES-FeOx
PBS
Gly-FeOx
Ser-FeOx
EDA-FeOx
TEPA-FeOx
SAHBA-FeOx
CMPVA-FeOx
APTS-FeOx
APTES-FeOx
PBS
Gly-FeOx
Ser-FeOx
EDA-FeOx
TEPA-FeOx
ABA-FeOx
CMPVA-FeOx
APTS-FeOx
APTES-FeOx
PBS
Gly-FeOx
Ser-FeOx
EDA-FeOx
TEPA-FeOx
ABA-FeOx
SAHBA-FeOx
APTS-FeOx
APTES-FeOx
PBS
Gly-FeOx
Ser-FeOx
EDA-FeOx
TEPA-FeOx
ABA-FeOx
SAHBA-FeOx
CMPVA-FeOx
APTES-FeOx
PBS
Gly-FeOx
Ser-FeOx

-36.00187*
-31.92981*
57.40156*
-24.99856*
-29.07636*
-32.40698*
-42.40754*
-30.88420*
-91.55184*
-93.40343*
-89.33137*
-57.40156*
-82.40012*
-86.47792*
-89.80854*
-99.80910*
-88.28576*
-9.15172
-11.00330
-6.93125
24.99856*
82.40012*
-4.07780
-7.40841
-17.40898
-5.88564
-5.07392
-6.92551
-2.85345
29.07636*
86.47792*
4.07780
-3.33062
-13.33118
-1.80784
-1.74330
-3.59489
.47716
32.40698*
89.80854*
7.40841
3.33062
-10.00056
1.52277
8.25726
6.40567
10.47773
42.40754*
99.80910*
17.40898
13.33118
10.00056
11.52334
-3.26608
-5.11766
-1.04561

7.87508
7.38748
7.04369
7.38748
7.87508
7.04369
7.04369
7.04369
7.87508
7.87508
7.38748
7.04369
7.38748
7.87508
7.04369
7.04369
7.04369
8.18402
8.18402
7.71597
7.38748
7.38748
8.18402
7.38748
7.38748
7.38748
8.62672
8.62672
8.18402
7.87508
7.87508
8.18402
7.87508
7.87508
7.87508
7.87508
7.87508
7.38748
7.04369
7.04369
7.38748
7.87508
7.04369
7.04369
7.87508
7.87508
7.38748
7.04369
7.04369
7.38748
7.87508
7.04369
7.04369
7.87508
7.87508
7.38748
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.002
.003
.000
.045
.020
.001
.000
.003
.000
.000
.000
.000
.000
.000
.000
.000
.000
.980
.937
.996
.045
.000
1.000
.990
.376
.998
1.000
.998
1.000
.020
.000
1.000
1.000
.793
1.000
1.000
1.000
1.000
.001
.000
.990
1.000
.914
1.000
.987
.998
.915
.000
.000
.376
.793
.914
.823
1.000
1.000
1.000

-62.2955
-56.5954
33.8838
-49.6642
-55.3700
-55.9247
-65.9253
-54.4019
-117.8454
-119.6970
-113.9970
-80.9193
-107.0657
-112.7715
-113.3263
-123.3268
-111.8035
-36.4768
-38.3284
-32.6936
.3330
57.7345
-31.4029
-32.0740
-42.0746
-30.5512
-33.8771
-35.7287
-30.1786
2.7828
60.1843
-23.2473
-29.6242
-39.6248
-28.1014
-28.0369
-29.8885
-24.1884
8.8893
66.2908
-17.2572
-22.9630
-33.5183
-21.9949
-18.0363
-19.8879
-14.1879
18.8898
76.2914
-7.2566
-12.9624
-13.5172
-11.9944
-29.5597
-31.4113
-25.7112

-9.7083
-7.2642
80.9193
-.3330
-2.7828
-8.8893
-18.8898
-7.3665
-65.2582
-67.1098
-64.6658
-33.8838
-57.7345
-60.1843
-66.2908
-76.2914
-64.7680
18.1734
16.3218
18.8311
49.6642
107.0657
23.2473
17.2572
7.2566
18.7799
23.7293
21.8777
24.4717
55.3700
112.7715
31.4029
22.9630
12.9624
24.4858
24.5503
22.6987
25.1428
55.9247
113.3263
32.0740
29.6242
13.5172
25.0405
34.5509
32.6993
35.1433
65.9253
123.3268
42.0746
39.6248
33.5183
35.0411
23.0275
21.1759
23.6200

EDA-FeOx
30.88420*
TEPA-FeOx
88.28576*
ABA-FeOx
5.88564
SAHBA-FeOx
1.80784
CMPVA-FeOx
-1.52277
APTS-FeOx
-11.52334
*. The mean difference is significant at the 0.05 level.

7.04369
7.04369
7.38748
7.87508
7.04369
7.04369

.003
.000
.998
1.000
1.000
.823

7.3665
64.7680
-18.7799
-24.4858
-25.0405
-35.0411

54.4019
111.8035
30.5512
28.1014
21.9949
11.9944

Table A12. Dunnett two-sided post-hoc tests results for WST-1 cell proliferation assay at 48
hours.
(I) Treatment

(J)
Treatment

Mean
Difference
(I-J)
1.85159
-2.22047
-34.15028*
-91.55184*
-9.15172
-5.07392

Std.
Error

Sig.

95% Confidence Interval
Lower Bound

Upper Bound

Gly-FeOx
PBS
8.62672 1.000
-22.0678
Ser-FeOx
PBS
8.18402 1.000
-24.9124
EDA-FeOx
PBS
7.87508
.001
-55.9856
TEPA-FeOx PBS
7.87508
.000
-113.3871
ABA-FeOx
PBS
8.18402
.811
-31.8436
SAHBA8.62672
.994
-28.9933
PBS
FeOx
CMPVA-1.74330 7.87508 1.000
-23.5786
PBS
FeOx
APTS-FeOx PBS
8.25726 7.87508
.853
-13.5780
APTES-3.26608 7.87508 1.000
-25.1014
PBS
FeOx
b. Dunnett t-tests treat one group as a control, and compare all other groups against it.

25.7710
20.4715
-12.3150
-69.7165
13.5402
18.8455
20.0920
30.0926
18.5692

Table A13. Colony Assay Descriptive Statistics.

N Mean
No Particle - 0
min
Particle - 0 min
Extra Particle - 0
min
No Particle - 10
min
Particle - 10 min
Extra Particle 10 min
No Particle - 15
min
Particle - 15 min

Std.
Deviation

Std.
Error

95% Confidence Interval
for Mean
Lower
Bound
Upper Bound Minimum Maximum

6 100.017

26.4299 10.7899

72.280

127.753

66.1

137.6

6 87.167

14.2152

5.8033

72.249

102.085

68.8

110.1

6 89.900

12.6366

5.1589

76.639

103.161

74.3

110.1

6 100.450

19.2761

7.8694

80.221

120.679

77.1

132.1

6 62.850

13.4213

5.4792

48.765

76.935

44.0

85.3

6 55.033

10.8971

4.4487

43.598

66.469

44.0

71.6

6 107.333

22.4136

9.1503

83.812

130.855

71.6

137.6

6 53.667

9.9631

4.0674

43.211

64.122

35.8

63.3
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Extra Particle 15 min
Total

6 26.600

7.0798

2.8903

19.170

34.030

13.8

33.0

54 75.891

30.1153

4.0982

67.671

84.111

13.8

137.6

Table A14. Colony Assay ANOVA Results.

Between Groups
Within Groups
Total

Sum of Squares
36155.034
11912.472
48067.505

df Mean Square F
Sig.
8
4519.379 17.072 .000
45
264.722
53

Table A15. Colony Assay Dunnett (2-sided) Post Hoc Test Results.
Multiple Comparisons
Dependent Variable: Survival
Dunnett t (2-sided)a

(I) Group
Particle - 0 min

(J) Group
No Particle - 0
min
Extra Particle - 0
No Particle - 0
min
min
No Particle - 10 min No Particle - 0
min
Particle - 10 min
No Particle - 0
min
Extra Particle - 10 No Particle - 0
min
min
No Particle - 15 min No Particle - 0
min
Particle - 15 min
No Particle - 0
min
Extra Particle - 15 No Particle - 0
min
min

Mean Difference (IJ)

Std.
Error

95% Confidence Interval
Lower
Upper
Sig.
Bound
Bound

-12.8500

9.3936 .644

-38.778

13.078

-10.1167

9.3936 .841

-36.045

15.811

.4333

9.3936 1.000

-25.495

26.361

-37.1667*

9.3936 .002

-63.095

-11.239

-44.9833*

9.3936 .000

-70.911

-19.055

7.3167

9.3936 .965

-18.611

33.245

-46.3500*

9.3936 .000

-72.278

-20.422

-73.4167*

9.3936 .000

-99.345

-47.489

*. The mean difference is significant at the 0.05 level.
a. Dunnett t-tests treat one group as a control, and compare all other groups against it.
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Table A16. Colony Assay Tukey HSD Post Hoc Test Results.
Multiple Comparisons
Dependent Variable: Survival

(I) Group
(J) Group
No Particle - Particle - 0 min
0 min
Extra Particle - 0 min
No Particle - 10 min
Particle - 10 min
Extra Particle - 10 min
No Particle - 15 min
Particle - 15 min
Extra Particle - 15 min
Particle - 0
No Particle - 0 min
min
Extra Particle - 0 min
No Particle - 10 min
Particle - 10 min
Extra Particle - 10 min
No Particle - 15 min
Particle - 15 min
Extra Particle - 15 min
Extra Particle No Particle - 0 min
- 0 min
Particle - 0 min
No Particle - 10 min
Particle - 10 min
Extra Particle - 10 min
No Particle - 15 min
Particle - 15 min
Extra Particle - 15 min
No Particle - No Particle - 0 min
10 min
Particle - 0 min
Extra Particle - 0 min
Particle - 10 min
Extra Particle - 10 min
No Particle - 15 min
Particle - 15 min
Extra Particle - 15 min
Particle - 10 No Particle - 0 min
min
Particle - 0 min
Extra Particle - 0 min
No Particle - 10 min
Extra Particle - 10 min
No Particle - 15 min

Mean Difference
(I-J)
12.8500
10.1167
-.4333
37.1667*
44.9833*
-7.3167
46.3500*
73.4167*
-12.8500
-2.7333
-13.2833
24.3167
32.1333*
-20.1667
33.5000*
60.5667*
-10.1167
2.7333
-10.5500
27.0500
34.8667*
-17.4333
36.2333*
63.3000*
.4333
13.2833
10.5500
37.6000*
45.4167*
-6.8833
46.7833*
73.8500*
-37.1667*
-24.3167
-27.0500
-37.6000*
7.8167
-44.4833*
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Std.
Error
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936

Sig.
.904
.975
1.000
.007
.001
.997
.000
.000
.904
1.000
.886
.220
.033
.456
.022
.000
.975
1.000
.967
.121
.015
.646
.010
.000
1.000
.886
.967
.007
.001
.998
.000
.000
.007
.220
.121
.007
.995
.001

95% Confidence Interval
Lower
Upper
Bound
Bound
-17.746
43.446
-20.480
40.713
-31.030
30.163
6.570
67.763
14.387
75.580
-37.913
23.280
15.754
76.946
42.820
104.013
-43.446
17.746
-33.330
27.863
-43.880
17.313
-6.280
54.913
1.537
62.730
-50.763
10.430
2.904
64.096
29.970
91.163
-40.713
20.480
-27.863
33.330
-41.146
20.046
-3.546
57.646
4.270
65.463
-48.030
13.163
5.637
66.830
32.704
93.896
-30.163
31.030
-17.313
43.880
-20.046
41.146
7.004
68.196
14.820
76.013
-37.480
23.713
16.187
77.380
43.254
104.446
-67.763
-6.570
-54.913
6.280
-57.646
3.546
-68.196
-7.004
-22.780
38.413
-75.080
-13.887

Particle - 15 min
Extra Particle - 15 min
Extra Particle No Particle - 0 min
- 10 min
Particle - 0 min
Extra Particle - 0 min
No Particle - 10 min
Particle - 10 min
No Particle - 15 min
Particle - 15 min
Extra Particle - 15 min
No Particle - No Particle - 0 min
15 min
Particle - 0 min
Extra Particle - 0 min
No Particle - 10 min
Particle - 10 min
Extra Particle - 10 min
Particle - 15 min
Extra Particle - 15 min
Particle - 15 No Particle - 0 min
min
Particle - 0 min
Extra Particle - 0 min
No Particle - 10 min
Particle - 10 min
Extra Particle - 10 min
No Particle - 15 min
Extra Particle - 15 min
Extra Particle No Particle - 0 min
- 15 min
Particle - 0 min
Extra Particle - 0 min
No Particle - 10 min
Particle - 10 min
Extra Particle - 10 min
No Particle - 15 min
Particle - 15 min

9.1833
36.2500*
-44.9833*
-32.1333*
-34.8667*
-45.4167*
-7.8167
-52.3000*
1.3667
28.4333
7.3167
20.1667
17.4333
6.8833
44.4833*
52.3000*
53.6667*
80.7333*
-46.3500*
-33.5000*
-36.2333*
-46.7833*
-9.1833
-1.3667
-53.6667*
27.0667
-73.4167*
-60.5667*
-63.3000*
-73.8500*
-36.2500*
-28.4333
-80.7333*
-27.0667

9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936
9.3936

.986
.010
.001
.033
.015
.001
.995
.000
1.000
.087
.997
.456
.646
.998
.001
.000
.000
.000
.000
.022
.010
.000
.986
1.000
.000
.121
.000
.000
.000
.000
.010
.087
.000
.121

-21.413
5.654
-75.580
-62.730
-65.463
-76.013
-38.413
-82.896
-29.230
-2.163
-23.280
-10.430
-13.163
-23.713
13.887
21.704
23.070
50.137
-76.946
-64.096
-66.830
-77.380
-39.780
-31.963
-84.263
-3.530
-104.013
-91.163
-93.896
-104.446
-66.846
-59.030
-111.330
-57.663

39.780
66.846
-14.387
-1.537
-4.270
-14.820
22.780
-21.704
31.963
59.030
37.913
50.763
48.030
37.480
75.080
82.896
84.263
111.330
-15.754
-2.904
-5.637
-16.187
21.413
29.230
-23.070
57.663
-42.820
-29.970
-32.704
-43.254
-5.654
2.163
-50.137
3.530

*. The mean difference is significant at the 0.05 level.

Table A17. The means and medians for survival time of each treatment group.
Meana

Treatment
Estimate

PBS
FeOx
177
Lu-DOTA

29.375
26.625
31.375

Std.
Error

1.085
.844
.905

Median

95% Confidence
Interval
Lower
Upper
Bound
Bound
27.249
31.501
24.971
28.279
29.601
33.149

212

Estimate

28.000
26.000
31.000

Std.
Error

.943
1.414
.306

95% Confidence
Interval
Lower
Upper
Bound
Bound
26.152
29.848
23.228
28.772
30.400
31.600

177

46.625
43.250
35.450

Lu-D-SAHBA-FeOx
177Lu-D-CMPVA-FeOx
Overall

7.486
2.724
2.000

31.953
37.911
31.529

61.297
48.589
39.371

40.000
42.000
31.000

3.423
1.369
1.054

33.290
39.316
28.934

46.710
44.684
33.066

a. Estimation is limited to the largest survival time if it is censored.

Table A18. Results of pairwise comparison of log rank (Mantel-Cox) test for each treatment in
the survival study.
Treatment

PBS
ChiSquare

FeOx
Sig.

PBS

ChiSquare
3.586

177Lu-DOTA
Sig.
.058

3.586

.058

177

1.079

.299

12.494

.000

177

12.479

.000

16.897

16.964

.000

16.897

FeOx
Lu-DOTA
Lu-D-SAHBAFeOx
177
Lu-DCMPVA-FeOx

ChiSquare
1.079

Sig.
.299

12.494

.000

.000

11.396

.001

.000

13.327

.000

213

177Lu-D177Lu-DSAHBA-FeOx
CMPVA-FeOx
ChiSig.
ChiSig.
Square
Square
12.479
.000
16.964 .000
16.897

.000

16.897

.000

11.396

.001

13.327

.000

.007

.933

.007

.933
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